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1. INTRODUCTION 
1.1 Gene delivery 
In recent years, gene therapy has emerged as a promising strategy for the treatment of 
several diseases such as Prakinson s´ disease, Alymphocytosis and cancers.
1-3
 However, 
genetic materials cannot enter intact cells by simple diffusion due to their anionic nature and 
the hydrophobicity of the membrane lipid bilayer as well the negative charges on cell 
surface.
4,5
 Therefore, efficient gene delivery vectors are required to realize the efforts of gene 
therapy. The main functions of vectors are DNA/RNA condensation, cellular uptake of the 
resulting complexes and subsequently release from endosome to cytosol or nucleus.
6-8
 
Additionally, the condensation of genetic materials with vectors can provide protection 
against enzymatic degradations.
9
 
  Generally, gene delivery vectors can be classified into two categories: virus-based and 
non-viral vectors. Although recombinant viruses have been demonstrated as the most efficient 
vectors in the delivery of genetic materials, their medical applications are limited due to their 
toxicity and immunogenicity etc.
10,11
 On the other hand, non-viral delivery systems have 
attracted more and more interests in the field of gene therapy. Cationic lipid Lipofectamine 
and polymers polyethylenimine (PEI) are widely accepted as standard reagents in gene 
transfection experiments.
12
  
In particularly, peptide based gene transfection vectors have attracted increasing interests in 
recent years due to their ease of synthesis, lower toxicity at least compared to polymeric 
transfection vectors and versatility of functionalization.
13
 Of the most often used peptidic 
vectors, arginine rich cell penetrating peptides have been identified as being highly efficient in 
cellular uptake and thus are widely tested as gene delivery vectors. However, a minimum of 6 
positive charges is usually required for cellular uptake and even more charges are necessary 
for efficient gene delivery.
14,15
 Even with the current prevailing strategy of adding a 
hydrophobic aliphatic chain onto the peptide sequence to increase their endosomal release 
ability, at least 8 to 9 arginines were still necessary for decent gene transfection.
16,17
 The 
transfection efficacy as well cytotoxicity of these peptides requires further improvement, with 
regard to future applications. Although other cationic peptides such as lysine oligomers have 
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been used for gene transfection, their efficacies are usually even worse than arginine rich 
peptides.
18
 A new modification strategy for CPPs is therefore in high demand to develop 
efficient gene delivery vector. 
1.2 Peptide assembly 
Supramolecular chemistry has developed several strategies to achieve efficient and also 
controlled peptide assembly. Various nanostructures such as fibers, tape-like aggregates, 
nanotubes and helix assemblies can be obtained by rationally design of peptide based building 
blocks.
19
 For example, amphiphilic peptides can readily form peptide fibers and nanobelts in 
aqueous solutions.
20
 Also naturally occurring peptides such as amyloid and coiled-coil peptide 
are interesting building blocks in constructing nanotube structures.
21,22
 These peptide 
assemblies can be applied to variety of applications such as stimuli-responsive materials, 
tissue engineering and regenerative medicines etc.
23,24
 
On the other hand, short peptides that adopt helical and sheet structures under physiological 
conditions have profound impact on biological systems. One current goal of supramolecular 
chemistry is to design artificial self-assembling systems that could mimic these structures 
under biomimetic conditions.
25
 This could not only largely enhance our understandings of its 
functions in biological process but also provide alternatives for the development of 
biomaterials.  
 In summary, short peptides have demonstrated to be very promising in the development of 
gene delivery vectors. However, the efficiency of such peptides in gene delivery still needs to 
be optimized for future clinical application. The purpose of this thesis is thus to develop new 
peptide based gene delivery vectors with improved transfection efficiency. We hypothesized 
that the introduction of tailor made anion binding receptors in the side chains of peptides 
could enhance their interactions either with cell membrane or with DNA. This property could 
eventually lead to a better performing peptide in cellular uptake and gene delivery. The same 
strategy, i.e. modification of peptide with anion receptor could also be applied to provide 
novel peptide based supramolecular nanomaterials. 
BACKGROUND INFORMATION 
3 
2. BACKGROUND INFORMATION 
2.1 GCP-oxoanion recognition 
2.1.1 GCP-oxoanion binding interactions 
In biological systems, the majority of macromolecules such as protein and DNA which 
sustain body functions are anionic in nature. Even cell membrane which provides a stable and 
suitable environment for the basic need of cells is highly negatively charged. Development of 
artificial receptors which can bind anions such as sulfate, phosphate and carboxylate could 
enormously benefit the discovery of drugs and drug carriers.
26-29
  
 
Figure 1. Schematic representation of the binding between GCP and carboxylate 
Guanidinium group has been known as a relatively strong binding moiety with oxoanions 
because of the electrostatic interactions and additional hydrogen bonds.
30
 However, the 
complexes formed between guanidinium cations and carboxylates are normally easy to 
dissociate in polar solvents such as DMSO and water.
31
 Guanidiniocarboxylpyrrole 
(abbreviated as GCP), a rigid and planar moiety, was thus introduced by Schmuck et al. to 
improve the anion binding ability of guanidinium group (Figure 1).
32,33
 This moiety possesses 
several advantages compared to simple guanidines, which makes it an attractive candidate for 
the binding of carboxylates even in aqueous solvents: 
• the pKa of acyl guanidino is around 7–8 which increases the acidity and favors the 
formation of hydrogen bonded ion pairs. 
• Additional hydrogen bond donors such as the amide NH can further enhance the stability 
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of the complex. 
• GCP motif is planar and rather rigid and therefore ideally pre-organized for the binding of 
planar anions such as carboxylates. 
• Additional secondary interactions between the side chain of GCP and carboxylate can be 
easily introduced to achieve selectivity.  
As consequence, the binding constants between GCP and carboxylates can reach the 
magnitude of 10
5
 M
-1
 in DMSO.
34
 Even in aqueous media the anion binding ability of GCP is 
still sufficiently strong (10
3
 M
-1
).
35
 Considering the difficulty to achieve strong binding 
interactions in water, a highly competitive solvent, the GCP moiety then represents a unique 
and useful tool to study anion related interactions in biological systems. 
2.1.2 GCP recognition of amino acids and short peptides 
  In biological world the guanidinium moiety is widely applied as a mediator of specific 
non-covalent binding such as the substrate binding of enzyme, DNA and protein interactions 
etc.
36-39
 Naturally, GCP moiety, an improved guanidinium binding moiety, has been 
thoroughly examined as artificial receptors for biomolecules owing to its superior binding 
ability towards anions. 
2.1.2.1 Amino acids recognition 
The design of artificial receptors which bind amino acids under physiological conditions is 
still challenging. Most amino acid receptors either required hydrophobic or metal–ligand 
interactions to achieve efficient substrate binding in water. However, Schmuck et al. were able 
to develop efficient amino acid receptors in high competitive solvents through the utilization 
of GCP binding moiety. 
  In 1999, Schmuck et al. reported that molecule 3 bound N-acetyl amino acids with binding 
constants ranging from K = 360 to 1700 mol
-1 
in 40% H2O–DMSO solution (Figure 2).
40
 The 
recognition process of 3 was selective for the chemical structures of amino acid side chain. 
The binding with phenylalanine was much stronger than that of alanine or lysine. Molecular 
modelling suggested that the aromatic ring stacked with the acylguanidinium unit and thus 
provided extra stabilization. 
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Figure 2. Side chain selective binding of N-acetyl-amino acid carboxylates by 3 
Later, Schmuck et al. determined the energetic contributions of the individual interactions in 
3 through systematic variations of its structure. A series of GCP based receptors were thus 
designed and synthesized.
41
 Studying their binding properties with carboxylates revealed that 
not all the hydrogen bonds in 3 contributed equally to the stabilization of the final complex. 
The results demonstrated that the amide NH next to the pyrrole ring was critical for stronger 
binding whereas the pyrrole NH and the terminal carbamoyl group contributed less to the 
overall binding affinity. Additionally, replacement of the pyrrole moiety with pyridine 
weakened the binding ability with carboxylate due to unfavorable electrostatic and steric 
effects in pyridine.
42
 The electrostatic repulsions between the lone pair in the pyridine 
nitrogen and the bound carboxylates destabilized the resulting complex. 
 
Figure 3. Side chain selective binding of N-acetyl-amino acid carboxylates by 4. Adapted with 
permission from Reference 35 .Copyright (2016) American Chemical Society." 
Introduction of additional positive charges into 3 can further stabilize the final complex. 
Tri-cation 4, with two extra positive charges relative to 3, showed efficient binding with 
amino acid carboxylates in water at millimolar salt concentrations (Figure 3).
35
 The binding 
constant was increased up to the range of 10
3
. Furthermore, 4 exhibited cooperative 2:1 
complex formation with N-acetyl glutamates but not aspartate. This differentiation ability is 
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rather impressive considering the structural similarity of both amino acids. On the other hand, 
additional interactions can also be introduced on the backside of molecule 3. N’-substituted 5, 
which was obtained by the activation of a Boc-protected guanidiniocarbonyl pyrrole with 
triflic anhydride, showed efficient complexation with amino acid carboxylates in water 
(Figure 4).
43
 
 
Figure 4. Binding of N’-substituted guanidiniocarbonyl pyrrole 5 with carboxylic acid 
2.1.2.2 Short peptides 
While recognition of negatively charged amino acids such as aspartic acid and glutamic 
acid has been achieved, Schmuck et al. further applied the GCP moiety in the recognition of 
short peptides. Short peptides have various important functions in biological systems such as 
amyloid formation, cell signaling and modulators of many regulatory processes etc. 
Development of artificial receptors for short peptides could largely benefit the understanding 
of biological phenomenon and also drug discovery. 
In 2004, Schmuck et al. designed and synthesized a cationic prototype receptor 6 which 
showed efficient binding ability towards dipeptide in water (Figure 5).
44
 The binding constant 
between 6 and Val-Val can be up to 54,300 M
-1
 which was 10 fold larger compared with the 
binding of other GCP-based carboxylate receptors with simple amino acids (K = 10
3 
M
-1
). 
Obviously the H-bonds between the backbone amides and interactions with the imidazol 
group played an important role in the stabilization of resulting complex. Further introduction 
of a hydrophobic group such as naphthyl and additional amino acid residues showed 
preferential complexation of N-acetyl dipeptide carboxylates containing alanine at the 
C-terminus.
45,46
 Schmuck et al. also attached a cyclo-tribenzylene substituted alanine onto the 
GCP based receptor. The hydrophobic bowl-shaped cavity was just spacious enough to bind a 
methyl group but not any larger alkyl chain. This property led to a binding preference of 
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alanine over valine. As consequence, Ac-D-Ala-D-Ala-OH can bind 10 fold stronger with this 
receptor than Ac-D-Val-D-Val-OH. 
 
Figure 5. Binding of 6 with dipeptide and respective binding constants. Reprinted with permission 
from Reference 44. Copyright (2016) American Chemical Society." 
  Moreover, Schmuck et al. demonstrated the GCP moiety can be applied to achieve tetra- 
peptide and amyloid beta peptide recognition.
47,48
 Tetra-peptide Ac-Val-Val-Ile-Ala-OH, a 
segment sequence of amyloid-β-peptide responsible for the formation of protein plaques in 
the brains of patients suffering from Alzheimer's disease, was used as anionic model peptide. 
This short tetra peptide forms insoluble, fibril-like aggregates upon prolonged incubation in 
solution underlining its high tendency to self-aggregate. Thus it is a suitable model to study 
the self-aggregation process of amyloid-β-peptide. In this work, they established a 
combinatorial library of receptors on solid support featured with the modification of GCP in 
N-terminus (Figure 6). Their binding properties were determined directly on bead using a 
quantitative fluorescence assay. To accomplish this assay, model tetra peptide 
Ac-Val-Val-Ile-Ala-OH was modified with dansyl group through different linkers. A 
schematic representation of the screening methods is shown in below:  
 
Figure 6. A peptide based library of cationic GCP receptors designed for binding  
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Comparison of the binding data revealed that the recognition of model tetra peptide with 
these receptors required both electrostatic and hydrophobic interactions. The binding ability 
of these receptors was very efficient with binding constants around 10
3
 M
-1
 in water. Also it 
was shown that all the good binding receptors were featured with the use of Lys(Boc) group 
in the position next to GCP moiety. Molecular dynamic simulation suggested that the 
favorable hydrophobic interactions between bulky t-Boc group and the first (Val) and third 
(Ile) amino acid residues of model tetra-peptide were mainly responsible for this preference. 
By studying their effect on the fibrillogenesis process of Aβ(1–42) in comparison to Aβ(1–40), 
these receptors indeed inhibited the fibril formation in vitro through the selectively binding to 
the C-terminus.
49
 
 
Figure 7. Chemical structure of peptide receptor 7 
Besides hydrophobic tetra-peptides, polar tetra-peptide was also selected as target to study 
the binding with GCP based receptors. With the same principle as described above, they 
established another medium-sized but focused combinatorial receptor library.
50,51
 Quantitative 
experimental screening and statistical QSAR (quantitative structure–activity relationship) 
analysis demonstrated that artificial receptor 7 can bind with polar tetra-peptide without 
additional hydrophobic and metal-ligand interactions in water (Figure 7). The binding 
constant can reach 15,400 M
-1
 with tetra-peptide N-Ac-EKAA-OH as model. However, when 
the sequence of target peptide was inversed (N-Ac-AAKE-OH), the binding constant 
decreased 2-3 folds (6000 M
-1
) which underlined the importance of amino acid sequence in 
the design of artificial peptide receptor.  
2.1.2 GCP recognition of nucleotides and DNA 
In biological systems, peptides and proteins are not the only negatively charged 
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macromolecules. DNA and RNA are also anionic in nature due to the phosphodiester linkages 
between each nucleotide. Therefore, the superior anion binding ability of GCP moiety makes 
it very suitable to be applied to develop efficient DNA and RNA receptors. Schmuck et al. 
thus reported a series of GCP containing compounds which showed interesting properties in 
DNA binding and gene transfection studies. 
In 2008, they demonstrated that a novel pyrene-GCP cation 8 exhibited DNA binding 
ability in aqueous condition (Figure 8).
52
 Pyrene, a well-known polarity-sensitive 
fluorescence probe, was covalently linked to a GCP cation via a flexible alkyl chain. The 
length of linker was rational designed so that the pyrene moiety can intercalate into the 
nucleic acid double strands and meanwhile GCP moiety can still ion-pairing with the sugar 
phosphate backbone in the grooves. Also four carbon length of linker was not too flexible to 
lose too much binding energy in entropy. They tested the binding property of 8 at pH 5 and 7 
as GCP moiety was only protonated at pH 5.  
 
Figure 8. Chemical structure of molecules 8 and 9 
Preliminary study showed that molecule 8 exhibited strong affinity (log Ks = 5.1-6.0) with 
either DNA or RNA at pH 7 even though it was not protonated. Moreover, molecule 8 was 
able to differentiate dsDNA from dsRNA when it was protonated. At pH 5, the addition of 8 to 
all ds-DNA studied resulted in a significant decrease of the circular dichroism (CD) bands and 
induced a new strong CD (ICD) band. The changes in the CD bands, however, were 
completely different when ds-RNA was added. No ICD bands in the region of 300 - 360 nm 
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were observed in the CD spectra with the addition of ds-RNA. Instead, an excimer 
fluorescence emission was appeared exclusively upon the addition of RNA. Replacement of 
the four carbon linker in 8 to a shorter, rigid two carbon linker resulted in totally different 
spectroscopic responses.
53
 Molecule 9 (Figure 8) equipped with a neutral carboxylic-ester side 
chain interacted strongly with ds-DNA but only negligibly with ds-RNA. The CD spectrum of 
ds-RNA upon addition of 9 did not change significantly and no ICD bands were observed. In 
contrast to this, the addition of 9 to ds-DNA at either pH 5 or pH 7 resulted in pronounced 
changes. Further study revealed that 9 showed strong selectivity toward AT-DNA with respect 
to GC-DNA.  
 
Figure 9. Chemical structures of molecules 10 and 11 
Introduction of additional binding sites in the linker resulted in a different series of GCP 
derived receptors 10 and 11 (Figure 9).
54
 Titration studies suggested that these two 
compounds interacted strongly with ds-DNA, but only weakly with ds-RNA. The changes of 
fluorescence emission of 10 and 11 were remarkably dependent on the secondary structure of 
the polynucleotide added. Additionally, the heterocyclic moieties within the central part of 
linker switched the binding mode from intercalative (as described above for 8 and 9) to minor 
groove binding. For example, a negative ICD band at >330 nm was observed when 8 was 
added to ds-DNA due to the intercalation of the pyrene. On the contrary, addition of 10 and 11 
to ds-DNAs resulted in a positive ICD band at 330–350 nm, strongly indicated the positioning 
of pyrene within the minor groove of the double helix. Molecular modelling suggested that 
the heterocyclic moiety controlled the alignment of the molecules within DNA minor grooves 
by steric and hydrogen bonding effect. 
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Afterwards, Schmuck et al. reported a systematic study of the nucleic acid binding property 
of GCP - aryl derivatives.
55
 Three parameters were thoroughly examined: 1, the size of the 
aromatic ring conjugates (benzene, naphthalene, pyrene and acridine); 2, the length, flexibility 
and polarity of the linker in between; 3, the number of positive charges at different pH values. 
A series of compounds were thus designed and synthesized (Figure 10).  
 
Figure 10. Chemical structure of molecules 12 – 17 
Spectroscopic results showed that 12 and 13 did not significantly interact with DNA/RNA 
while compound 16 was able to intercalate with DNA which suggested a minimal requirement 
of aromatic surface area for nucleic acid binding. Introduction of more flexibility and 
additional positive charges in the linker enhanced the stabilization effect as compared by 8, 14 
and 15. At pH 5, the fluorescence of 15 was strongly quenched by G–C base pairs, whereas 
A-T or A-U base pairs induced a strong fluorescence increase. The quenching was probably 
caused either through aromatic stacking interaction or by electron-transfer through the stacked 
DNA helix. Molecule 15 was even able to produce a strong positive ICD band at 310 nm upon 
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the addition of ds-DNA at pH 7 owing to its additional charge. This property was not 
observed with other GCP derivatives. However, 15 did not show any specific fluorimetric 
response with ds-RNA. Most probably the steric hindrance and/or charge repulsion in 15 
prevented dimer formation within the ds-RNA major groove.  
Furthermore, Schmuck et al. also determined the biological activity of these compounds for 
their potential antiproliferative applications. Molecule 15, with its suitable size of aromatic 
ring and additional charges in the linker region, exhibited significantly better activity 
compared to other similar compounds. 
Schmuck et al. also prepared nucleic acid receptors with two GCP moiety modifications 
(Figure 11).
56
 The two GCPs were connected with oligo-amide linkers differing in the number 
of positive charges. The results again underlined the importance of charge interactions as all 
three compounds 18 - 20 showed significant better binding affinity at pH 5 than 7. Without 
the aromatic ring such as pyrene and acridine, those molecules exclusively bind to the minor 
grove of DNA and major grove of RNA. AFM experiments revealed a condensation process 
of DNA upon the addition of 19. 
 
Figure 11. Chemical structure of molecules 18 – 20 
  Inspired by the di-GCP receptors, Schmuck et al. designed a tweezer like GCP containing 
peptide based receptor 21.
57
 The new receptor was well soluble in water owing to the peptide 
scaffold. All nucleotides tested in this work (ADP, ATP, AMP etc.) bound strongly with 21 in 
pure water with binding constants varying from 10
4
 to 10
5 
M
-1
. Intriguingly, 21 favored the 
binding of adenosine monophosphate (AMP) over adenosine diphosphate (ADP) and 
adenosine triphosphate (ATP). This property was unprecedented since ATP has more negative 
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charges than AMP. The tweezer shape of molecule 21 provided a cavity within itself which 
obviously played an important role in the recognition process of the nucleotide. Molecular 
modelling suggested π-π stacking interactions facilitated the differentiation of nucleotides 
from phosphate or pyrophosphate. 
Besides oligonucleotides recognition, this kind of GCP containing receptor also showed 
astonishing ability in gene transfection. Green fluorescence protein (GFP) plasmid, a typically 
used reporter DNA in gene delivery studies, can bind with artificial peptide based receptor 21 
and 22 (Figure 14).
58
 The binding ability of both molecules was examined with an ethidium 
bromide (EB) displacement assay and isothermal titration calorimetry (ITC). Both receptors 
showed strong binding affinity with DNA with binding constants ranging from 10
6
 - 10
7
. Thus, 
they were able to condense DNA into tightly packed aggregated. However, only receptor 22 
with three armed binding sites successfully transferred GFP plasmid into cells and led to the 
expression of the protein. Further studies suggested that although both receptors transported 
plasmid into cells, only the plasmid transported by 22 escaped from endosome and reached 
the cell nucleus. The low pKa value of GCP moiety, around 7, may facilitate the release of 
plasmid DNA from endosome through a proton sponge effect. Nevertheless, peptidic receptor 
22 is among the smallest peptide based gene transfection vectors that was reported so far since 
these types of vector normally require at least eight positive charges to achieve decent 
transfection. 
 
Figure 12. Chemical structures of molecules 21 and 22 
Later, Schmuck et al. further extended the applications of GCP moiety in gene transfection. 
A combinatorial library was established to optimize the binding affinity with DNA.
59
 By 
screening a small but focused combinatorial library of 259 molecular tweezers equipped with 
GCP binding moieties, receptors with three orders of magnitude enhanced binding affinity 
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compared to original receptor 21 was identified. However, the significantly improved binding 
property with DNA did not guarantee a successful gene transfection as the best DNA 
receptors remained ineffective. Therefore, a lipophilic tail was added to those DNA receptors 
to facilitate the endosomal escape of DNA inside cells. A new class of artificial transfection 
vectors was thus obtained, which was comparable in efficiency to the current gold standard 
Lipofectamine 2000. Notably, the new vectors did not require additional helper lipid which is 
necessary for Lipofectamie 2000. 
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2.2 Gene delivery  
2.2.1 Gene therapy. 
Nucleic acids are the basic and central macromolecules regulating the necessary functions 
of life. The central dogma of molecular biology points out that any abnormal phenomenon 
regarding to nucleic acids such as incorrect splicing, mutation and abruption in the 
transcription and translation process have significant influences in body functions.  
A gene is a region of DNA that encodes a functional RNA or protein. Advances in 
molecular biology and biotechnology as well as the completion of the Human Genome Project 
in 2000 greatly improved our understanding of genetic diseases. Reports (WHO) suggested 
that more than 10,000 single gene disorders are related to diseases such as cystic fibrosis, 
cardiovascular and infectious diseases, Huntington’s disease, hemophilia, and sickle cell 
anemia. Therefore, it has long fascinated scientists to develop therapeutic strategies to treat 
these kinds of diseases at their genetic root. Moreover, the discovery of RNA interference in 
1998 highlighted the potentials of using genetic materials to treat disease which is now known 
as gene therapy.
60
 
Gene therapy can thus be defined as the utilization of genetic materials for the treatment of 
diseases. Most gene therapy utilized DNA that encodes a functional, therapeutic gene to 
replace a mutated gene. Other approaches include swapping/repairing an abnormal gene and 
regulating the degree to which a gene is turned on or off. The first attempt at gene therapy was 
performed by Martin Cline in 1980. However, it was until 1989 that the first clinical trial of 
gene therapy was conducted.
61
 Afterwards, the interests in developing successful methods for 
gene therapy grew rapidly as can be seen by the increase of the numbers of clinical trials 
(Figure 13).
62
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Figure 13. Numbers of clinical trials in gene therapy approved worldwide 1989-2012. Reference 62, 
copyright (2016) Wiley. Used with permission from John Wiley and Sons. 
The main advantage of gene therapy is that it has the potential to serve as a platform 
technology for treating various diseases since the concept of gene therapy is rather 
straightforward and adaptable. A variety of diseases such as cancer, cardiovascular and 
infectious diseases have been tested in clinical trials for gene therapy which makes it a very 
promising strategy in clinical applications.
11,63,64
 However, genetic materials such as DNA and 
RNA cannot penetrate into cells on their own and they are usually not stable for storage and 
application. Therefore, it is necessary to develop methods to deliver these genetic materials to 
desired target cells for the treatment of diseases.  
2.2.2 Gene delivery process 
A typical gene delivery process is mainly composed of three stages (Figure 14).
7
 The first 
step is the complexation and condensation of genetic materials by vectors which are usually 
positively charged. The resulting complexes or aggregates are taken up by cell which 
represents the second step. The crucial step is however the release of genetic materials from 
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endosome and lysosome before they are degraded by enzymes. 
 
Figure 14. Gene delivery process. 1) Complexation of plasmid DNA with vectors. 2) Cellular 
uptake of the DNA/vector complex.3) Endosomal release of DNA into cytosol and nucleus 
2.2.2.1 Complexation of genes   
Genetic materials such as DNA and RNA are subject to constant degradation. Due to the 
existence of electrostatic repulsions, they are not able to passively translocate through cell 
membranes. Condensation and complexation of genetic materials prior to transfection is thus 
the first step and perhaps also the most important step in gene delivery as it determines the 
fate of genes once entered into cell. 
Most transfection vectors bind to DNA by electrostatic interactions between cationic 
moieties on the vectors and anionic phosphate backbone in DNA. However, it is still not 
possible so far to determine the best formulation strategy for gene delivery as the 
complexation and transportation strategy largely vary between different kinds of vectors. The 
morphology and property of the resulting DNA-vector complexes, referred either as 
polyplexes, nanoplexes or lipoplexes, depend heavily on the type of transfection vector 
employed. For example, the condensation of DNA with cationic polymers leads to complexes 
with sizes proportional to the length and molecular weight of the polymer used.
9
 In the case of 
lipophilic vectors, the head group and hydrophobic domain both significantly influence the 
binding and condensation process of DNA.
65,66
 Furthermore, this process is also dependent on 
external conditions such as pH and ionic strength of the solutions.
67,68
 As consequence, it is 
necessary to investigate this process for each type of vectors respectively.  
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2.2.2.2 Cellular Uptake  
The main mechanism for the uptake of DNA/vector complexes and other polar 
macromolecules is endocytosis although other pathways such as membrane fusion have also 
been reported.
69,70
 During this process, the complexes are taken up by cell membrane and 
delivered into cells through vesicle structures.
71
 Therefore, these DNA complexes first need to 
approach the negatively charged phospholipid bilayer of the cell membrane, which is why it is 
usually important for a transfection vector to compensate the negative charge of the 
DNA-backbone.  
Endocytosis can be induced not only by unspecific charge interactions, but also by specific 
receptors located on cell membrane.
72
 Such process, i.e. receptor mediated endocytosis, is 
responsible for the internalization of growth factors, antibodies etc. The receptor mediated 
endocytosis usually involves clathrin, a protein crucial in the formation of coated vesicles 
which fuse into endosomes. This strategy can thus be applied for targeting DNA-vector 
complexes to a specific tissue. The complexes formed with specific targeting ligands such as 
folate can enter target cells through receptor mediated endocytosis.  
2.2.2.3 Endosomal Escape 
The normal fate of molecules in endosomes is rapid degradation for cell nutrition.
73
 This 
process starts almost immediately after the endosome is formed, as an ATP driven proton 
pump in the endosomal membrane decreases the pH from neutral to around 6. Due to the 
activity of V-ATPase, the pH of the vesicular media is further decreased to ca. 5. Those late 
endosomes can fuse with intracellular acidic vesicles (lysosomes) that contain a number of 
enzymes while the pH is continually decreased to ca. 4.5.
74
  
Several strategies have been reported for the release of genetic materials entrapped in 
endosome after endocytosis. One of the widely explored mechanisms is pH sponge effect. In 
polyplexes of DNA and a vector (e.g. PEI), which contains many primary, secondary and 
tertiary amine moieties in close proximity, it is likely that a large proportions of these amines 
are not protonated under physiological conditions. These free but still basic moieties can 
buffer the decreasing pH within the endosome, which will further promote V-ATPase activity. 
As more protons are pumped into the endosomal lumen, more counter ions (mainly chloride) 
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will influx as well. This process increases the osmotic pressure, and water will passively 
diffuse into the endosome which eventually leads to membrane rupture and release of the 
genetic materials. 
2.2.3 Non-viral gene transfection vector 
Two strategies have been developed so far to transport genetic materials into cells: physical 
methods and non-physical method.
75,7
 Physical methods such as gene-gun, electroporation are 
in most cases limited in lab studies.
76
 Non-physical methods then represent a more promising 
strategy in the application of gene therapy in clinical trials. .   
Gene transfection vectors can be classified into two categories: viruses based vector and 
non-viral based vector. Viruses are by far the most efficient delivery vectors in gene therapy.
77
 
In fact, most clinical trials conducted with gene therapy rely on retroviruses or adenoviruses 
to deliver the genetic materials as shown in Figure 15.
62
 Other viruses based vectors include 
adeno-associated viruses, vaccinia virus, lentiviruses, poxviruses and herpes viruses which 
differ in how well they transfer genes to the cells. Despite the overall high efficiency of virus 
based vector, their safety has been questioned the first day since their application. Problems 
and risks such as immune responses and virus transmission exist in the utilization of virus 
which prevents their further applications in gene therapy.  
 
Figure 15. Vectors used in gene therapy clinical trials. Reference 62, copyright (2016) Wiley. Used 
with permission from John Wiley and Sons. 
As consequence, there is more and more interest in the development of non-viral based 
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gene transfection vectors. It is now becoming a rather active area in the field of chemistry. 
Chemists have developed several kinds of non-viral gene transfection vectors such as cationic 
polymers, cationic lipids, cell penetrating peptides and nanoparticles over recent years. 
Among them, several systems have successfully been applied in molecular biology as a 
powerful tool to study the functions of various proteins and enzymes. For examples, 
commercially available cationic polymer polyethylenimine (PEI) and the cationic lipid 
Lipofectamine are both currently the standard reagents used in gene transfection studies. This 
will largely benefit the transition of gene therapy from lab studies to clinical trials and finally 
become a feasible method in the treatment of various diseases.   
2.2.3.1 Cationic polymer 
DNA molecule is highly negatively charged. Positively charged polymers were naturally 
considered first in the development of gene delivery vectors. In fact, most of early gene 
delivery studies utilized cationic polymers, such as poly-lysine (PLL), polyethylenimine (PEI) 
and polyamidoamine dendrimers (PAMAM) as vectors.
78
 
Polylysine 
Polylysine can be obtained in a large variety of molecular weights. It was previously used 
as delivery vector for small drugs due to its polypeptide nature which can be easily degraded 
by cells.
79
 As a poly-cation, its DNA condensation property has also been extensively studied 
even before the concept of gene therapy was introduced.
80,81
 
In 1991, Xiaohui Zhuo et al. reported that low molecular weight polylysine conjugated 
with phospholipid group was very effective in the transfection of mammalian cell lines.
82
 The 
unmodified polylysine, however, exhibited little activity. In 1996, Gottschalk S. et al. 
constructed DNA complexes with short synthetic peptides with a lysine rich peptide sequence 
and a pH-dependent endosomal releasing agent.
83
 Transfection with these complexes resulted 
in high-levels of gene expression in a variety of cell lines. However, it should be noted that in 
order to prepare homogenous, small and soluble DNA complexes, parameters such as salt 
concentration, charge ratio and size of polylysine must be thoroughly examined.  
Additional advantage of polylysine based polymers is that the epsilon amino group is a 
good target site to covalently attach ligands to realize receptor mediated gene delivery.
84
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Ligands such as folate, insulin and proteins have been covalently linked to the side chain of 
lysine. These systems have been tested not only in vitro, but also showed promising results in 
in vivo studies.   
Polyethylenimine (PEI) 
The application of polyethylenimine (PEI) in gene therapy is a landmark in the 
development of gene transfection vectors.
85
 Among the various poly-cations used for gene 
delivery, PEI is exceptional attractive due to its superior ability of DNA condensation and its 
potential in endosomal escape.  
 
Figure 16. Loosely condensed polymer/plasmid complexes consisting of linear PEI 22 kDa (left) 
compared to complexes with branched PEI 25 kDa (right). Reference 87, Copyright (2016) Wiley. 
Used with permission from John Wiley and Sons. 
PEI exists both in linear and branched forms as shown in Figure 16. Studies suggested that 
the secondary structures of PEI played an important role in the physicochemical and 
biological properties of the complexes with DNA.
86
 AFM studies showed that branched PEI 
can condense DNA more densely than linear PEI (Figure 16).
87
 The condensation process 
between PEI and DNA is mostly driven by electrostatic interactions. The release of counter 
ions from the backbone of DNA upon binding is considered to be the main driving force for 
the formation of PEI/DNA complex.  
It is now well known that endocytosis is the major cellular uptake pathway for PEI 
mediated gene delivery. The size of the complexes formed between PEI and DNA are 
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normally below 200 nm which is ideal for endocytosis. Consequently, most of the DNA 
transfected with PEI stay entrapped in endosomes. Incubation of cells with bafilomycin, an 
endosomal escape inhibitor, completely abolished the transfection ability of PEI which further 
confirmed the importance of endocytosis in PEI mediated gene delivery. Recent study showed 
that there were two kinds of PEI in DNA/PEI complex, the bound chains and the free 
chains.
88
 The bound PEI was mainly responsible for the condensing of DNA to form 
DNA/PEI complex. As the N/P ratio increased, most of PEI chains existed as free chains in 
DNA complex which not only accelerated the cellular uptake process, but also facilitated the 
endosomal release of DNA by preventing the development of late endosomes. This might be 
the reason that long chains PEI are more effective than short ones in gene transfection.  
In general, the transfection efficiency of PEI is quite high which makes it suitably to be 
applied as a standard in gene transfection experiment. However, the severe toxicity of PEI 
hindered its further application in clinical trials. It has been shown that even in in vitro 
experiments, 70% of cells died because of the transfection with PEI. The toxicity of PEI is 
closely related to its molecular weight and structure.
89
 Low molecular weight PEI has lower 
toxicity in cell studies. Increasing the degrees of branches of PEI leads to higher toxicity.  
As consequence, several strategies have been developed to improve the gene delivery 
property of PEI. The most common used method is the conjugation of biocompatible polymer 
polyethylenglycol (PEG) to PEI which is the so-called “PEGylation”.90,91 Depending on the 
nature of the chemical bond in the conjugation, PEG-PEI copolymers can be classified into 
non-biodegradable and biodegradable polymers.
92
 Non-biodegradable polymers, which are 
usually constructed with urethane and urea, are naturally more stable and easier to synthesis. 
However, their pharmaceutical behavior after cellular uptake would become a severe issue. 
On the other hand, biodegradable PEG-PEI copolymers have attracted more interests recently. 
Thomas Kissel et al. reported that by linking several low molecular weight PEI blocks with 
oligo (L-lactic acid-co-succinic acid), a water-soluble PEG-PEI copolymer was constructed 
which could be degraded via base-catalyzed amide bond cleavage.
93
 Besides the lower 
toxicity, the new polymer showed significant enhancement in the transfection efficiency 
compared to unmodified PEI. PEGylation also increased the solubility of PEI in water and its 
biocompatibility. Moreover, the application of PEG has been reported to reduce the 
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immunogenicity of drug delivery systems. The interaction of cationic polymer PEI with 
proteins can be inhibited with the shield from PEG shell.
91
 This strategy is thus very 
promising in the long term application of PEI based gene delivery vectors.  
Besides the modification with PEG, disulfide linkage has also been introduced to 
construct redox responsive PEI based gene delivery vectors. The application of disulfide bond 
provides an outstanding method to utilize the redox environment inside cells (Figure 17).
94
 
DNA, which was condensed with PEI prior to cellular uptake, can be easily released into 
cytosol through the redox reaction of disulfide bond with glutathione (GSH). Qi Peng et al. 
reported that by utilization of ring opening reactions, thiol group was introduced into low 
molecular weight PEI to obtain PEI-SH.
95
 Subsequently oxidation gave rise to disulfide linked 
cationic polymer PEI-SS-PEI. The resulting biodegradable polymer showed a lower toxicity 
and enhanced transfection efficiency even compared to high molecular weight PEI. Moreover, 
PEGylation often resulted in the decease of transfection efficiency of cationic polymers. 
Introduction of disulfide bond into PEGylated polymers can thus increase their transfection 
efficiency. Copolymers constructed with polylysine, PEG and PEI through disulfide bond 
showed successfully delivery of small interfering RNA (siRNA) into cells.
96
 
 
Figure 17. Schematic illustrations of the gene delivery by bio-reducible polymeric vector. Reference 
94, Copyright (2016) Wiley. Used with permission from John Wiley and Sons. 
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Mallory A. Cortez et al. recently reported another interesting strategy to improve the gene 
delivery property of PEI.
97
 A set of cyclic PEIs and its exact linear analogues with same 
molecular weight were designed and synthesized. Transfection experiments showed that the 
cyclic PEIs exhibited significantly better efficiency with lower cytotoxicity compared to 
linear PEIs. This result highlighted the importance of secondary structure of polymer in the 
efficiency of PEI mediated gene transfection. 
Other polymers 
Besides polylysine and PEI, other types of cationic polymers such as carbohydrate based 
polymers,
98
 linear poly (amidoamine)
99
 and dendrimer based vectors
100
 have also been applied 
for gene delivery. Utilization of the unique property of different polymers can provide 
interesting functions in gene delivery system. Introduction of targeting ligands after the 
complexation of polymer with DNA can also be achieved. For example, M. E. Davis et al. 
firstly introduced linear cationic cyclodextrin polymers in the development of gene delivery 
vectors.
101
 The new polymers were able to bind DNA through electrostatic interactions and 
formed nanoparticles around 100 nm in size. This system showed comparable transfection 
efficiency to PEI and Lipofectamine and also exhibited significant less cytotoxicity in several 
cell lines.  
Later, they further extended this system to siRNA delivery as a result of the discovery of 
RNAi therapy (Figure 18).
102
 The formulation for siRNA delivery is featured with three 
components: the key is cationic cycoldextrin polymers which provide multiple functions such 
as complexation with RNA and protection against nuclease degradation. Cyclodextrins are 
incorporated in the backbone of the polymer which is linear and water soluble. Other two 
components are adamantane functionalized PEG (PEG-AD) and Transferrin (Tf-PEG-AD). 
The inclusion of adamantane with cyclodextrins decorates PEG chains on the surface of 
cyclodertein-RNA nanoparticles. PEGylation then provides steric protection for systematic 
delivery of RNA. The addition of transferrin could target these nanoparticles to cancer cells 
which are known to overexpress transferrin receptors. Notably, the sizes of the nanoparticles 
formed between polymer and siRNA are important. By using a two vial formulation strategy 
(Figure 18b), nanoparticles around 70 nm in size were obtained which proved to be best in 
delivery. In 2008, they demonstrated the first targeted delivery of siRNA in human trials with 
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this system. Experimental therapeutic drug was initiated in phase Ι trial and the first patient 
was treated in May of 2008. 
 
Figure 18. (a) The delivery components: cyclodextrin-containing polymer (CDP), adamantane 
(AD)-PEG conjugate, human transferrin (Tf) conjugated adamantane (Tf-PEG-AD). (b) The 
formulation contains two vials, one with siRNA and the other with the delivery components. Reprinted 
with permission from Reference 102. Copyright (2016) American Chemical Society." 
2.2.3.2 Cationic lipids 
Cationic lipids are arguably the most widely used non-viral vectors in the field of gene 
delivery.
103
 They normally contain a cationic head group and one or several hydrophobic tails 
(Figure 19).
69
 The amphiphilic nature of such cationic lipids results in the formation of 
structures such as micelle and vesicle in water solutions. The head group is mainly 
responsible for the binding with DNA and the hydrophobic tails can also facilitate the 
condensation of DNA. Genetic materials can thus be entrapped into this compartment and be 
transferred into cells.  
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Figure 19. Schematic illustrations of cationic lipid gene delivery vector. Adopted with permission 
from Reference 65. Copyright (2016) American Chemical Society." 
Utilization of these carrier systems for gene delivery can date back to the early 1980s. 
Claude Nicolau et al. reported that a fragment of plasmid DNA was isolated and entrapped in 
liposomes of different phospholipid compositions.
104
 The incubation of DNA-liposome with 
synchronized cells resulted in the uptake of DNA with efficiency around 2000 molecule per 
cell. In 1987, Philip Felgner et al. firstly reported a synthetic unsaturated cationic lipid that 
can successfully transfer plasmid DNA into a variety of cells with high efficiency.
105
 Cationic 
lipid N-[1-(2, 3-dioleyloxy) propyl]-N,N,N-trimethylammonium chloride (DOTMA, Figure 
19) interacted strongly with DNA and 100 % DNA entrapment was realized. This discovery 
inspired many researchers to extend the scope of cationic lipids for gene delivery. A variety of 
cationic lipids with different chemical structures and physical properties has been reported. 
However, most cationic lipids reported so far require a “helper lipid” to fulfill their function 
in gene delivery experiments. Neutral lipids such as cholesterol
106
, 
dioleoylphosphatidylethanolamine (DOPE)
107
 and dioleoylphosphatidylcholine (DOPC)
108
 are 
often additionally added to the complexes formed between cationic lipids and DNA. It is the 
appropriate combination of cationic lipid, DNA and helper lipid that determines the final 
formula for cationic lipid mediated gene delivery.  
The role of helper lipid in transfection is however in debate. Some evidence suggested that 
the addition of DOPE determined the structural transition pH of the final complexes when the 
pH decreased from 7 to 5 inside cells.
109
 Others pointed out that the presence of helper lipid 
such as cholesterol and DOPE facilitated the DNA complexes to adopt a fusogenic, inverted 
hexagonal phase which promoted the release of DNA from endosome to cytosol.
110,111
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Nevertheless, it is clear without doubt that helper lipids are in most cases necessary for the 
gene transfection mediated by cationic lipids. Therefore, all the cationic lipid systems used in 
gene transfection experiments mentioned in this context are performed with the addition of 
helper lipids unless otherwise noted.  
The positively charged head groups are crucial in the DNA complexation process. 
Depending on the structure of the hydrophilic head groups, cationic lipids can be roughly 
classified as quaternary ammoniums, guanidiniums and other head groups based.
65
 
Quaternary ammoniums 
Quaternary ammoniums are by far the most often used head groups in cationic lipid 
mediated gene delivery. A number of elegant cationic lipid transfection systems are equipped 
with quaternary ammoniums such as DOTAP, DDAB and CTAB (Figure 20).
112
 The 
positively charged head groups provide sufficiently strong binding ability with negatively 
charged DNA. However, it has been demonstrated that the transfection efficiency of these 
types of cationic lipids is closely related to the hydration ability and charge density of the 
ammonium head group region. Therefore, two strategies have been developed to improve 
their efficiency: addition of hydroxyl groups and introduction of more than one charged 
groups. 
 
Figure 20. Chemical structures of cationic lipid gene delivery vector 
The addition of hydroxyl groups on the hydrophilic domains of cationic lipids could 
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increase their performance in gene delivery. DORIE and DORI (Figure 20), with additional 
hydroxyl group on the head groups demonstrated better transfection ability in HeLa cell 
lines.
69,113
 It was proposed that the hydroxyl group could hydrogen-bond with cell membrane 
or simply enhancing the electrostatic interactions to achieve better affinity. Also the bilayer 
structures of these cationic lipids benefited from the intermolecular hydrogen bonding 
between each molecules and the interaction with aqueous phase. The hydroxyl groups might 
also involve in the binding with DNA through hydrogen bonds. As consequence, cationic 
lipids bearing more hydroxyl groups in the head groups were designed and synthesized. For 
example, Rajkumar Banerjee et al. reported a series of non-glycerol-based transfection lipids 
containing two hydroxyethyl groups in the head groups.
114
 The transfection efficiency of these 
cationic lipids was even better than Lipofectamine, the current golden standard in transfection 
experiment. They further studied the possibility of using sugar molecules as a source of 
hydroxyl groups in the head groups.
115
 The complexation behaviors with DNA were indeed 
different from other cationic lipids without hydroxyl groups. Compared to cationic lipids with 
two hydroxyl groups, these newly developed lipids showed an improvement in the 
transfection efficiency and also exhibited lower cytotoxicity.  
 
Figure 21. Chemical structures of cationic lipid 23 and 24 
Another often used strategy is to introduce more positive charges in the head group which 
lead to the formation of dimeric lipids. Introduction of additional charges could increase their 
binding affinity with DNA. Howard Rosenzweig et al. reported a new class of cationic lipids 
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23 and 24 for mediating transfection of DNA in mammalian cell lines (Figure 21).
116
 The 
advantage of these reagents is that they do not need helper lipids in transfection process. Their 
transfection efficiency was comparable to commercial available transfection reagents such as 
Lipofectin, Lipofectace and Lipofectamine. The spacer between the two ammonium groups in 
23 and 24 significantly influenced the physiochemical property of the resulting complexes. 
Additionally, head groups bearing three or four positive charges are also very promising in the 
application of gene delivery vectors.
117
 For example, the low micellar sizes and high critical 
micellar concentration endowed by the higher charge density are very attractive for the 
development of cationic lipid based gene delivery system. 
Guanidiniums 
The amino acid sequences of natural DNA-binding proteins and peptides such as 
protamines are featured with their exclusive use of arginine.
118,119
 Protamines are small, 
highly positively charged peptides used by cells to package DNA at very high densities in 
sperm nuclei. Of the 32 amino acids of salmon protamine, 21 are arginines. Bovine protamine 
has 26 arginines of its 50 total amino acids and human protamines also consist half of arginine 
residues in their sequences. The guanidinium cation in the side chain of arginine, with pKa 
around 12, is prominently positively charged under physiological conditions. Moreover, 
guanidinium cations could form bidentate hydrogen bonds with oxoanions such as the 
phosphodiester linkage in DNA backbone. Therefore, cationic lipids with guanidinium head 
groups often possess high DNA binding affinity and result in highly condensed DNA 
complexes compared to that of ammonium head group based cationic lipids. A number of 
guanidinium head group based cationic lipids thus have been explored in gene delivery 
experiments.
120
 
 
Figure 22. Chemical structures of guanidinium based cationic lipids 
In 2004, Jean Herscovici et al. reported the synthesis of new cationic lipids with a 
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hydrophobic tails connected to guanidinium moiety by an unsaturated glycoside scaffold. 
These lipids can efficiently compact DNA to form stable lipoplexes.
121
 Joyeeta Sen et al. then 
demonstrated that guanidinium containing lipids were rather effective in gene transfection 
experiments (Figure 22).
122
 The efficiencies of cationic lipids 25 - 27, in particular, were 
better than that of Lipofectamine in the transfection of several cell lines. In comparison, lipids 
28 - 30 were less effective due to the absence of additional positive charges in the head groups. 
Further introduction of tertiary amine center in the head groups allowed more efficient siRNA 
binding compared to other cationic lipids.  
 
Figure 23. Chemical structures of guanidinium based cationic lipid 31 and 32 
T-shaped head groups with two guanidinium cations were first designed and synthesized by 
Lehn et al. in 1996 (Figure 23).
123
 The utilization of cholesterol as hydrophobic domain 
provided their unique property in the interaction with cell membranes. 
Bis-guanidinium-tren-cholesterol (31, BGTC) was very efficient in gene transfection when it 
was applied as micellar solution. When it was formulated with neutral helper lipid to form 
liposome, it was able to efficiently transfect airway epithelial cells in vivo. They also 
incorporated an acid sensitive acylhydrazone linkage to connect the bis-guanidinium head 
group to an unsaturated cholest-4-enone (32).
124
 Acid catalyzed hydrolysis was confirmed for 
BACKGROUND INFORMATION 
31 
32 which implied their potential application in acidic environment such as tumor tissue. The 
new series of T-shaped bis-guanidinium cationic lipids displayed significant less cytotoxicity 
and were able to transfect cells both in vitro and in vivo. 
Recently, Charlotte Gehin et al. demonstrated a dynamic cationic lipids library to screen for 
the delivery of siRNA in HeLa cell lines and human primary fibroblasts.
125
 This method 
provided a rapid access to fairly large libraries of complex structures and possible ways to 
assist uptake and minimize toxicity. Both guanidinium and ammonium cation head groups 
were applied in the library. The best structure found in this study knocked out 60% of target 
gene compared to 30% from Lipofectamine. More importantly, the best hit was not 
predictable from literature reports and thus underlined the importance of conceptually 
innovative screening approaches.    
Other head groups 
 
Figure 24. Chemical structures of pyridinium based cationic lipid 33-36 
Besides ammonium and guanidinium head groups, there are also several other types of 
positively charged head groups. For example, pyridine and pyridinium are among the most 
frequently used hetercyclic polar head groups in the design of cationic lipids.
65
 In 2000, 
Engberts and colleagues reported the synthesis of a series of pyridinium based cationic lipid 
amphiphiles (33 – 36) to examine the influence of structural parameters on transfection 
experiments (Figure 24).
126
 The report showed that all the studied compounds can form stable 
and well-defined complexes with DNA. The introduction of additional charges in the head 
group and unsaturation of the hydrophobic domain significantly affected the transfection 
efficiency in eukaryotic cells. They further introduced bio-degradable ester bond to connect 
the pyridinium and hydrophobic tails.
127
 The new lipids demonstrated better transfection 
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efficiency than their parent lipids through influencing both the overall morphology and DNA 
releasing ability of the formed lipoplexes. Other kinds of linkage have also been tested such 
as ether, amide, urethane, or phosphonate ester groups.
128
 
Imidazole contains an amine with pKa within the physiological range of 4.5 to 8. Thus, 
Vladimir Budker et al. designed a class of pH sensitive cationic lipids with imidazole as head 
group.
129
 Despite that there were no permanent positive charges in the head groups, these 
lipids were able to condense and incorporate DNA into liposomes. Transfection efficiency 
was naturally dependent on the acidification process of endosome. Interestingly, lipids bearing 
imidazole head groups can also be used as helper lipid to replace DOPE in cationic lipid 
mediated gene transfection. Mathieu Mevel et al. demonstrated that these new helper lipids 
can improve the transfection by a factor of up to 100 compared to the usage of DOPE as 
co-lipid.
130
  
Neutral or low cationic surface charged head groups represent another interesting class of 
cationic lipids. Ammonium, guanidinium and other fully positively charged head groups are 
mostly suitable for DNA binding. However, they also lost their protonation abilities once 
inside cells which could hinder the release of DNA to cytosol. Therefore, primary, secondary 
and/or tertiary amine head groups have been developed which process better buffering 
property to facilitate endosomal release. The well-known and commercially available 
transfection reagent DC-Chol with a tertiary amine head group is a typical example.
131
 It was 
reported by Huang Leaf et al. in 1991 and showed remarkable transfection efficiency in a 
variety of cell lines. This reagent was rather easy to synthesize and proved to be stable for 
several weeks.  
2.2.3.3 Cell penetrating peptides 
Cell penetrating peptides were first discovered in 1988 when it was observed that HIV-Tat 
regulatory protein could efficiently penetrate into cells.
132
 Bernard Lebleu et al. then 
successfully identified that a short truncated HIV-1 Tat protein basic domain rapidly 
translocated through cell membrane and accumulated in nucleus.
133
 The result was very 
inspiring because they demonstrated that all peptides containing this basic domain can 
penetrate cell membrane within 5 minutes with concentration as low as 100 nM. A secondary 
BACKGROUND INFORMATION 
33 
structure such as a full α-helix was not required in cellular uptake. In the meantime, parallel 
studies revealed another class of peptides originating from the homeodomain of Antennapedia 
(a Drosophila homeoprotein) which was able to penetrate cells in a receptor-independent 
manner.
134
 In 1994, Alain Prochiantz et al. found that the third helix of the homeodomain of 
Antennapedia was necessary and sufficient for the translocation through cell membrane.
135
 A 
16 amino acids peptide was thus discovered and later named “penetratin”.  
Several families of cell penetrating peptides derived from natural occurring proteins are 
known today such as transportan
136
, signal sequence based peptides
137
 and arginine 
nonamer
138
 (Figure 25). The discovery of cell penetrating peptides is particular interesting in 
the field of gene delivery. Most gene delivery systems (polymer, lipid etc.) suffered from 
severe toxicity either in vitro or in vivo. Peptides such as arginine oligomers then provide a 
useful tool to transfer genetic materials into cells due to the cationic nature of most cell 
penetrating peptides. Their compatibility with cells is in most cases significantly better than 
other transfection systems. Additionally, these peptides can penetrate cells even at 4
o
C and 
other conditions which prevent normal endocytosis. Their penetration process is in most cases 
not receptor mediated thus it is cell type unspecific. This advantage makes cell penetrating 
peptides interesting as universal vectors for a variety of genetic materials.  
 
Figure 25. Typical cell penetrating peptides 
HIV-Tat peptide 
One of the earliest utilization of Tat peptide for gene delivery experiment was demonstrated 
by Anna Astriab Fisher et al. through the conjugation of antisense oligonucleotide in 2000.
139
 
The antisense oligonucleotide was designed to inhibit the cell surface expression of 
P-glycoprotein. Effective inhibition was realized with submicromolar concentrations of 
Tat-antisense conjugates in the presence of serum, in contrast with other approach of nucleic 
acid delivery. Akiko Eguchi et al. later extended the application of Tat peptide to DNA 
BACKGROUND INFORMATION 
34 
delivery.
140
 Recombinant phage particles displaying Tat peptide on their surfaces were 
constructed and mammalian genes were incorporated as reporter. Significant expression of 
phage marker genes was induced when the cells were exposed to Tat-phage. Additionally, 
Carsten Rudolph and coworkers constructed several oligomers of Tat peptide for gene 
delivery.
141
 The oligomers showed excellent ability to compact plasmid DNA to particles with 
sizes ranging from 70 to 90 nm depending on the charge ratio. Transfection efficiency was 6 
fold higher than polyarginine. Remarkably, when DNA was pre-compacted with Tat peptides 
and PEI, the transfection efficiency was 390 fold higher than commercial vectors.  
Despite the initial success, gene transfection mediated by Tat peptide alone remained low 
effective. Therefore, Vladimir P. Torchilin et al. prepared a series of liposomes with different 
composition of Tat peptides on their surfaces.
142
 The modification with Tat peptides resulted 
in the cellular uptake of relatively large liposomes (200 nm). Further decoration with 
PEG-2000 abolished the internalization of liposomes which underlined the importance of 
direct contact between Tat peptides with cell membrane. These liposomes can transfect mouse 
NIH cell lines and rat H9C2 cardiomyocytes with a high efficiency in vitro. Moreover, 
intra-tumoral injection of TAT-liposome–DNA complexes into the Lewis lung carcinoma 
tumor of mice resulted in the expression of gene in situ.
143
  
  The application of Tat peptide in gene delivery is mostly limited by its poor endosomal 
releasing ability and the instability of peptide/DNA complexes. Shu Wang et al. thus modified 
Tat peptides with histidine and cysteine residues which could promote endosomal escape of 
DNA.
144
 Up to 7000 fold enhancement in the transfection efficiency of Tat peptide fused with 
10 histidine residues was observed compared to original Tat peptide. Further introduction of 
cysteine led to disulfide bond formation after air oxidation upon binding to DNA. This 
property improved the stability of the resulting complex which eventually resulted in an even 
better transfection. Recently, Erlei Jin et al. modified the lysine residue in Tat peptide with 
succinyl amides (
a
Tat) to inhibit its nonspecific interactions in the blood compartment (Figure 
26).
145
 The function of Tat peptide was thus deactivated in normal conditions. Once 
a
Tat 
peptide reached the acidic tumor interstitium or internalized into cell endo/lysosomes, a quick 
hydrolysis from the succinyl amides were triggered due to the low pH and thus reactivated Tat 
peptides.   
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Figure 26. Amidization of TAT’s primary amines and their acid-triggered hydrolysis. Adopted with 
permission from Reference 145. Copyright (2016) American Chemical Society." 
Seiichi Yamano et al. combined the advantages of cationic polymers and Tat peptide to 
develop a novel gene transfection vector.
146
 Polyethylenimine (see chapter 2.2.3.1), a cationic 
polymer widely studied as an efficient gene delivery vector, was formulated with mTat 
peptide modified with histidine and cysteine residues. The sizes of the particles formed 
between mTat/PEI/DNA complex and DNA were significantly smaller than that of mTat or 
PEI alone. As consequences, mTat/PEI produced 5-fold improvement in transfection 
efficiency through caveolae-mediated endocytosis. Experiments in vivo showed that animals 
administered with mTat/PEI/DNA intramuscularly exhibited a rather long luciferase 
expression about seven months without any associated toxicity.  
Arginine oligomers 
Inspired by the discovery of HIV Tat peptides, chemists also developed arginine oligomers 
which showed excellent cell penetration ability in a variety of cell lines. Studies suggested 
that at least six positive charges are required for arginine oligomers to penetrated cell 
membrane.
14
 Despite the controversies as how these extremely polar peptides successfully 
translocate through cell membrane, their gene transfection abilities were tested to be 
comparable to other peptides. Moreover, the rather simple peptide sequences of arginine 
oligomers make them attractive in the hybridization with other type of transfection vectors 
such as polymers and inorganic nanoparticles. 
Arginine oligomers previously proved to be very effective in cellular uptake. However, 
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their DNA transfection efficiency was far less than commercial reagents such as Lipofecamine. 
In 2001, Shiroh Futaki et al. modified a series of arginine oligomers with different 
hydrophobic groups on the N-terminus (Figure 27).
16
 It was found that stearyl-R8 formed 
significantly larger complexes with DNA than polyarginine and Lipofectamine. Transfection 
mediated with stearyl-R8 was increased approximately 100 times to reach the same order of 
magnitude as that of Lipofectamine. The differences in the efficiency of transfection between 
modifications with stearyl, lauryl and cholesteryl were however negligible. Later, it was 
discovered that stearyl-R8 could also be used to achieve efficient siRNA delivery into primary 
hippocampal neurons via endosomal pathway.
147
 The transfection efficiency was comparable 
with cationic liposome while being less cytotoxic in primary neurons. 
 
Figure 27. Modification of arginine oligomers with hydrophobic groups. Adopted with permission 
from Reference 16. Copyright (2016) American Chemical Society." 
Another interesting application of arginine octamer (R8) is to decorate multifunctional 
envelop nano-device (MEND) as shown in Figure 28.
148
 MEND device was prepared with a 
programmed packaging approach. Firstly, DNA was condensed with polycation such as 
polylysine. Afterwards, a lipid film hydration process was performed for the electrostatic 
binding of condensed DNA. Final sonication to package the condensed DNA with lipids 
resulted in the multifunctional envelop nano device. R8 peptide was incorporated into MEND 
to enhance the transfection ability. The resulting R8-MEND then produced a high transfection 
activity without cytotoxicity.
149
 Its transfection mechanism was found to be dependent on 
micropinocytosis. Furthermore, the condensation ability of polylysine, stearyl-R8 and 
protamine was examined in order to deliver siRNA into cells. Only stearyl-R8 was able to 
condense siRNA to form nanoparticles around 100 nm. 
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Figure 28. Multifunctional envelope-type nano-device (MEND) modified with stearyl-R8. 
Reprinted from Reference 148, Copyright (2016), with permission from Elsevier 
Besides arginine octamer, another representative arginine rich cell penetrating peptide, 
arginine nonamer (R9), proved to be effective in the delivery of siRNA. Won Jong Kim et al. 
conjugated cholesteryl group on the N-terminus of R9.
150
 Simple complexation of siRNA with 
Chol-R9 efficiently delivered siRNA into cells in vitro. Local administration of 
Chol-R9/siRNA complex in a mouse model led to the regression of tumor. Interestingly, Priti 
Kumar et al. demonstrated a transvascular delivery of small interfering RNA to central 
nervous system with a hybrid R9 peptide.
151
 R9 was fused to the C-terminus of RVG, a short 
peptide derived from rabies virus glycoprotein (RVG) that could specifically bind to the 
acetylcholine receptor expressed by neuronal cells, to enable siRNA binding. After 
intravenous injection into mice, the chimeric peptide RVG-R9 could delivery siRNA across 
blood brain barrier to neuronal cells. Moreover, repeated injection of RVG-R9/siRNA complex 
did not induce any inflammatory responses which implied its potential application in clinical 
trials. 
Other types of peptides 
Other types of cell penetrating peptides such as penetratin, KALA peptides and transportan 
have also been applied in gene delivery experiments. For examples, B. Allinquant et al. first 
demonstrated the application of penetratin peptide, originated from the third helix of the 
homeodomain of Antennapedia, in the delivery of antisense oligonucleotide designed to block 
the expression of amyloid precursor protein.
152
 Additionally, antisense oligonucleotide aiming 
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at luciferase reporter gene was also covalently conjugated to penetratin peptide.
153
 The 
antisense-penetratin conjugate entered into cells over a period of hours in a dose-dependent 
manner. Interestingly, the conjugate displayed similar binding affinity and selectivity 
compared to those of unmodified oligonucleotides.  
David R. Corey et al. conjugated penetratin with a novel type of DNA analogue, peptide 
nucleic acid (PNA).
154
 Peptide nucleic acids are featured with their backbones composed of 
repeating N-(2-aminoethyl)-glycine units linked by peptide bonds. About 99% of cells were 
transfected with PNA-penetratin conjugate at a concentration as low as 500 nM, an efficiency 
rarely observed with other transfection techniques. Jingsong Ou et al. reported that penetratin 
could be applied to increase the transfection efficiency of Lipofectamine 2000 when it was 
linked with a water soluble amphiphilic helical peptide.
155
 However, the new conjugate must 
be directly associated with liposomes prior to transfection for optimal transfection of 
endothelial cells. In 2008, Helene L. Åmand et al. demonstrated that when all the lysine 
residues of penetratin were replaced with arginine residues, cellular uptake was increased. The 
internalization occurred predominantly through micropinocytosis.
156
 
Tara B. Wyman et al. designed and prepared a cationic amphipathic peptide KALA 
(WEAKLAKALAKALAKHLAKALAKALKACEA) which exhibited DNA binding 
ability.
157
 A conformation transformation from random coil to amphipathic α-helical of KALA 
was identified when the pH was increased from 5.0 to 7.5. Thus, it has a strong propensity for 
α-helix conformation that positions seven lysine residues on one face to mediate a reversible 
association with DNA. Once the DNA was compacted, it was able to cross the cell membrane 
to enter the cytoplasm. This peptide could also induce membrane leakage as evidenced by the 
fully release of entrapped dyes from neutral liposomes.  
Antonio Bernad et al. later prepared another cell penetrating peptide RAWA 
(RAWARALARALRALARALRALAR) in analogue to KALA peptide.
158
 Given the 
favorable structural and pKa properties of the guanidinium group for DNA interaction, the 
lysine residues were replaced with arginine. Tryptophan was introduced in the third position 
due to the finding that a tryptophan residue near N-terminus appeared to enhance gene 
transfection property. RAWA exhibited an improved DNA condensation effect and weaker 
membrane destabilization ability compared to KALA. The diminished membrane perturbation 
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property resulted in a less cytotoxicity which makes it suitable for gene transfection 
experiment. Transfection efficiency with RAWA was comparable to a number of commercial 
reagents such as Lipofectamine Plus and Superfect.  
2.2.3.4 Inorganic nanoparticles  
Inorganic nanoparticles are generally suitable to carry drug molecule into cells due to their 
tunable sizes, facile modification, and easy preparation.
159
 The chemistry of inorganic 
nanoparticle is well established and thus provides an abundant choice of particles with 
different properties. Another advantage of inorganic nanoparticles is their inherent physical 
property. Most inorganic particles have rather rigid and stable framework which is more 
resistant to environmental stimulus like pH, heat and mechanic stress.
160
 The high surface area 
could also improve the loading amount of drug molecules. More importantly, the unique 
physical properties of inorganic nanoparticles which cannot be obtained by other kinds of 
vectors provide several additional benefits. For example, gold nanoparticles can be used in 
imaging related areas such as computed tomography and surface enhanced Raman 
spectroscopy.
161
 Magnetic nanoparticles such as iron oxide provide further manipulation 
through magnetic field which could benefit clinical applications.
162
  
Inorganic nanoparticles usually cannot work as gene transfection vector by itself due to the 
lack of condensation ability of genetic materials. Therefore, chemical and/or biological 
modification is necessary in order to achieve efficient condensation. Cationic moieties are 
thus decorated onto the surface of inorganic nanoparticles. The modification strategy usually 
depends on the nature of nanoparticles. Gold nanoparticles generally utilize thiol chemistry to 
conjugate cationic species onto its surface while charged nanoparticles such as silica 
nanoparticles prefer co-condensation or grafting.
163,164
 Inorganic nanoparticle provides an 
ideal platform for the hybridization of different kinds of transfection vectors. Cationic 
polymer, liposome and cell penetrating peptides have all been successfully applied. 
Inorganic nanoparticle – Polymer hybrids 
Nanoparticles decorated with cationic polymers are well studied in gene transfection 
experiments and easy to obtain. Such a system has a very good condensing ability towards 
genetic materials and is usually water soluble. Among them, magnetic nanoparticle has 
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become the most appealing strategy to achieve efficient and target transfection. Transfection 
mediated by magnetic nanoparticle was pioneered by Planck and coworkers who also coined 
the term ‘magnetofection’.165 Magnetofection (MNP) is usually rather fast with high 
efficiency and low cytotoxicity. As shown in Figure 29, superparamagnetic nanoparticles are 
applied as the core and cationic polymer is decorated to their surfaces. During the transfection 
process, magnetic nanoparticles can be manipulated by the application of magnetic gradient 
fields.
166
 This unique property offers the possibility for this method to treat local diseases.  
 
Figure 29. Schematic representation of magnetofection. Plasmid conjugated magnetic nanoparticles 
moved to the cell surface on the magnetic sheet upon application of magnetic force. Then, the 
magnetic force drove this complex toward and into the target cells. Journal of Artificial Organs, 
Efficient transfection method using deacylated polyethylenimine-coated magnetic nanoparticles, 14, 
2011, 215, Daisuke Kami, With permission of Springer 
Although numbers of surface modification strategies have been developed for magnetic 
nanoparticle based gene delivery vector, cationic polymer polyethylenimine (PEI) remains to 
be the most efficient modification reagent and is often used in combination with other 
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polymers.
167
 However, its role in magnetofection still remains to be discovered. Amal Rose et 
al. showed that PEI played a critical role in controlling the sizes and surface charges of MNP 
vectors as well as DNA binding.
168
 The coating with PEI resulted in smaller aggregates with 
narrower size distribution compared to uncoated ones probably because of the repulsions 
caused by the electrostatic charges and steric stabilization. Additional PEI might be required 
for a decent transfection although contrary result has also been reported with iron-oxide silica 
nanoparticles.
169
  
Besides linear PEI modified magnetic nanoparticles, dendrimeric polymer has also been 
applied. Transfection efficiency depends heavily on the generation of dendrimer and the 
presence of magnetic field.
170
 Huang Shiwen et al. prepared a six generation poly-amidoamine 
dendrimer modified superparamagnetic nanoparticle which can be used to improve the 
transfection efficiency of PEI.
171
 High level gene expression was achieved even with a rather 
short incubation time and low DNA dose when magnetic field was applied. It is possible that 
magnetic field quickly gathered the magnetic gene complex to the surface of cell and 
enhanced the subsequent cellular uptake. 
Gold nanoparticle has its own advantage in cellular uptake and biocompatibility. The 
decoration of gold nanoparticle with PEI has also been demonstrated. Gold nanoparticles 
provide high surface to volume ratio which could maximize the grafting density of PEI. 
Alexander M. Klibanov et al. conjugated 2 kD PEI to the surface of gold nanoparticle through 
thiol chemistry. These gold particles showed better transfection efficiency compared to that of 
25 kD PEI.
172
 Moreover, it was shown that gold nanoparticles conjugated with 2 kD PEI were 
safe for the cornea and thus can potentially be useful for corneal gene therapy in vivo.
173
 Zhuo 
Renxi et al. reported that 800 D PEI decorated gold nanoparticles can transfect cells 3-4 folds 
more efficient than 800 D PEI alone.
174
 TEM experiments revealed that gold nanoparticles 
with higher PEI grafting density on their surfaced led to more compact and smaller complexes 
with DNA. Notably, the transfection ability of gold/PEI vectors retained even in the presence 
of serum.  
Interestingly, the combination of silica inorganic nanoparticle with PEI can reduce the 
toxicity of PEI while maintaining its transfection ability. Huang Shiwen et al. demonstrated 
that the cytotoxicity of PEI-silica nanoparticle prepared through one pot synthesis was 
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significant lower than conventional used PEI.
175
 Meanwhile, the efficiency of these 
nanoparticles was also better than that of PEI in the presence of serum.  
Inorganic nanoparticle – Lipid hybrids 
Liposomes formed by the assembly of cationic lipids have been shown to be highly 
efficient in gene transfection, for example the widely used commercially available vector 
Lipofectamine. Thus, coating of inorganic nanoparticle with lipids has been developed to 
improve the cellular uptake and endosomal release ability of nanoparticle/gene complexes. 
Also, the unique physical and chemical properties of inorganic nanoparticles could be used to 
improve the transfection ability of cationic lipid.  
Huang Leaf et al. prepared calcium phosphate nanoparticles coated with traditional cationic 
lipid 1, 2-dioleoyloxy-3-(trimethylammonio) propane chloride (DOTAP) and helper lipid 
cholesterol.
176
 Calcium phosphate nanoparticle is expected to disassemble after entering the 
cell due to the low pH in the endosomes which results in endosome swelling and bursting to 
release the entrapped siRNA. The release ability of this system was confirmed by the increase 
of intracellular Ca
2+
 concentration through a calcium specific dye. As a result, the application 
of calcium phosphate improved the silencing effect 3–4 folds in vitro compared to previous 
formulation.  
Interestingly, Erkang Wang et al. reported a new class of cationic lipid coated gold 
nanoparticles (DDAB-AuNPs).
177
 Although these nanoparticles cannot transfect cells when 
applied alone, they could enhance the efficiency of other cationic liposomes mediated 
transfection. It was found that more DNA molecules were bound to cationic lipids upon the 
addition of DDAB-AuNPs. Flow cytometry results showed that the cellular uptake efficiency 
of DNA molecules was also increased which might explain the improved transfection. 
Another merit of decoration of spherical inorganic nanoparticle with liposomes is to 
improve the capacity and stability of liposome. Also targeted delivery and controlled release 
properties could be realized. C. Jeffery Brinker et al. reported an elegant porous nanoparticle 
supported lipid bilayers that synergistically combined the properties of liposomes and 
nanoparticles as depicted in Figure 30.
178-180
 In this system, cationic liposomes were fused to a 
spherical, high-surface-area, porous silica core to obtain supported lipid bilayer structures. 
The silica core could suppress large-scale bilayer fluctuations which result in a better stability 
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than unsupported liposomal bilayers. Additionally, other functional moieties such as targeting 
peptide, PEG and fusogenic peptide can be added to liposome coating. The combination of 
these molecules thus could improve the capacity, selectivity and stability of liposomes and 
also enable targeted delivery and controlled release of cargos. The most interesting property 
of this system is that it can be loaded simultaneously with combinations of therapeutic agents 
such as siRNA, toxins and diagnostic agents. They demonstrated that all these cargos were 
successfully transported into cells through endocytotic pathway. The release of cargo was 
proposed to depend on the destabilization of lipid bilayer triggered by endosome acidification. 
The gene transfection ability of this system was shown to be correlated with the sizes of 
nanoparticles. Transfection efficiency dramatically decreased when the sizes were increased.  
 
Figure 30. Schematic illustration of the nanoporous particle-supported lipid bilayer, depicting the 
disparate types of therapeutic and diagnostic agent that can be loaded within the nanoporous silica core, 
as well as the ligands that can be displayed on the surface. Reprinted by permission from Macmillan 
Publishers Ltd: [Nature materials] (reference 180), copyright (2011) 
Inorganic nanoparticle – Cell penetrating peptide hybrids 
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The combination of inorganic nanoparticles and cell penetrating peptides to enhance 
cellular uptake has been extensively studied in the field of cellular labeling and molecular 
imaging during last decade.
181,182
 The pioneering work of Weissleder et al. demonstrated that a 
100-fold higher efficiency of intracellular magnetic labeling with dextran-coated 
superparamagnetic iron oxide nanoparticle could be achieved when it was conjugated with 
HIV-Tat peptide.
183,184
 However, applications of such systems in gene delivery are less 
explored. One possible reason is that large amount of cell penetrating peptide is relatively 
more difficult to obtain for the decoration of inorganic nanoparticles. Nevertheless, the 
excellent biocompatibility of cell penetrating peptides makes it an interesting decoration 
strategy for inorganic nanoparticle based gene delivery vector. 
 Wang Shu et al. reported the hybridization of magnetic nanoparticles and cell penetrating 
HIV-Tat peptide can be used for gene transfection experiments (Figure 31).
185
 The magnetic 
ion beads were first coated with PEI to condense plasmid DNA. A cysteine residue containing 
Tat peptide was added subsequently. The resulting complexes exhibited a 4-fold improvement 
in gene transfection compared to its counterpart without Tat peptide in vitro. The enhancement 
of transfection could still be observed in vivo. Additionally, the injected DNA complexes 
could respond to a moving magnetic field. Shifting away the magnetic field from the injection 
site resulted in transgene expression in a remote region.    
  
Figure 31. Schematic illustration of the structure of PolyMag/DNA/Tat complex. "Reprinted from 
reference 185, copyright (2016), with permission from Elsevier 
The combination of calcium phosphate nanoparticle and arginine rich cell penetrating 
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peptide for gene delivery has also been reported by Cory Berkland et al.
186
 Condensation of 
nascent CPP/DNA complex with CaCl2 provided rather small and stable nanoparticles which 
led to a higher gene expression than PEI. It also showed negligible cytotoxicity in vitro and 
can still function in the presence of serum. 
To summarize, gene therapy is now considered to be an extremely promising technique for 
the treatment of a variety of diseases. However, the lack of suitable gene delivery vectors for 
clinical trials limit its potentials. Despite the numerous non-viral vectors developed during the 
last 30 years, optimal vectors with efficient gene delivery ability comparable to viral vectors 
and excellent compatibility both in vitro and in vivo still remain to be realized. Development 
of such gene delivery vectors is in high demand.    
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2.3 Peptide assembly 
  Two approaches have been developed to fabricate nanomaterials: top-down and bottom-up 
approaches.
23,187
 Top-down approach is essentially the breaking down of macro-materials to 
create nanoscale devices by techniques such as machining and etching. It is most useful in 
micro-patterning techniques such as photolithography and inkjet printing. For example, this 
approach is often applied in semiconductor industry to fabricate an integrated circuit on a 
silicon wafer.
188
 Bottom-up approach, in contrast, relies on the chemical property of 
individual atoms or molecules to self-organize and self-assemble to construct macroscopic 
structures.
189
 In particularly, materials generated from self-assembling strategy possess unique 
properties such as fast response towards external stimuli and structural unity in nanoscale. 
Self-assembled materials have been applied in the design of chemical sensors, regenerative 
medicines and tissue engineering etc.
20
  
The building blocks for assembling process are rationally designed and allowed to interact 
with each other through non-covalent forces such as π-π stacking, hydrogen bonding and 
hydrophobic interactions. Supramolecular chemistry has developed several strategies to 
achieve efficient and controlled self-assembling.
190
 Among them, peptide based materials are 
particular interesting due to their biocompatibility, easy preparation and versatility of 
functionalization. Several peptide self-assembling systems have been developed. Depending 
on the structure of basic building block, they can be classified as amphiphilic peptides, cyclic 
peptides, amyloid and collagen peptides etc. 
2.3.1 Amphiphilic peptide assembly 
Self-assembling of amphiphilic molecules is the one of the most widely used strategy in 
constructing supramolecular nanomaterials. Amphiphilic molecules usually contain a 
hydrophobic domain and a hydrophilic head group. They can self-assemble into a variety of 
nanostructures (Figure 32) depending on their chemical structures, solvents, concentration and 
temperature etc.
191-193
 A well-established model theory has been developed by Israelachvili et 
al. to predict the aggregation morphology from the chemical structures of individual 
amphiphile. 
194
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Figure 32. Schematic representation of amphiphilic molecules and assembly. Reprinted with 
permission from Reference 193. Copyright (2016) American Chemical Society." 
In the assembly of amphiphilic peptides, the hydrophobic domain provides the main driving 
force through hydrophobic interactions. The head groups, built from short peptides, could 
interact with each other through hydrogen bonds. Three types of hydrophobic domains have 
been developed: aliphatic tails, aromatic rings and hydrophobic amino acid residues.  
2.3.1.1 Aliphatic tails  
The research on amphiphilic peptide assembly was pioneered by Samuel Stupp et al.
20
 In 
2001, they reported the self-assembly and mineralization of a peptide amphiphile nanofiber.
195
 
The research was inspired by the structure of bone tissue which essentially constructed 
through the organization of collagen fibers and hydroxyapatite (HA) crystals. Thus, an alkyl 
tail with 16 carbon atom was attached in the N-terminus of an ionic peptide (Figure 33A, 1). 
This peptide could assemble into cylindrical micelles in water due to the overall conical shape. 
The alkyl tail then packed in the center of micelle which consequently exposed the 
hydrophilic peptide segment on the surface.  
In the peptide segment, four cysteine amino acid residues were incorporated to covalently 
link the assembled nanofibers through oxidation of thiol groups (Figure 33A, 2). 
Phosphorylate group, being highly efficient in the formation of calcium phosphate minerals, 
was introduced to nucleate the formation of HA in proper environment (Figure 33A, 4). 
Additional RGD peptide sequence was coupled to the N-terminus to facilitate the adhesion of 
cells (Figure 33A, 5). They found out that inorganic material was concentrated on the surface 
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of nanofibers 10 minutes after the treatment with CaCl2. Shortly after, plate-shaped 
polycrystalline mineral was visible throughout the surface of the fibers. The c axes of the HA 
crystals were co-aligned with long axes of the fibers which may be of interest to the design of 
materials.  
 
Figure 33. (A) Region 1 is a long alkyl tail, region 2 is composed of four consecutive cysteine residues 
for cross-linking, region 3 is a flexible linker region, region 4 is a single phosphorylated serine residue 
to interact with calcium ions, region 5 displays the cell adhesion ligand RGD. (B) Molecular model of 
the peptide amphiphile. From reference 195. Reprinted with permission from AAAS 
In 2005, they applied the same strategy to realize the recognition between peptide fibers 
and avidin receptor protein.
196
 Biotin molecules were introduced onto a branched peptide 
amphiphile which assembled into fibers in water. The binding of chromophore-conjugated 
avidin protein to biotinylated nanofibers was confirmed by measurement of fluorescence 
signals.       
Later, Stupp et al. investigated the influences of amino acid sequences and the length of 
alkyl tails in the formation of nanofibers.
197
 Twelve derivatives of peptide amphiphiles were 
studied. Nanofibers varying in morphology, surface chemistry, and potential bioactivity were 
thus obtained. Two methods of self-assembling, drying on surfaces and addition of divalent 
ions such as calcium, were established. However, the formation of these peptide fibers 
required a relatively low pH (~4). They then explored that efficient self-assembly could be 
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achieved at physiological pH when two oppositely charged peptide amphiphiles bearing 
different biological signals were mixed in aqueous solution.
198
  
Jeffrey D. Hartgerink et al. studied the self-assembling process of peptide amphiphiles by 
systematic modification of the hydrogen bonding and amphiphilic packing ability.
199
 A series 
of 26 PA derivatives, including 19 N-methylated variants and 7 alanine mutants were obtained 
by solid phase synthesis. A combination of the results obtained from circular dichroism 
spectroscopy, Fourier transform infrared spectroscopy, rheology and vitreous ice 
cryo-transmission electron microscopy provided a detailed insight in the mechanism of 
self-assembling of peptide amphiphiles. It was found that the four amino acids closest to the 
core of nanofiber were crucial in the formation of peptide fibers. These residues were 
hydrogen-bonded with each other which resulted in a β-sheet conformation oriented primarily 
down the Z-axis of the nanofiber in the hydrophilic peptide region. Disruption of these 
hydrogen bonds led the peptide amphiphiles to assemble into spherical micelles instead of 
elongated, cylindrical fibers. Amino acids further away from the core of the nanofiber played 
however a less important role in the stabilization of nanofiber, thus may accommodate a 
variety of functionalities.  
 
Figure 34. Schematic molecular-graphics representation of peptide amphiphile nanofibers. The 
vertical bar indicates the gradient of solid-like to liquid-like dynamics (blue and red, respectively) 
through the nanofibers’ cross-sections. Reprinted by permission from Macmillan Publishers Ltd: 
[Nature materials] (reference 200), copyright (2014) 
Moreover, using site-directed spin labelling and electron paramagnetic resonance 
spectroscopy, Stupp et al. examined the conformational dynamics of self-assembled nanofiber 
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in water through its 6.7 nm cross-section.
200
 It was found that the innermost residues and 
adjacent sites of peptide amphiphile fiber had a rather low dynamic behavior which suggested 
a solid-like shell surrounding the viscous core (Figure 34). This result experimentally 
confirmed the simulations from molecular dynamics.  
 
Figure 35. (A) Molecular graphics illustration of an IKVAV-containing peptide amphiphile. B) 
Scanning electron micrograph of an IKVAV nanofiber. (C and D) Micrographs of the gel formed by 
adding to IKVAV peptide amphiphile solutions (C) cell culture media and (D) cerebral spinal fluid. (E 
Micrograph of an IKVAV nanofiber gel surgically extracted from an enucleated rat eye. From 
reference 201. Reprinted with permission from AAAS 
Stupp et al. then extended the application of peptide amphiphile to the selective 
differentiation of neural progenitor cells.
201
 A pentapeptide epitope isolucinelysine- 
valine-alanine-valine (IKVAV), known to promote neurite sprouting and to direct neurite 
growth, was incorporated into the peptide amphiphile (Figure 35A). Another feature of this 
amphiphile was the utilization of glutamic acid residue to provide a net negative charge at pH 
7.4 so that the cationic species in cell culture mediums can screen electrostatic interactions 
and trigger self-assembly when cell suspensions were added. These nanofibers were shown to 
form 3D networks and produced a gel-like solid with cell culture media (Figure 35C, D, E). 
Moreover, these artificial peptide based nanofiber scaffold induced very rapid differentiation 
of cells into neurons, while the development of astrocytes was suppressed. They also 
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demonstrated that replacement of IKVAV epitope with RGD peptide sequences in such 
peptide amphiphiles could successfully entrap osteoblast precursor cell lines.
202
 In the 
presence of polyvalent metal ions, the assembling process was triggered by adding PA 
solutions to cell culture media or other physiological fluids. The cells entrapped in the 
nanofibrillar matrix could survive in culture for at least three weeks. Afterwards, the peptide 
fibers were internalized by the cells and possibly were utilized in the metabolic pathways.  
In addition of bioactive peptide sequences, other types of functional moieties could be 
incorporated into peptide amphiphiles.
203-205
 For example, pyrene moiety could be conjugated 
to the aliphatic tail. The self-assembly process thus can be studied with fluorescence 
measurement in solution owing to the excimer formation property of pyrene.
206
 It was 
demonstrated that pyrene excimer can only be observed when the peptide amphiphile 
assembled into cylindrical fibers, not spherical aggregates. Covalently linking a derivative of 
1,4,7,10-tetraazacyclododecane- 1,4,7,10 tetraacetic acid (DOTA) to peptide amphiphile 
resulted in magnetic resonance (MR) active molecules that could enhance relaxation time.
207
  
Even large moieties such as inorganic nanoparticles and carbon nanotubes can be applied to 
decorate the fibers formed by these peptide amphiphiles. In 2005, Stupp et al. showed that one 
dimensional inorganic assembly could be templated with peptide fibers.
208
 The peptide 
amphiphile used to form fibers was modified with thymine in the hydrophobic aliphatic tail. 
Gold nanoparticles were decorated with lipophilic diaminopyridine. Due to the high binding 
efficiency between thymine and diaminopyridine in aprotic environments, gold nanoparticles 
were linearly aligned on the surface of peptide fibers which could be observed with 
transmission electron microscope. The length of the array of gold nanoparticles extended for 
several microns.  
The nanofibers formed by peptide amphiphiles also possess excellent ability to form 
hydrogel which could be applied for injectable therapies in regenerative medicine. A series of 
peptide amphiphiles with different peptide sequences were thus synthesized to study their 
gelation kinetics.
209
 Stupp et al. found out that gelation time increases with the bulkiness and 
number of polar groups in the PA molecule. Circular dichroism (CD) spectroscopy 
measurements suggested the pre-existence of hydrogen-bonded aggregates in the solution 
state even before the trigging of self-assembly process. It was proposed that these aggregates 
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acted as nuclei to accelerate the gelation kinetics following typical nucleation-based 
mechanism for self-assembly. They further observed that large birefringent domains occurred 
in gels formed from heated solutions, whereas those formed from unheated solutions appeared 
completely isotropic with no birefringence.
210
 The former solution could be dragged on a 
surface covered by a thin layer of this medium (Figure 36).  
 
Figure 36. Schematic representation of amphiphilic peptide and nanofiber. (a, b) A peptide 
amphiphile solution coloured with trypan blue injected into phosphate-buffered saline after heat 
treatment. (c) The same solution dragged through a thin layer of aqueous CaCl2 to form a noodle-like 
string. Reprinted by permission from Macmillan Publishers Ltd: [Nature materials] (reference 210), 
copyright (2010) 
2.3.1.2 Aromatic peptide amphiphiles 
The low cost for the preparation of dipeptide and amino acids relative to longer peptides 
and proteins makes them attractive in the design of self-assembling system. These low 
molecular weight molecules can function as hydrogelators which can fundamentally achieve 
all the hydrogel features associated with longer peptides as described above.
211
  
One of the earliest amino acids based hydrogels was reported in 1921 (Figure 37).
212
 
However, it was not until 1995 that this hydrogel network had been examined with modern 
instrumental techniques.
213,214
 It was then confirmed that the hydrogel consisted of fibrils 
around 50 nm in diameter that entangled in solution. X-ray crystal structure revealed that the 
gel fiber was held together by a favorable backbone orientation enhanced by 
hydrogen-bonding and π- π stacking interactions.  
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Figure 37. Chemical structure of aromatic peptide gelator 37  
In 2003, Ehud Gazit et al. reported that H-Phe-Phe-OH dipeptide, derived from 
Alzheimer’s β-amyloid diphenylalanine structural motif, self-assembled into discrete and stiff 
nanotubes in water.
215
 Reduction of ionic silver within the nanotubes, followed by enzymatic 
removal of the outer shell of peptide nanotubes, resulted in the production of discrete 
nanowires. This peptide is however unable to form a hydrogel. Fmoc-Phe-Phe-OH, the 
precursor of diphenylalanine peptide, was thus tested for its self-assembling property (Fmoc: 
9-fluorenylmethoxycarbonyl).
216,217
 Besides the expected hydrophobic interactions between 
Fmoc groups, the introduction of aromatic functionality in the N-terminus provided additional 
stacking interactions. Dissolving of this peptide at higher concentration thus resulted in the 
formation of a hydrogel which consisted of a fibrous network with fibril diameters ranging 
from 10 to 100 nm. Compared to the original tubular structure assembled from 
diphenylalanine peptide, the fibers formed with Fmoc protected diphenylalanine peptide were 
much more flexible with branching characteristics. Further experiments showed that the 
hydrogel can be used to encapsulate fluorescein, a small organic molecule. A slow release of 
fluorescein was observed when the gel containing the fluorescent molecule was covered with 
water.  
Rein V. Ulijn et al. characterized the assembly behavior of Fmoc-FF peptide in detail.
218
 
Circular dichroism experiments showed a negative peak at 218 nm which was in consistent 
with β-sheet structure for molecular assembly. Fourier transform infrared spectroscopy (FT-IR) 
spectrum of Fmoc-FF gel had two peaks, at 1630 and 1685 cm
–1
, which further confirmed the 
β-sheet structure and possibly implied an anti-parallel arrangement of the peptides. In addition, 
fluorescence spectroscopy revealed an excitation maximum absorption at 350 nm, 
significantly red shifted when compared to the absorption of Fmoc alone, clearly indicating a 
large degree of π- π stacking interactions between the fluorenyl groups.  
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Combining the information described above, if Fmoc-FF were stacked in an antiparallel 
β-sheet arrangement, the fluorenyl group would be too far from each other for π- π stacking 
interactions (Figure 38A). However, the fluorenyl groups could interlock with one another 
when the second stack of Fmoc-FF was placed alongside the first sheet but staggered by one 
peptide (Figure 38B).  
 
Figure 38. Model structure created for Fmoc-FF peptide. (A) Fmoc-FF peptides arranged in an 
anti-parallel β-sheet pattern. (B) Interlocking of Fmoc groups from alternate β-sheets to create 
π-stacked pairs with interleaved phenyl rings. Top view (C) and side view (D) of the structure created 
in (B). Reference 218, copyright (2016) Wiley. Used with permission from John Wiley and Sons. 
Another important feature of Fmoc-FF peptide is that it can self-assemble at physiological 
pH. This feature is actually intriguing since the free carboxylic acid group in the C-terminus 
would be negatively charged under this condition (pKa of -COOH: 3.5). Charge repulsions 
should then prevent the fiber formation. However, it was found that the self-assembling 
process of Fmoc-FF resulted in two apparent pKa shifts of ∼6.4 and ∼2.2 pH units above the 
theoretical pKa (3.5).
219
 Therefore, self-assembly of Fmoc-FF resulted in a suppressed 
ionization which led to dramatic pKa shifts related to significant structural transitions. 
Introduction of phosphorylated amino acids in the design of Fmoc based short peptide 
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endowed a unique property to the self-assembling system.
220,221
 In 2004, Zhimou Yang et al. 
reported a rather simple approach to develop assays based on the hydrogelation ability of 
short peptides for the detection of enzyme inhibitors.
222
 In this system, the precursor which 
acted as the substrate of an enzyme could transform into a hydrogelator. When the inhibitor 
inhibited the function of an enzyme, such conversion were thus blocked which resulted in a 
macroscopic sol – gel transition (which can be observed visually).  
They later demonstrated that following this strategy, even a hydrophobic molecule can 
unprecedentedly form supramolecular hydrogel (Figure 39).
223
 A phosphatase was applied to 
convert hydrophilic precursor 38 to hydrophobic 39. Interestingly, molecule 38 was not able 
to form hydrogel when it was tested alone due to its poor solubility. However, when 39 was 
conversed from 38, an opaque hydrogels were formed. They suggested that the nanofibers 
were mainly formed by 39 and doped with hydrophilic 38 which provided the stability of 
nanofibers in aqueous solutions. Rein V. Ulijn et al. also observed similar transition from a 
micellar solution into a fibrous hydrogel upon enzymatic de-phosphorylation.
224
  
 
Figure 39. Schematic illustration of enzymatic conversion of 38 and 39 in nanofibers. Reprinted 
with permission from Reference 223. Copyright (2016) American Chemical Society. 
Bing Xu et al. demonstrated that this process can be reversed.
225
 A kinase/phosphatase 
switch was used to control the phosphorylation and de-phosphorylation process of the short 
aromatic peptide amphiphile containing tyrosine residue. The kinase and phosphatase can thus 
function as external regulations for the formation of hydrogel. In the presence of adenosine 
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triphosphates (ATP), adding kinase to the short peptide phosphorylated the tyrosine and thus 
altered the amphiphilic nature of peptide. This eventually resulted in the disruption of 
self-assembly and induced a gel-sol phase transition. On the other hand, treating the resulting 
solution with a phosphatase dephosphorylated the tyrosine residue, thus restored the 
self-assembly of short peptide to form the hydrogel. 
Replacement of the Fmoc group with other aromatic molecules such as naphthalene in 
peptide amphiphile still preserved their self-assembly behavior. In 2007, Bing Xu et al. 
prepared a series of molecular hydrogelators based on the conjugates of dipeptide and 
(naphthalen-2-yloxy) acetic acid.
226
 The chirality of the dipeptide dictated the handedness of 
resulting nanofiber: fibers formed with D-amino acid were left-handed and those obtained 
from L-amino acids were right-handed. They further demonstrated that introduction of 
D-glucosamine, a naturally occurring aminosaccharide, could allow these peptide based 
hydrogelator to be applied to wound healing.
227
 The mice treated with these hydrogels 
exhibited a much faster wound healing process and smaller scars compared to those of control 
group.  
 
Figure 40. Multifunctional short peptide based hydrogelator. Reprinted with permission from 
Reference 228. Copyright (2016) American Chemical Society. 
Later, Bing Xu et al. reported a novel class of multifunctional supramolecular hydrogelators 
based on a short peptide (Figure 40).
228
 The hydrogelators consisting of nucleobase, amino 
acid, and glycoside not only exhibited excellent biocompatibility but also facilitated the 
transfer of nucleic acids into cytosol and nuclei of cells. This result highlighted the possibility 
of utilizing basic building blocks (i.e. nucleobase, amino acid, and glycoside) of the three 
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major bio-macromolecules (i.e. nucleic acid, proteins, and glycans) to build complex 
nanostructures. Compared to glycosyl-nucleoside-lipid based hydrogelators, the inclusion of a 
peptide imparts more diverse functions than a lipid does. 
2.3.1.3 Hydrophobic amino acid residues 
Peptide amphiphiles could also be constructed with hydrophobic amino acid residues 
instead of aliphatic tails and aromatic rings. In 2002, Shuguang Zhang et al. designed several 
surfactant-like short peptides that exhibited self-assembling properties as shown in Figure 
41.
229
 Each peptide contained seven to eight amino acids residues with a length around 2 nm. 
Charged residues such as aspartic acid and lysine were applied as hydrophilic head group. 
Non polar alanine, valine and leucine residues were incorporated as hydrophobic domain. 
Thus, these peptides were amphiphilic in nature when dissolved in water. These peptides were 
able to form nanotubes and vesicles with an average diameter of 30-50 nm with a helical twist. 
Dynamic laser scattering measurements revealed a rather narrow size distribution of these 
peptides which implied the good regularity of the assembled structures. Visualization of these 
structures with transmission electron microscopy from quick-freeze/deep-etch sample 
preparation showed a network of open-ended nanotubes and vesicles.  
 
Figure 41. Chemical structure of surfactant-like short peptides. Reference 229, reproduced by 
permission of The Royal Society of Chemistry. 
The authors then proposed a mechanism for the self-assembling process. First, two peptide 
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monomers pack in dimeric tail-to-tail fashion to form a bilayer creating a unilamellar shell. 
Owing to the intrinsically twisted nature of individual peptide monomer, these bilayer 
structures would have a curvature. As consequence, each peptide may interact with one 
another to form closed rings which in turn stack on top of one another to form tubular 
structure. Subsequently stacking of the tubular arrays through noncovalent interactions 
ultimately led to longer nanotubes.  
Inspired by the shape of natural lipid, Shuguang Zhang et al. also designed a cone-shaped 
amphiphilic lipid-like peptide Ac-GAVILRRNH2 with the larger part made of arginine and 
smaller part made of glycine (Figure 42, left).
230
 Atomic force microscopy experiments found 
that this peptide assembled into donut-shape structures. It is plausible that at low 
concentration, peptide Ac-GAVILRRNH2 was randomly oriented and distributed in solution 
(Figure 42A, right). When the concentration increased above critical micelle concentration, 
spherical micelles were formed similarly to common surfactants (Figure 42B, right). At even 
higher concentration, fusion or elongation of these spherical micelle occurred which led to the 
formation of short nano-pipes (Figure 42C, right). These short nano-pipes tended to bend 
gradually to form donut like structures to reduce the surface free energy as a result of the 
geometry restriction of cone-shaped peptide monomer (Figure 42D, right).    
 
Figure 42. Modelled structure of peptide Ac-GAVILRRNH2 and its assembling mechanism. 
Reprinted with permission from Reference 230. Copyright (2016) American Chemical Society. 
These short amphiphilic peptides are excellent candidates to model bilayer membrane 
structures. It is known that membrane proteins are crucial in almost every aspect of cellular 
activities. However, their structures and functions are poorly studied due to the lack of 
suitable surfactants. In 2006, Shuguang Zhang et al. demonstrated that peptide surfactants 
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were capable of stabilizing a well characterized membrane protein bovine rhodopsin.
231
 In the 
presence of lipids and common surfactants, these short peptides not only enhanced the 
stability of bovine rhodopsin, but also significantly stabilized rhodopsin even under thermal 
denaturation conditions. In 2011, they further showed that these short peptides can be used to 
address another critical issue related to membrane proteins.
232
 Using peptide surfactants in 
commercial Escherichia coli cell-free systems, milligram quantities of G protein coupled 
receptors (GPCRs) could be obtained. These receptors were nicely soluble and had α-helical 
secondary structures, suggesting that they were properly folded.  
2.3.2 Cyclic peptide assembly 
Nanotubes (NTs) structures are particular interesting in the development of nanomedicines, 
sensors and nanotechnology engineering etc. Since the first synthesis of carbon nanotube in 
the early 1990’s, interests in fabrications of other types of nanotubes have grown rapidly.233 
For example, a variety of inorganic nanotubes such as tungsten (IV) sulfide and titanium 
dioxide have been prepared and exhibited unique mechanical, optical and electrical 
properties.
234-237
 However, the drawbacks of these materials including poor solubility, toxicity 
and lack of uniformity limited their applications. Therefore, supramolecular organic nanotube 
constructed with the assembly of cyclic peptides emerges as alternative and promising 
nanomaterials with tubular structures. Additionally, the well-established peptide chemistry 
provides excellent toolbox for the preparation and versatile functionalization of such 
materials.  
2.3.2.1 Design of cyclic peptide nanotube 
The utilization of cyclic peptides to prepare nanotubes was first realized by M. Reza 
Ghadiri et al. in 1993.
238
 In their pioneering paper entitled “Self-assembling Organic 
Nanotube Based on Cyclic Peptide Architecture”, a cyclic peptide constructed from eight 
amino acid residues (Figure 43) was rationally designed. An even number of alternating D and 
L amino acids were used in order to adopt a low energy ring shaped flat conformation in 
which all the amide functionalities were positioned approximately perpendicular to the plane 
of the ring. Of the eight amide groups, four carbonyl groups were placed above the ring 
whereas the adjacent –NH groups pointed downwards. The main driving force for the 
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self-assembling process was thus the hydrogen-bonding interactions between each cyclic 
peptide backbone to produce a continuous β-sheet structure. Moreover, because of the 
alternating D and L amino acids composition, the side chains of peptides must lie on the 
outside of entire assembly which resulted in the tubular structure. 
As expected, they observed in TEM that this cyclic peptide assembled into bundle-like 
structures when a suitable pH was applied. Cryo-TEM revealed that each bundle consisted of 
hundreds of tightly packed nanotubes with a spacing of 14.9 Å  as expected for the center to 
center distance of the peptide rings. Electron diffraction patterns of this cyclic peptide sample 
showed a 4.73 Å  axial periodicity. This distance was ideal for an antiparallel β-sheet structure 
which suggested that each nanotube was made up of several stacked rings. Modelling results 
confirmed the assembling mechanism since the only way to pack two peptides to within 4.7 Å  
was to let the peptide backbones hydrogen bonding with each other.  
 
Figure 43. Chemical structure of a cyclic peptide  
The length of this type of nanotube assembled from cyclic peptides is however very 
difficult to control owing to their inherent assembling mechanism which was determined 
through the study of assembling thermodynamics with N-alkylated cyclic peptide 
analogues.
239-242
 Alkylation resulted in the hydrogen bonding interactions occurred only at one 
face of the ring, which leads to dimer formation instead of nanotubes. The equilibrium 
constant for the dimer was determined to be in the vicinity of 3000 M
-1
, far lower than would 
be expected for supramolecular nanotubes.
243-245
 Considering the remarkable stability of 
non-alkylated cyclic peptide nanotubes, this suggested a cooperative growing mode for their 
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formation. Additionally, Jeffrey D. Hartgerink et al. reported that the stability of peptide 
nanotubes can be attributed to the highly cooperative nature of the noncovalent interactions.
246
 
Enthalpically driven hydrogen bonding interactions between each stacked rings were 
reinforced with entropically driven hydrophobic interactions in aqueous solutions.  
 
Figure 44. Chemical structures of (a) Mba-8CP and (b) its conventional analogue 8CP. Snapshots of 
equilibrium structures calculated from molecular dynamics simulations, showing cross-sectional (c,d) 
views of Mba-8CP and 8CP nanotubes respectively. Reprinted with permission from Reference 251. 
Copyright (2016) American Chemical Society.  
The internal diameter of cyclic peptide nanotubes is relatively easy to optimize. Simple 
adjustment of the number of amino acid residues in the ring would effectively change the 
diameter of final assembled nanotubes. For example, Ghadiri et al. reported the internal 
diameter of cyclic peptide nanotubes constructed with eight residues was around 7-8 Å .238 
Since then, a number of nanotubes varying in their diameters assembled from different cyclic 
peptides have been realized. Cyclic peptides with four, six and ten amino acid residues are all 
capable of forming nanotubes with diameters ranging from 2 Å  to 13 Å .247-250 Interestingly, 
Rami Hourani et al. recently reported a different route to generate cyclic peptide nanotubes 
with tunable interiors.
251
 An unnatural amino acid 3-amino-2-methylbenzoic acid (Mba) was 
incorporated into the D, L-alternating primary sequence of a cyclic peptide (Figure 44a). 
Molecular dynamic (MD) simulations suggested that the methyl group pointed into the 
interior of the pore as designed. This placement of the hydrophobic methyl group significantly 
reduced the internal diameter to an estimated 4.7 Å. As comparison, the pore size of the 
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original cyclic peptide was around 7.6 Å. The incorporation of non-natural amino acid Mba 
did not altered the self-assembling ability of cyclic peptide as tubular structures were readily 
observed in acetonitrile. The hydrogen bonding interaction between each stacked ring was 
confirmed with FT-IR measurements. Moreover, 2D NOESY spectra of Mba-8CP dissolved in 
d
6
-DMSO revealed the through space correlation between the methyl group’s proton with the 
protons in amide. This result further confirmed the structure obtained with MD simulations as 
shown in Figure 44c.  
 
Figure 45. Cyclic peptide–polymer nanotubes with two corona configurations. (a) Janus assembly 
with ‘demixed’ corona. (b) Hybrid assembly with ‘mixed’ corona. Reprinted by permission from 
Macmillan Publishers Ltd: [Nature materials] (reference 252), copyright (2013)  
A major advantage to construct nanotubes with cyclic peptides is that it allows facile 
functionalization of the exterior of nanotube. The side chains of amino acids residues such as 
lysine and glutamic acid provide ideal active sites for a variety of modifications. Maarten 
Danial et al. reported a self-assembling cyclic peptide–polymer nanotube with dual 
functionality in the form of either a Janus or mixed polymeric corona (Figure 45).
252
 The 
polymers used in this study were terminated with either thiol or alkyne functionalities. 
Well-known click chemistry of thiol-ene reaction and copper catalyzed azide-alkyne 
cycloaddition (CuAAC) were used to conjugate different polymers to cyclic peptide. The 
self-assembling ability of cyclic peptide was not affected by the conjugation of polymers as 
determined by FT-IR and dynamic light scattering studies. Small-angle neutron scattering 
(SANS) experiments confirmed the formation of nanotubes in deuterated chloroform. More 
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importantly, the Janus character of this type of polymer decorated nanotube may create a new 
way to access synthetic transmembrane protein channel mimics.  
Robert Chapman et al. described the assembly of polymer–cyclic peptide conjugates into 
nanotubes in solution through in situ measurements.
253
 A series of polymers with degrees of 
polymerization (DPs) ranging from 16 to 195 were conjugated to a cyclic peptide. The 
assembled nanotubes have a remarkable stability. Even in neat TFA, a highly competitive 
solvent, it still took several hours to completely break up the nanotubes. They further 
demonstrated that the length of nanotubes can be controlled by varying the degree of 
polymerization of outer polymers due to steric bulkiness. Also by selectively deuterating one 
block of the polymer shell, the internal structures of nanotubes were altered.   
 
Figure 46.Coupled cyclic peptide nanotubes (blue) and carbon nanotubes (white). Reprinted with 
permission from Reference 256. Copyright (2016) American Chemical Society.   
Besides polymers, other molecules such as fullerene and naphthalene tetracarboxylic 
diimide (NDI) could also be used to decorate the surface of cyclic peptide nanotubes.
254,255
 
Recently, Javier Montenegro et al. successfully coupled two main types of nanotubes, carbon 
nanotubes and cyclic peptide nanotubes together (Figure 46).
256
 To achieve such design, 
one of the lysine residues in cyclic peptides was modified with a pyrene “paddle”. This 
pyrene paddle can establish efficient π-π stacking interactions with carbon nanotubes in water. 
They found out that carbon nanotubes functioned as template to assist the formation of cyclic 
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peptide nanotubes. The hybrid nanotubes exhibited semiconducting properties in aqueous 
dispersions rather than metallic carbon nanotubes. 
2.3.2.1 Application of cyclic peptide nanotubes 
The main applications of cyclic peptide nanotubes are in the field of biochemical science 
such as ion channels and antibacterial agents.
257
 Other applications including gene delivery 
inhibitor, responsive materials and electronic devices have also been reported but less 
explored.
258-260
  
In 1994, M. Reza Ghadiri et al. demonstrated that cyclic peptide nanotube could be used as 
artificial transmembrane ion channels.
261
 A planar lipid bilayer was selected to model cell 
membranes. The cyclic peptide was constructed with alternating L-tryptophan and D-leucine 
residues. Two forces can contribute to the self-assembling process when the peptide monomer 
was mixed with lipids. The main driving force remained to be the hydrogen bonding 
interaction between each stacked peptide subunit. Another contribution came from the 
increase of entropy for the lipid chains when they were interacted with the side chains of 
tryptophan and leucine. FT-IR experiments supported the formation of transmembrane 
channels resulted from the assembly of cyclic peptide nanotubes. This system displayed 
ion-transport activity with rates around 10
7
 per second for both sodium and potassium cations 
which was comparable to naturally occurring transmembrane channels such as gramicidin A. 
Shortly after, they demonstrated that glucose, a small organic hydrophilic molecule, can also 
across through bilayer membrane with assistance from cyclic peptide nanotubes.
248
 For the 
passage of glucose through the cylindrical cavity of the tubular structure, a pore size >9 Å  was 
required. Therefore, a ten residue cyclic peptide was designed and synthesized. The 
assembled peptide nanotubes displayed uniform 10 Å  internal diameter and efficiently 
allowed glucose to across model membrane.  
Owing to its pore formation ability in bilayer membrane, cyclic peptides were also tested as 
potential antibacterial agents. The nanotubes can easily form within bacterial membrane 
without involving proteins and specific receptors which makes them attractive over traditional 
antibiotics. The princinples of cyclic peptide nanotubes as antibacterial agens were first 
demonstrated by M. Reza Ghadiri et al. in 2001 (Figure 47).
262
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Figure 47. Tubular architecture of the assembled cyclic peptide and modes of membrane permeation. 
a, intramolecular pore; b, barrel stave; and c, carpet-like (cyclic peptides are depicted as ring 
structures). Reprinted by permission from Macmillan Publishers Ltd: [Nature] (reference 262), 
copyright (2010) 
It was previously observed that amphiphilic cyclic peptides composed of three consecutive 
hydrophilic residues and five L-tryptophan and D-leucine residues self-assembled into 
nanotubes in synthetic membranes. Thus, a series of six- and eight-residue amphiphilic cyclic 
peptides were synthesized to examine their antibacterial activity. Escherichia coli and 
methicillin-resistant S. aureus (MRSA) were selected as target bacteria. It was found that 
glutamic acid residue had a deleterious effect on the antibacterial activity whereas basic 
amino acid residues were preferred. This is most likely due to the unfavorable electrostatic 
interactions of the carboxylate side chain with negatively charged cell membrane. Moreover, 
linear control peptides with identical amino acids sequences displayed little activity against 
MRSA. This highlighted the role of cyclic D, L-peptide structure in the formation of 
functional tubular assembly in bacteria membrane. In overall, the effectiveness of this class of 
cyclic peptides provides a promising new type of candidate in the developments of antibiotics.  
James T. Fletcher et al. developed a combinatorial approach that could rapidly identify 
hexamer cyclic peptide sequences for the application of antibacterial agents.
263
 Gram-positive 
MRSA and gram-negative E. coli and two eukaryotic marine algae, Ulva linza and Navicula 
perminuta were screened. A reliable, high-throughput assay was established to facilitate the 
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examination by correlating toxicity to the fluorescence intensity of chlorophyll. Previous 
results showed that the selectivity of cyclic peptide against bacteria was highly sensitive to 
minor changes in amino acid composition. This finding was then extended to the scope of 
eukaryotic species as well. 
Leila Motiei et al. prepared a series of cationic cyclic peptides bearing D-glucosamine, 
D-galactose, or D-mannose glycosyl side chains.
264
 This design was inspired by the discovery 
and structure elucidation of a new class antibiotic named mannopeptimycin in 2002.
265
 
Mannopeptimycin is in striking structural similarity to the previous described self-assembling 
cyclic peptide. The major difference in mannopeptimycin is the glycosylation in the side chain 
of tyrosine (Figure 48). Thus, the authors envisioned the introduction of glycosyl chains could 
improve the performance of cyclic peptide based antibacterial agents. Indeed, they found out 
that specific glycosylation not only preserved their activities against drug-resistant 
gram-positive bacteria but also significantly reduced their toxicity. 
 
Figure 48. Chemical structure of mannopeptimycin 
2.3.3 Other peptides assembly 
Peptide assembly can be achieved with a variety of structurally different peptide based 
building blocks. Besides amphiphilic peptides and cyclic peptides, there are several other 
rather efficient peptide based assembling systems.
22
 For example, coiled-coil peptides, in 
which several helices are coiled together, have been shown to be able to assemble into 
cages.
266
 β-hairpin peptides can fold with itself and induce gelation process.267,268 Peptides 
with strong tendency to form β-sheet can assemble into tape-like aggregates.269,270   
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2.3.3.1 Metal-peptide assembly 
Peptide self-assembling trigger by metal ions is emerging as a quite active field of research 
nowadays.
271
 Supramolecular structures assembled with the combination of peptides and 
metal ions are extremely interesting in the application of biomaterials and biomedicines due to 
the fact that natural proteins often require metal ions as cofactor to fulfill their functions. 
Additionally, the coordination with metal ion can change the conformation of peptides which 
could in turn alter and regulate their physiological properties.  
To achieve peptide assembly with metal ions, appropriate ligands are in most cases 
incorporated into the amino acids sequences. In 2005, Mary Elizabeth Williams et al. 
synthesized two peptides with pyridine or bipyridine ligands.
272
 Titrations with Cu
2+
 and Fe
2+
 
showed that both peptides bound stoichiometric quantities of transition metals. Interestingly, 
the peptides bearing bipyridine ligands cross-linked with each other through metal ion centers 
to form duplex structures. Modelling results suggested that the backbones of this peptide 
served as a scaffold for the directed assembly of copper cations.  
 
Figure 49. Concept of peptide Gly-Pro-Pro assembly with metal ions. Reference 273, copyright 
(2016) Wiley. Used with permission from John Wiley and Sons. 
Similarly, Tomohisa Sawada and Makoto Fujita et al. constructed a short proline containing 
peptide with two pyridine ligands on both terminals (Figure 49).
273
 The rather simple peptide 
Gly-Pro-Pro was able to assemble into polyproline-II helices through the coordination of 
silver ion with pyridine ligand in aqueous alcohol. Crystallographic studies revealed two 
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unique helical channel structures in this material. The larger one was approximately 2 nm in 
diameter and able to encapsulate guests such as BF4
-
 anion, chiral organic molecules and 
linear penta-saccharides.   
Futoshi Fujimura et al. designed a cyclic tri-β-peptide having a terpyridine ligand.274 The 
peptide itself was not able to form nanotubes due to the introduction of bulky terpyridine 
groups that prevented the intermolecular hydrogen bonding interactions. However, the 
rod-shaped crystals obtained from the cyclic tripeptide can efficiently bind to copper cations 
and exhibited weak fluorescence. Masatoshi Ikemi et al. reported a ca. 9 nm M12L24 
coordination sphere coated with 24 hexa-peptide aptamers.
275
 The sphere was assembled from 
12 Pd (II) ions and 24 terpyridine containing peptide (Arg–Lys–Leu–Pro–Asp–Ala) ligands at 
their convex. The formation of nano-sphere was confirmed by diffusion-ordered NMR 
spectroscopy (DOSY). 
Nitrilotriacetic acid (NTA) is a strong chelating agent for metal ions such as Ca
2+
, Cu
2+
 and 
Fe
3+
. Variant of NTA is widely used for protein isolation and purification in the His-tag 
method. Jean Chmielewski et al. then designed a triple helical peptide modified with a His 
moiety on its C-terminus and a NTA unit on its N-terminus in order to create collagen-based 
supramolecular assemblies.
276
 Upon addition of metal ions, the self-assembling process is 
triggered and higher ordered aggregates such as sheet-like structures and nanoparticles can be 
observed in solution. This process was fully reversible when EDTA, a competing metal 
cHeLating agent, was added to the assemblies. They further demonstrated that the final 
morphologies of assemblies were controllable by defining the number of Pro-Hyp-Gly 
repeating units in collagen peptide.  
2.3.3.2 Amyloid peptide assembly 
The aggregation of amyloid β-peptide (Aβ) into oligomers or fibrils is now considered as a 
key cause of Alzheimer's disease (AD).
277,278
 Amyloid β-peptides, normally containing 36-43 
amino acids, are the main component of the amyloid plaques found in the brains of Alzheimer 
patients. The assembling property of Aβ peptide has thus inspired numbers of 
researches.
279-281
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Figure 50. Assembly of Aβ (16-22) peptide fibers and nanotubes a) pH 6 (b, c, d) pH 2. Reprinted 
with permission from Reference 282. Copyright (2016) American Chemical Society.   
Anil K. Mehta et al. found out that the short Aβ (16-22) peptide, a segment from Aβ peptide, 
assembled into amyloid fiber which was morphologically identical from the full-length 
peptide fiber.
282
 However, this peptide was also capable of forming different structures under 
distinct conditions. At slight acidic solutions, long and unbranched amyloid fibrils were 
observed with TEM. Decreasing the pH to 2 resulted in the formation of nanotubes as shown 
in Figure 50. Molecular dynamic simulations showed that these fibers were featured with both 
a polar and a nonpolar face, while the same side chains displayed on each face of tubes. 
Aβ peptide is thought to contain a set of structures when dissolved in solution. As 
consequences, it cannot be crystallized and most structural knowledge on this peptide comes 
from NMR and molecular dynamics. James S. Nowick et al. then incorporated a key region of 
Aβ into a macrocyclic peptide that could stabilize oligomers.283 This strategy facilitated the 
structural elucidation by X-ray crystallography. Crystallographic structures were thus 
obtained from the macrocycle containing Aβ (15−23) peptide. Later, they showed that 
macrocycle containing both Aβ (15−23) peptide and Aβ (15−23) hybrid strand could also be 
crystallized.
284
 An extended β sheet comprised of two dimers interacting through hydrophobic 
interactions was observed in solid state. This eventually led to fibril-like assembly formation 
that ran the length of the crystal lattice.   
Interestingly, David G. Lynn et al. demonstrated the switching ability of amyloid formation 
with metal ions.
285
 By examining the structures of fibrils formed by Aβ (10-35) peptides, they 
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noticed that the side chains of the histidine residues at positions 13 and 14 were directed to 
opposite surfaces of the β sheet which provided an ideal site for Zn2+ chelating. The results 
showed that in the absence of Zn
2+
, a nucleation phase lasting several hours was observed 
which was followed by a longer growth phase. Addition of Zn
2+ 
to Aβ (10-35) peptide 
solution, however, diminished the nucleation phase. They further demonstrated that varying 
the concentrations of Zn
2+
 dramatically altered both self-assembly kinetics and fibril 
morphology. With higher Zn
2+
 concentration, the nucleation time was significantly eliminated 
(Figure 51b). In the rapid assembly process, formation of helical thick ribbons could be 
observed in both AFM and TEM. 
 
Figure 51. (a) CD spectra over time of Aβ peptide at pH 5.6. (b) Mean residue molar ellipticity as a 
function of time for Aβpeptide in the presence of different Zn2+concentrations. Reprinted with 
permission from Reference 2854. Copyright (2016) American Chemical Society.   
2.3.3.3 Collagen peptide assembly 
Collagen is the most abundant protein in mammals and the main component of connective 
tissues. However, collagen isolated from natural sources is difficult to modify and can induce 
immunological side effects. Synthetic peptides which could assemble into collagen-like 
structures thus attract many interests. In 2008, Ronald T. Raines et al. reported that short 
collagen fragments prepared through conventional solid phase peptide synthesis could also 
self-assemble into triple helices, characteristic structure of collagen.
286
 Cysteine residues were 
incorporated to hold together the three strands by disulfide bonds. The self-assembling of this 
peptide is comprised of two processes. Firstly, individual peptide fragments formed a 
triple-helix through intramolecular hydrogen bonding interactions. Afterwards, intermolecular 
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hydrogen bonding interactions allowed elongated fibril formation. CD and TEM 
measurements revealed that these fibrils resembled the triple helix structure of natural 
collagen and were longer (400 nm) than any known collagens.  
Jeffrey D. Hartgerink et al. designed a peptide that replicated each steps of the 
self-assembling of typical collagens (Figure 52: peptide chains to triple helices to nanofibers 
and finally to hydrogel).
287
 This peptide utilized the proline–hydroxyproline–glycine 
repeating units of collagen with additional salt-bridged hydrogen bonds between lysine and 
aspartate residues to stabilize the triple helix. The hydrogel formed with collagen mimetic 
peptides can be degraded by collagenase and it is also temperature sensitive due to the 
unfolding property of triple helix at 40℃. 
 
Figure 52.Self-assembly of collagen (a) compared to that of collagen mimetic peptide (b). Reprinted 
by permission from Macmillan Publishers Ltd: [Nature chemistry] (reference 287), copyright (2011) 
The assembling property of collagen peptides can be used to construct other types of 
supramolecular structures.
288-291
 For example, Tushar Gore et al. demonstrated that adding 
lipophilic tails can control the assembly morphology of model collagen peptides.
292
 Short tails 
such as C12 and C14 resulted in the formation of spherical micelles. Increasing the length of 
tails led to the formation of disk-like micelles. Double tails with lengths of C18 and C20 gave 
rise to crystalline structures. Armando E. Reimer et al. reported that when aromatic FITC 
moiety was attached to a non-helical collagen peptide, tubular structures were well observed. 
293
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3. PROJECT AND OBJECTIVES 
  Peptide based materials have gained much interests in recent years due to its functional 
versatility and biocompatibility. Applications such as gene delivery vector and self-assembled 
nanomaterials have been widely explored. On the other hand, the excellent anion recognition 
ability of GCP moiety provides another useful tool for applications regarding anions such as 
DNA and peptides. Therefore, we hypothesized that the combination of GCP and peptide 
scaffold could largely improve the performance of peptide based materials in the above 
applications. This hypothesis is thus demonstrated in the following projects.     
3.1 Development of novel cell penetrating peptide  
Among the various strategies which have been applied in drug delivery so far, cell 
penetrating peptides are considered highly promising owing to their biocompatibility and 
functional versatility. These peptides are mostly featured in the use of cationic amino acid 
residues especially arginine due to the anionic nature of cell membrane. Although the exact 
mechanism of cellular entry of arginine rich cell penetrating peptides have not been fully 
understood, it is clearly shown that cell surface proteoglycan played an important role in this 
process.  
 Based on these findings, we hypothesized that enhancing the hydrogen bonding ability of 
arginine rich cell penetrating peptides could improve their interactions with 
glycosaminoglycan on cell surface (Figure 53). GCP moiety has previously been 
demonstrated high binding affinity toward oxoanions. Therefore, we envisioned that 
introduction of GCP groups into the side chains of peptides could provide a more effective 
peptide in cellular uptake. 
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Figure 53. Schematic representation of the designing principles  
3.2 Development of cell penetrating peptide based gene 
transfection vector 
Peptide based gene transfection vectors have attracted increasing interests in recent years 
due to their ease of synthesis, lower toxicity at least compared to polymeric transfection 
vectors and versatility of functionalization. Of the most often used peptidic vector, arginine 
rich cell penetrating peptides have been identified as being highly efficient in cellular uptake 
and thus are widely tested as gene delivery vectors. However, at least 8 to 9 arginines were 
still necessary for decent gene transfection even with these amphiphilic arginine oligomers. 
The transfection efficacy as well cytotoxicity of these peptides requires further improvement, 
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with regard to future applications. 
Although other cationic peptides such as lysine oligomers have been used for gene 
transfection, their efficacies are usually even worse than arginine rich peptides. Owing to the 
superior anion binding ability of GCP moiety, we hypothesized that the replacement of 
guanidine with GCP in arginine-rich cell penetrating peptides (CPPs) should further improve 
the binding ability between CPPs and both DNA and the cell membrane which might result in 
a better performing vector (Figure 54).  
 
Figure 54. Schematic representation of the designing principles  
3.3 Development of cyclic peptide nanotube based gene 
transfection vector 
Besides individual peptides, self-assembled peptide aggregates have also been tested as 
gene transfection vectors. For example, M. Yolamanova et al. recently reported that an 
amphiphilic 12-amino acid peptide derived from the HIV-1 glycoprotein gp120 forms cationic 
nanofibers which boost virus mediated gene transfection.
294
 Only the nanofibers, not 
individual peptides, enhanced gene transfection probably by functioning as an “electrostatic 
nanobridge” between virus and cell membrane. It has also been reported that nanotubes 
formed from cationic dipeptides bind single strand DNA.
295
 Upon dilution these nanotubes 
PROJECT AND OBJECTIVES 
75 
rearrange into vesicles which are taken up by cells.  
 
Figure 55. Schematic representation of the designing principles  
Cyclic peptide nanotubes have become a highly interesting scaffold for a variety of 
applications since their first discovery in the 90’s. However, cyclic peptide nanotubes 
normally cannot be positively charged under physiological conditions since charge repulsion 
then prevents tube formation. Unfortunately, positive charges are usually critical for DNA 
binding and also gene transfection due to the anionic nature of DNA. Hence, cyclic peptide 
nanotubes were not used for DNA binding or even gene transfection so far. Therefore, we 
hypothesized that functionalization of a cationic cyclic peptide with our GCP group could 
significantly alter its self-assembly and DNA binding features (Figure 55). 
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3.4 Development of supramolecular β-helix mimetic peptide  
One current goal of supramolecular chemistry is to design artificial self-assembling systems 
that could mimic biological important helix structures under biomimetic conditions. A variety 
of assembly strategies based on peptide building blocks have been thus developed. However, 
while peptide assembly aiming to resemble α-helix structure has been demonstrated by 
several studies, reports on β-helix mimics are rare. Mainly because α-helix is one of the most 
common secondary structures of proteins and therefore examples on such structures are 
abundant. On the other hand, there are only very few peptides which exhibit β-helix properties 
and thus are poorly studied due to insufficient data.  
Gramicidins are fascinating examples of such structures designed by nature. It is generally 
believed that this peptide can only form a unique head-to-head associated dimer of two single 
stranded β-helices (the channel form) in the presence of membrane mimics, such as vesicles. 
In organic solvents it exists in totally different structures, such as a double strand inter-twined 
helix (the non-channel form). Although there have been reports that demonstrated that similar 
structural properties as of gramicidin A can be realized with artificial non peptidic systems 
such as aromatic hydrazide oligomer and synthetic triazole compounds, they normally require 
carefully designs and adjustments. A strategy for a self-assembling peptide forming a β-helix 
structure has not yet been developed. 
The interaction of a GCP moiety with carboxylates in water is sufficiently strong as 
described above. Therefore, we hypothesized that this supramolecular recognition pair 
(GCP—COO-) can be applied to stabilize a β-helix structure and might also provide 
additional self-assembling property when it is approximately positioned (Figure 56). 
 
Figure 56. Schematic representation of the designing principles 
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3.5 Development of functionalized amphiphilic peptide assembly 
Self-assembling Fmoc-based dipeptides are highly interesting in the development of 
supramolecular materials. Their assembling properties are rather robust and can be realized in 
aqueous conditions. However, the variety of Fmoc-based dipeptides is limited. Hydrophobic 
amino acid residues are in most cases required to achieve efficient peptide assembly. 
Post-assembly modification of this system is thus difficult to achieve compared to that of 
amphiphilic peptides with aliphatic chains. 
Therefore, we hypothesized that the introduction of a GCP moiety in the side chains of 
Fmoc-based dipeptides could provide further manipulation of the assembled peptide fibers 
(Figure 57). The GCP moiety is most likely not protonated under neutral conditions due to its 
low pKa value (~7). This property renders a hydrophobic domain in the side chains of peptide 
47 which is structurally similar to the Fmoc-FF peptide but with additional anion binding 
ability. Post-assembly modification is thus plausible through the anion recognition ability of 
GCP moiety arrayed on the surface of fibers. This property allows us to further manipulate the 
assembled peptide fibers with other components such as monomers which can be covalently 
polymerized, small organic molecules which could chelate metal ions etc. Thus, this peptide 
could serve as a platform or a template for a variety of applications including DNA binding 
and hybrid material fabrication. 
 
Figure 57. Schematic representation of the design principle 
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4. RESULTS AND DISCUSSION 
  In this chapter, we describe that through the utilization of the excellent anion binding 
ability of GCP moiety, a variety of artificial peptides could be obtained which showed 
interesting properties in cellular uptake (section 4.1), gene delivery (section 4.2 and 4.3),  
and supramolecular assembly (section 4.4 and 4.5).  
4.1 Development of novel cell penetrating peptide 
4.1.1 Synthesis of GCP moiety 
In order to introduce the extremely strong anion binding motif GCP into the designed 
systems, it must be synthesized before peptide preparation. The route of synthesis for GCP is 
well established in the Schmuck laboratory as shown in Figure 58.  
 
Figure 58. Synthetic route of GCP moiety (56) 
  The synthesis of GCP started form commercial available pyrrole. Pyrrole (48) was first 
acylated with trichloroacetyl chloride in diethyl ether to give the trichloroacetyl-pyrrole (49). 
Trichloroacetyl-pyrrole 49 was then subjected to attack with benzylate and liberation of the 
trichloromethane anion directly yielded the benzyl ester 50. Vilsmeier–Haack formylation was 
then conducted on 50 to introduce an aldehyde functional group in the 5 position of pyrrole. 
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The Vilsmeier reagent, preformed from phosphoryl chloride and dimethylformamide, was 
added slowly under cooling to 50 and the reaction gave rise to 2’5-substituted pyrrole 51. 
Subsequently oxidation with potassium permanganate resulted in 52. Afterwards, molecule 52 
was allowed to couple with a tert-butyloxycarbonyl (Boc)-protected guanidino moiety using 
PyBop as coupling reagent. The activation is necessary due to the low reactivity of the 
carboxyl group in 52. The guanidinocarbonylpyrrole benzyl ester 55 directly precipitated 
when water was added to the reaction mixture. Finally, the benzyl ester group was cleaved off 
by hydrogenation with a catalytic amount of palladium to yield 56 as a while solid. GCP 
building block 56 possesses a carboxylate group which can facilitate the following 
modifications in peptides. The whole procedure can be operated on gram scale with an overall 
yield of 50%. 
4.1.2 Synthesis of dipeptide analogue 
4.1.2.1 Synthesis of dipeptide analogue 40 
  To examine the effect of GCP modification on the cellular uptake ability of cell penetrating 
peptides, a dipeptide analogue 40 was first designed. GCP units were introduced into the side 
chains of lysine through conventional coupling reactions. The preparation of 40 was 
performed on solid phase using Fmoc strategy (Figure 59). Rink amide MBHA resin was 
selected because it provide an amide functionality at the C-terminus after final cleavage. 
Commercially available amino acid Fmoc-Lys(Alloc)-OH was used to build the peptide 
scaffold (step 2). De-protection of the Alloc group with Pd(PPh3)4 resulted in free amine 
groups on the side chains of lysine (step 3). Subsequently coupling with GCP moiety (step 4), 
Fmoc de-protection (step 5) and cleavage from the resin (step 6) yielded the crude product. 
Purification with MPLC resulted in peptide 40 in 25 % yield with 96 % purity. 
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Figure 59. Synthetic route of dipeptide analogue (40) 
4.1.2.2 Synthesis of dipeptide 41 
  For comparison of binding affinities with glycosaminoglycan, we also synthesized peptide 
41, comprised of two arginine residues, as control peptide. The preparation of 41 was 
performed on solid phase using Fmoc strategy (Figure 60). Rink amide MBHA resin was 
selected. Commercial available amino acid Fmoc-Arg(Pbf)-OH was used to construct the 
peptide scaffold (step 2). Subsequently deprotection (step 3) and cleavage from the resin (step 
4) and purification with MPLC yielded peptide 41 as a white solid in 25 % yield. 
 
Figure 60. Synthetic route of dipeptide (41) 
RESULTS AND DISCUSSION 
81 
4.1.2.3 Synthesis of labeled dipeptide analogue 58 
 The cellular uptake ability of peptides can be examined in several ways. For example, the 
hydrophobicity of a molecule can be defined with partition experiment in which a two phase 
system (typically octanol and water) is constructed to measure the layer permeation ability of 
target molecule. The most often used and indeed most reliable method is to label the studied 
peptide with a fluorescent group and examine its cellular uptake directly. For this purpose, we 
labeled peptide analogue 40 with rhodamine B through conventional coupling reaction 
protected from light (Figure 61). Purification with flash chromatography resulted in a red 
solid 58 (38 % yield). 
 
Figure 61. Synthetic route of labeled dipeptide analogue (58) 
4.1.2.4 Synthesis of labeled dipeptide analogue 60 
 
Figure 62. Synthetic route of labeled dipeptide analogue (60)   
We also labeled peptide analogue 40 with fluorescein to confirm the results and also exclude 
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any artifacts caused by the property of the fluorophores. Fluorescein isothiocyanate was used 
to modify the N-terminus of peptide 40 through conventional conjugate addition reaction 
protected from light (Figure 62). Purification with flash chromatography resulted in a yellow 
solid 60 (90 % yield). 
4.1.3 Binding study with glycosaminoglycan 
  Although the exact mechanism of cellular entry of arginine rich CPPs has not been fully 
understood yet, it has been clearly demonstrated that cell surface proteoglycans played an 
important role in this process. The binding affinity of both peptides with glycosaminoglycan 
was therefore tested by isothermal titration calorimetry (ITC). ITC is at present the most 
effective tool to characterize the thermodynamic profile of interactions of small molecules 
with macromolecules such as DNA and proteins, providing valuable information about the 
enthalpic and entropic contributions to the Gibbs energy. Commercially available heparin 
sodium, a sulfated glycosaminoglycan (GAG), was selected as model due to its close 
structural similarity with respect to cell surface proteoglycans (Figure 63).  
The binding between control peptide 41 and heparin was negligible. Only the dilution 
effect of heparin can be observed when it was titrated into a solution of peptide 41 (Figure 64). 
However, in sharp contrast to this, the binding between dipeptide analogue 40 and heparin 
was extremely strong (10
7
) as shown in Table 1. Considering the structural similarity between 
the two peptides, clearly the favorable interactions between the GCP moiety in 40 and the 
oxoanions in heparin are mainly responsible for this enhancement. Moreover, the 
thermodynamic signature for the binding process between heparin and 40 were rather unusual. 
The enthalpy contribution in the binding process of peptide 40 with heparin reached to -60.5 
kJ/mol. This was however compensated with an unfavorable entropy change. Such classical 
enthalpy-entropy compensation indicated that the binding between peptide 40 and heparin 
was very specific. 
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Figure 63. Chemical structure of heparin disaccharide 
 
Figure 64. ITC titration curves of peptides 40 (A) and 41 (B) with heparin. Note that the heat exchange 
for the titration to 41 (-0.25) is 64 fold smaller compared to 40 (-16). Heparin (1 mM) was titrated into 
peptides 40 and 41 (50 µM) pH 7.4 cacodylate buffer solution, respectively. 
Table 1. Thermodynamic binding profiles of peptides 40 and 41 with heparin 
 Kd (M
-1
) N ∆H 
(kJ/mol) 
T∆S 
(kJ/mol) 
40 2.31 × 107 0.29 -60.5 ± 0.3 -50.4 ± 5.0 
41 no binding detected - - - 
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4.1.4 Cellular uptake study  
As described above, peptide 40 obviously exhibited rather high binding affinity with model 
glycosaminoglycan, we thus determined to test its cellular uptake ability in HeLa cell lines. 
Rhodamine labeled peptide 58 and fluorescein labeled peptide 60 was added to cell culture 
medium respectively and incubated for one hour at 37 ℃. After washing the cells with 
buffered water three times, they were directly examined with confocal fluorescence 
microscopy to determine cellular uptake ability. The cell experiment was conducted with the 
cooperation from prof. Shirley Knauer in biology department with Stefanie Schlesiger.  
The results clearly showed that peptide 58 entered into the cells after the incubation (Figure 
65). It is also can be seen that the cellular distribution of peptide 58 is concentration 
dependent. At lower concentration, the internalized peptides seemed to be entrapped in cell 
compartments. However, when the concentration increased to 20 μM, peptide 58 was well 
distributed in both cytosol and nucleus. These results were further confirmed with peptide 60 
bearing a green fluorophore (Figure 66). 
 
Figure 65. Confocal microscopy images of HeLa cells with peptide 58 
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Figure 66. Confocal microscopy images of HeLa cells with peptide 60 
Therefore, we tested the cellular distribution property of peptide 58 in co-localization 
experiments. Cell co-localization was conducted with 10 μM peptide 58 due to the fact that 58 
obviously entered into cytosol at higher concentration. Three cell organelles, Golgi apparatus, 
endosome and lysosome were stained with green fluorophore respectively. DAPI, a nucleic 
acid specific dye exhibiting blue fluorescence, was used to stain cell nucleus in each case.  
  As shown in Figure 67, peptide 58 did not co-localize with the Golgi apparatus in HeLa cell 
lines. We then labeled endosomes with a green fluorophore. Endosomes are in most cases the 
necessary pathway for endocytosis mediated cellular uptake. However, the internalized 
peptide 58 did not co-localize with endosomes neither which might suggest that endocytosis 
pathway was not mainly responsible for the cellular uptake process of peptide 58 (Figure 68).  
 
Figure 67. Co-localization images of Golgi apparatus with 10 μM peptide 58 
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 Figure 68. Co-localization images of endosome with 10 μM peptide 58 
We next labeled lysosomes, another cell organelle containing the materials taken up by the 
cells, with green fluorophore. The results shown in Figure 69 clearly demonstrated that most 
peptide 58 internalized by cells ended up in lysosomes under this concentration. Thus, the 
results implied that peptide 58 with its two GCP group modifications, ultimately ended up in 
lysosomes after 1 h incubation time with cells. However, this might be due to the incubation 
time for peptide 58 is too long that it already passes through other endocytosis related 
organelles such as endosome.  
 
Figure 69. Co-localization images of lysosome with 10 μM peptide 58 
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Importance for any future applications of cell penetrating peptides is their toxicity. 
Therefore, the cytotoxicity of the novel cell penetrating dipeptide analogue 40 was examined 
with alamar blue assay by means of metabolic activity. Different concentrations of peptide 40 
were tested in HeLa cell lines. The results showed that peptide 40 is essentially not toxic at 
least in vitro (Figure 70). Even treatment with 100 μM of peptide 40, a concentration well 
above the concentration tested in cellular uptake studies, exhibited negligible cytotoxicity.   
 
Figure 70. Normalized cell viability of different concentrations of peptide 40 in HeLa cell lines 
  In summary, the introduction of the GCP moiety into short peptides exhibited astonishing 
ability in the enhancement of cell penetration. In contrast to the common strategy of adding 
lipophilic tail, the combination of weak non-covalent forces, i.e. hydrogen bonds and ion pairs, 
provided the smallest cell penetrating peptide analogue known so far to be best of our 
knowledge. With its small size and negligible cytotoxicity, we envisioned peptide 40 would 
largely benefit the development of drug carriers.    
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4.2 Development of cell penetrating peptide based gene delivery 
vector 
  The first project successfully demonstrated that modification of short peptides with GCP 
moieties can enhance their cell penetrating ability. Therefore, we determined to utilize the 
same strategy to develop novel cell penetrating peptides based gene delivery vectors. 
4.2.1 Synthesis of tetra peptide analogues 
We thus designed and synthesized a series of tetra peptide analogues with different 
numbers of GCP modifications on the side chains to evaluate their transfection efficiency 
(Figure 71).  
 
Figure 71. Chemical structures of designed tetra peptide analogues 
4.2.1.1 Synthesis of GCP modified tetra-peptide analogues 
The strategy of synthesis for the tetra-peptide series was very similar. Alloc protected lysine 
was applied in each case for the coupling of GCP moiety into the side chain. An example of 
synthesis route for peptide 42 is shown in Figure 72. Synthesis for other GCP modified 
peptides can be found in experimental section 6.4.2. The preparation of 42 was performed on 
solid phase using Fmoc strategy. Rink amide MBHA resin was selected to provide an amide 
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group at the C-terminus after cleavage. Commercial available amino acid 
Fmoc-Lys(Alloc)-OH was used to build the tetra peptide scaffold (step 2). De-protection of 
the four Alloc groups in the side chains with Pd(PPh3)4 resulted in free amine groups on the 
side chains (step 3). The amine groups are in close proximity with each other which may 
suppress their reactivity. Therefore, a prolonged reaction time (8 h) and large excess of GCP 
were used to ensure the full coupling of amines (step 4). Subsequently de-protection (step 5) 
and cleavage from the resin (step 6) yielded the crude product. The resulting solid was 
purified by MPLC to obtain 42 as white solid (5 % yield) with 93 % purity by analytical 
RP-HPLC.  
 
Figure 72. Synthetic route of tetra peptide 42 
4.2.1.2 Synthesis of control tetra peptide 43 and 44 
Two control peptides arginine tetramer 43 and lysine tetramer 44 were synthesized for 
comparisons in DNA binding and gene transfection experiments. Commercially available 
amino acid Fmoc-Arg(Pbf)-OH was used to synthesize peptide 43 (Figure 73) After 
de-protection (step 3) and cleavage from the resin (step 4), the resulting solid was purified by 
MPLC to obtain 43 as white solid (19% yield) with 90 % purity by analytical RP-HPLC. 
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Figure 73. Synthetic route of tetra peptide 43 
Lysine tetramer 44 was prepared with commercially available amino acid 
Fmoc-Lys(Boc)-OH (Figure 74). After de-protection (step 3) and cleavage from the resin (step 
4), the resulting solid was purified by MPLC to obtain 44 as white solid (10 % yield) with 90 % 
purity by analytical RP-HPLC.  . 
 
Figure 74. Synthetic route of tetra peptide 44 
4.2.2 DNA binding study 
The binding affinity of these GCP modified tetra peptide analogues with DNA was first 
RESULTS AND DISCUSSION 
91 
studied with isothermal titration calorimetry (ITC) and ethidium bromide (EB) displacement 
assay. Both techniques serve as reliable means to examine the binding affinity of designed 
DNA binding molecules. Additional thermodynamic binding profiles can be obtained with 
ITC experiments. Commercially available fragmented calf thymus DNA (ctDNA) was 
selected as model DNA. 
Ethidium bromide is a red phenanthridine dye which can intercalate into nucleic acids. Its 
fluorescence emission at 600 nm increases by a factor of 50-100 upon binding to DNA. 
Ethidium bromide s´ binding constant with DNA was determined around 10
6
 M
-1 
in buffered 
water at pH 7.5. Addition of DNA-binding molecules such as the tetra peptide analogues 
could displace ethidium bromide from its EB/DNA complex which consequently results in a 
reduction of the EB emission band around 600 nm. The amount of ligand necessary to 
displace EB (EC50) is the most important information obtained from EB displacement assay to 
evaluate the binding affinity. However, it should be noted that only differences of ca. one 
order of magnitude or greater can be considered as significant due to the approximative 
character of EC50 value. Furthermore, EC50 values are only comparable for the same type of 
DNA due to different binding modes of ligands to nucleic acid sequences. 
 
Figure 75. EB displacement titration assay. 42 was added in aliquots (left); Excerpt at 600 nm 
corrected for EB s´ own emission, fitted with exponential decay first order function (right). 
Ethidium bromide (0.75 μM) was pre-incubated with ctDNA (3.0 μM) for 15 minutes. 
Afterwards, peptide 42 was added to the solution EB/DNA. The aliquot addition of 42 
resulted in decrease of the fluorescence emission intensity at 600 nm indicating that peptide 
42 displaced EB molecules through its binding with DNA (Figure 75). Other peptides 
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displayed similar behavior when they were added to EB/DNA solution (see experimental 
section). The EC50 values for each peptide were thus obtained as shown in Table 2. 
Table 2. EC50 values of different peptides obtained in EB displacement assay. 0.01M sodium 
cacodylate buffer at pH 7: [ctDNA] = 3.00 μM, [EB] = 0.75 μM. 
peptide 42 62 63 64 43 44 
EC50 (μM) 0.85 1.51 1.50 1.31 0.89 0.85 
As can be seen above, the concentrations of peptide analogues necessary to displace half of 
the EB molecules from its DNA complex were very similar to each other. Although tetra GCP 
modified peptide 42 and control peptides arginine tetramer 43 and lysine tetramer 44 required 
less amounts, such difference is negligible in EB displacement assay. This result indicated that 
all these tetra peptide analogues bind to DNA with similar affinity.  
ITC experiments were thus conducted to study the thermodynamic signature of these tetra 
peptide analogues with DNA. The binding constants of each peptide with DNA were directly 
obtained as well the contributions from enthalpic and entropic forces (Table 3). The results 
suggested that functionalization with GCP groups significantly enhanced the binding affinities 
of these peptides (10
6
) about one magnitude compared to original tetra lysine peptide (10
5
). 
However, these peptide analogues did not exhibited stronger binding with DNA compared to 
tetra arginine peptide. Moreover, the differences in the binding constants between these 
peptide were not significant taking into account the experimental and calculation errors in 
ITC. 
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Table 3. ITC binding data of peptide analogues (50 μM) with DNA (0.7 mM to 1.4 mM) in 0.01M 
pH 7.4 cacodylate buffer. 
Peptide Sequence Kd 
M
-1
 
ΔH 
kcal/mol 
TΔS 
kcal/mol 
42 NH2-G’G’G’G’-CONH2 2.19·10
6
 -25.6 -16.9 
62 NH2-KG’G’G’-CONH2 9.05·10
6
 -23.3 -13.8 
63 NH2-G’KKG’-CONH2 1.35·10
6
 -2.86 5.55 
64 NH2-KKKG’-CONH2 1.24·10
6
 -1.63 6.71 
43 NH2-RRRR-CONH2 9.23·10
6
 -12.3 -2.84 
44 NH2-KKKK-CONH2 2.52·10
5
 -2.87 4.64 
Despite the overall similar binding affinities of these peptide analogues, their 
thermodynamic profiles of the binding process with DNA were quite different. Table 3 clearly 
showed that the binding between DNA and control peptide 44, lysine tetramer, was mainly 
driven by entropy. However, modification of tetra lysine with GCP groups demonstrated 
amazing ability of shifting the thermodynamic signature to an enthalpically derived binding as 
GCP moiety has a much stronger hydrogen bonding ability. In sharp contrast to 44, the 
binding profiles of peptide 42 and 62 with DNA shifted strongly towards enthalpy. Enthalpy 
contribution for peptide 62 increased to - 23.3 kcal/mol which was almost 10 fold stronger as 
that of 63 (-2.86 kcal/mol). The enhancement in enthalpy contribution was even more 
significant in the case of peptide 42. Most likely, this enhancement in enthalpy is due to the 
fact that both peptides possess more GCP groups than positively charged ammoniums. Thus 
the binding contributions from the recognitions between GCPs and DNA phosphates 
overwhelmed the contributions from simple charge interactions. The binding processes of 
peptides 63 and 64 with DNA were still mainly driven by entropy with minor contributions 
from enthalpy. This is not surprising since there are less GCP groups than positively charged 
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ammoniums in both peptides. As consequence, their bindings with DNA is mostly driven by 
the release of counter cations from DNA backbone.  
Taken together, the results suggested that with more GCP group modifications, the binding 
between peptide and DNA became more enthalpy favored. However, entropic contribution to 
the binding process became significantly negative along with more GCP modifications. 
Plotting of entropy with enthalpy contributions of the binding data resulted in a fine linear 
relationship which is a typical sign of entropy-enthalpy compensation (Figure 76). Such 
entropy-enthalpy compensation is characteristic of specific complex formation.
296
 
 
Figure 76. Plot of entropy with enthalpy contributions of binding data 
Notably, similar compensation effect has been reported earlier with totally different peptide 
sequences containing GCP group modifications.
297
 Thus, the ability of GCP moiety of shifting 
the binding thermodynamics towards enthalpy is independent on the sequence of the peptides. 
It is also worth pointing out that GCP group not only enhanced the hydrogen bonding abilities 
of these peptide analogues, they also became more hydrophobic compared to unmodified 
peptide 44 as determined by their elution profiles of HPLC. 
The condensation ability of these tetra peptide analogues with DNA was tested by dynamic 
laser scattering (DLS) and atomic force microscopy (AFM). DLS measurements can provide 
information on the size and charge state of the formed DNA/peptide complexes. AFM results 
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are valuable in the determination of the morphology of those complexes or aggregates.  
 
Figure 77. Number distribution of the size of aggregates formed by 3 eq. peptide analogues (150 μM) 
and DNA (50 μM) in pH 7.4 cacodylate buffer 
DLS results demonstrated that all peptides exhibited excellent DNA condensation ability. 
For each measurement, three equivalence of peptide analogues (relative to DNA phosphate 
concentration) were used to complex DNA. Aggregates with sizes ranging from 20 nm to 500 
nm were well observed in cacodylate buffer solution for the studied peptide analogues (Figure 
77). However, the DNA condensation abilities of these peptides were quite different. Control 
peptide lysine tetramer 44 was only able to condense DNA into complexes or aggregates 
around 500 nm. Two GCP groups modified peptide 63 and mono-GCP peptide 64 exhibited 
better condensation ability as the size of both aggregates formed were around 200 nm. In 
contrast to this, tetra-GCP peptide 42 and tri-GCP peptide 62, which were characterized by 
their enthalpic binding mode with DNA, exhibited significantly enhanced DNA condensation 
ability. The aggregates formed by peptide 42 and 62 with DNA (20 nm and 60 nm, 
respectively) were much smaller than that of 63 and 64. Clearly, with more GCP group 
modifications, the binding between peptide analogues and DNA became more enthalpy 
favorable which eventually resulted in the formation of more compacted aggregates.  
This result was also confirmed with AFM studies. Figure 78 showed that those peptide 
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analogues formed particle–like aggregates with DNA under this ratio. The particles formed 
from tetra-GCP modified peptide 42 with DNA were significantly smaller compared to that of 
lysine tetramer 44.  
 
Figure 78. AFM phase images of aggregates formed by 3eq. peptide analogues and DNA 
Another important feature of DNA aggregates for potential gene transfection experiments is 
their charge state. Cell membrane is highly negatively charged. Therefore, aggregates with 
negative charges are generally considered not favorable in the cellular uptake process for gene 
delivery. Charge state can be examined with DLS. As shown in Figure 79, DNA molecules 
were highly negatively charged (-30 mV) before the addition of peptide analogues. Upon 
addition of positively charged peptides, DNA was condensed stepwise to neutralize the 
negative charges. Tetra lysine peptide 44 exhibited rather weak neutralization ability. Six 
equivalences of 44 were required to achieve full neutralization. Tetra arginine 43 displayed 
better condensation ability as the negative charges of DNA were neutralized with three 
equivalences of 43. Modification with GCP moiety significantly improved the neutralization 
ability of tetra lysine 44. For example, addition of three equivalences of peptide 61 and 62, 
both with three GCP groups functionalization, were sufficient to fully neutralize DNA 
molecules. Moreover, the complexes formed with peptide 61 and 62 under this ratio possessed 
more positively charges (+20 mV). This phenomenon is even more significant in the case of 
tetra-GCP peptide 42.   
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Figure 79. Zeta potential measurements of different ratio of peptide analogues and DNA 
4.2.3 Gene delivery study 
Since these peptide analogues are capable of condensing DNA into particle-like positively 
charged aggregates, we next tested their gene transfection ability in HeLa cell lines. Different 
concentrations of peptides were used to study their gene delivery ability. Commercial 
available PEI was applied as positive control. These peptides were directly mixed with green 
fluorescence protein (GFP) plasmid DNA, a typical reporter gene used in gene delivery study. 
No other reagents were required such as helper lipid which is normally necessary for other 
transfection systems. The mixture was allowed to incubate for 5 minutes at room temperature 
to ensure completely DNA condensation. Afterwards, the mixtures was added to cell culture 
medium and the transfection results were examined 24 and 48 hours after incubation. The 
expression of GFP gene in cell nucleus results in the production of green fluorescence protein 
which can be observed with fluorescence microscopy. The cell experiment was conducted 
with the cooperation from prof. Shirley Knauer in biology department with the help of 
Stefanie Schlesiger. 
4.2.3.1 Gene transfection ability  
  Transfection with peptides with less than four GCP modifications, however, did not 
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succeed (Figure 80). Only very few cells displayed fluorescence signals after 24h and 48h 
incubations in the case of tri-GCP modified peptides 61 and 62. Such weak signals indicated 
that the plasmid DNA complexes formed with these peptide analogues either did not enter 
into cells or failed to escape from endosomes. Also, it can be concluded that peptide 
sequences have no influences on the gene transfection ability of these peptides. 
Transfection with tetra-GCP modified peptide 42 resulted in significantly different results. 
As can be seen in Figure 93, 42 successfully transported plasmid DNA into cells. Most of the 
cells transfected with 42 exhibited green fluorescence similar to that of positive control PEI. 
The transfection efficiency of 42, defined as the percentages of transfected cells, was even 
better than the current golden standard PEI. Considering the low molecular weight and the 
number of charges of peptide analogue 42 relative to PEI, the transfection ability of 42 was 
even more remarkable. In comparison, tetra lysine peptide 43 and arginine tetramer 44 did not 
showed any transfection which in consistent with previous reports that cationic peptides 
require at least eight positive charges to achieve decent transfection. Moreover, the difference 
in the transfection results of peptide 42 with respect to 61 and 62 was very surprising. Both 61 
and 62 possessed three GCP group modifications, one less than that of 42. However, such a 
small structural difference resulted in a totally different transfection outcome. 
We also tested the transfection ability of peptide 42 under different concentrations. The 
results showed that peptide 42 delivered plasmid DNA into cells in a concentration-dependent 
manner. A minimum amount (0.05 mM) of peptide 42 was required as can be seen in Figure 
81. When the concentration increased to 0.25 mM per well, the efficiency of transfection with 
42 decreased possibly due to its toxicity at this concentration.  
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Figure 80. Transfection results of 0.15 mM peptide and 2 μg GFP plasmid in each well 
 
Figure 81. Transfection results with different concentrations of peptide 42 
  To further confirm the transfection results obtained above, these tetra peptides were also 
tested in human embryonic kidney cell line HEK-293 and in murine embryonic fibroblast cell 
line NIH/3T3. As shown in Figure 82, only tetra-GCP modified peptide 42 enabled successful 
transfection of the cells with a plasmid encoding GFP. Other peptide analogues did not show 
any detectable transfection. This result implicated that peptide 42 can be applied as a general 
gene transfection vectors irrespective of the type of cells. 
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Figure 82. Transfection efficiency of peptide analogues in HEK and NIH cell lines. 0.15 mM peptide 
and 2 μg GFP plasmid were incubated with HEK and NIH cells for 24 hours and examined with 
fluorescence microscopy. 
4.2.3.2 Gene transfection mechanism 
To elucidate the origin of the dramatically improved transfection efficiency of tetra-GCP 
peptide analogue 42 compared to the other tetra peptides, transfection experiments with the 
addition of chloroquine or bafilomycin were conducted.  
 
Figure 83. Transfection efficiency of peptide analogues with the addition of chloroquine 
The release of the transported DNA from the endosome into the cytosol is often a critical 
step in gene transfection. The addition of chloroquine, a weak organic base, increases the 
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buffer capacity within the endosome and facilitates cargo release. However, chloroquine had 
no effect on the cells transfected by other tetra peptides including arginine tetramer 43 and 
lysine tetramer 44 (Figure 83). This suggested that hardly any cellular uptake occurred in the 
case of 43 and 44. Thus, the main reason for the increased transfection efficiency of peptide 
analogue 42 relative to other peptide analogues is its enhanced cellular uptake, which most 
likely originates from a more specific binding interaction between the GCP group in 42 and 
negatively charged groups on the cell membrane. Moreover, chloroquine did not increased the 
transfection efficiency of peptide 42 which indicated that the DNA molecules transfected into 
cells by 42 were not entrapped in endosomes. 
Besides the better uptake of 42, the low pKa value of the GCP group also results in an 
increased buffering capacity within the endosomes, which facilitates endosomal escape by the 
proton-sponge effect. Accordingly, DNA transfection by 42 was completely inhibited by 
bafilomycin, which blocks the endosomal acidification process (Figure 84). In consequence, 
the DNA stayed trapped within the endosome and was degraded there before transfection 
occurs. This effect can also be observed with PEI mediated gene transfection process. PEI 
vector is known to utilize proton sponge effect to release the condensed DNA from endosome. 
The replacement of arginine by an artificial GCP-containing amino acid thus not only 
enormously enhances the endosomal uptake of peptide/DNA complexes by cells, but also 
facilitates the necessary release of the DNA from the endosomes to ultimately enable gene 
transfection.  
 
Figure 84. Transfection efficiency of peptide analogues with the addition of bafilomycin 
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4.2.3.3 Cell cytotoxicity 
Important for the applications of a new artificial transfection vector is its cytotoxicity, 
which for these tetra peptide analogues was examined in HeLa cells by measuring metabolic 
activity as an indicator of cell viability. Toxicity was negligible at 0.15 mm, the concentration 
at which 42 mediated DNA transfection experiments, while in the case of PEI, cell viability 
was reduced by nearly 70% (Figure 85). 
 
Figure 85. Alamar blue assay of 0.15 mM each peptide in gene transfection experiment A) 24 hours B) 
48 hours after transfection. Cytotoxicity was normalized for control group without any treatment. 
  In conclusion, the introduction of the GCP moiety in the side chain of tetra lysine resulted 
in a novel strategy to shift the thermodynamic signature of peptide DNA binding. Enthalpy 
contribution to binding process was significantly enhanced when the interaction between GCP 
and DNA were dominant. The exclusively enthalpically driven binding mode of peptide 42 
with DNA eventually led to higher compacted peptide-DNA complexes. This enormously 
enhances the cellular uptake of corresponding peptide/DNA polyplexes relative to peptides 
with only natural amino acids. Tetra-peptide 42 with only four of these artificial GCP groups 
is a highly efficient transfection vector, even better than the commercial reagent PEI but at the 
same time with significant lower cytotoxicity.  
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4.3 Development of a cyclic peptide nanotube based gene delivery 
vector 
The enhancement of cellular uptake and gene transfection ability of GCP moiety on short 
peptides was successfully demonstrated by the last two projects. We therefore determined to 
introduce GCP group into a cationic cyclic peptide. Cyclic peptides constructed with 
alternative D and L amino acids possess unique properties of assembling into nanotubes. 
However, this type of nanotubes normally cannot be positively charged under physiological 
conditions since charge repulsion then prevents tube formation. Unfortunately, positive 
charges are usually critical for DNA binding and also gene transfection due to the anionic 
nature of DNA. We thus designed a cyclic octamer peptide 45 and control peptide 65 to study 
their aggregation behavior and gene transfection ability (Figure 86). 
 
Figure 86. Chemical structures of cyclic peptide 45 and 65. 
4.3.1 Synthesis of cyclic peptides 
Cyclic peptides are more difficult to synthesize. The cyclization process is always 
accompanied by unwanted polymerization reaction. Two strategies of cyclization have thus 
been developed for the preparation of cyclic peptides: on-resin cyclization and in solution 
cyclization. On-resin strategy utilizes the pseudo dilution effect of solid phase which 
suppresses the formation of oligomers. On the other hand, in solution cyclization requires 
highly diluted conditions and careful adjustments of reaction parameters such as temperature, 
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stirring speed etc. Nevertheless, the advantage of this strategy is that it allows the preparation 
of large quantity of cyclic peptide. Therefore, we decided to use the in solution method to 
synthesize the target cyclic peptides. 
4.3.1.1 Synthesis of cyclic peptide 45 
The linear precursor of 45 was first synthesized on solid phase using Fmoc strategy. 
2-chlorotrityl chloride resin was selected. This resin is featured with a 2-chlorotrityl chloride 
functional group. The first amino acid can thus be attached to this resin through esterification 
under argon protection. Cleavage with acids results in a free carboxyl group in the C-terminus 
(Figure 87).  
 
Figure 87. Attachment on 2-chlorotrityl chloride resin and the final cleavage 
Commercially available amino acids Fmoc-d-Ala-OH, Fmoc-l-Lys(Boc)-OH and  
Fmoc-l-Lys(Alloc)-OH were used to build the peptide scaffold (Figure 88). De-protection of 
the Alloc groups in the side chain with Pd(PPh3)4 resulted in free amine group on the side 
chain (step 3). Subsequently GCP coupling (step 4) and Fmoc de-protection (step 5) yielded 
the linear precursor on the solid phase. Special cares must be taken in the next step of 
cleavage from resin. The cleavage of peptide segment from 2-chlorotrityl chloride resin 
requires acidic condition. However, the reaction condition cannot be too acidic avoiding 
de-protection of the Boc groups on the side chains of lysine. Therefore, a very mild condition 
with 1% TFA was used to yield the linear precursor 70. 
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Figure 88. Synthetic route of linear precursor 70 
 The linear precursor 70 was directly used for cyclization reaction without purification. 
Due to the presented carboxyl group and amine group on both terminals, 70 is easily 
subjected to polymerization or oligomerization through intermolecular coupling reaction. 
Thus, a highly diluted condition (~0.2 mM) was used for the cyclization process. Moreover, 
the solution of 70 needs to be cooled down to 0 ℃ before the addition of coupling reagent. 
Afterwards, DIPEA was added as catalyst slowly under cooling conditions. This procedure is 
to prevent intermolecular reactions before the fully mixing of the starting material. The 
cyclization of 70 yielded protected cyclic peptide 71. Final deprotection and purification gave 
rise to crude product of 45 as a white solid (Figure 89). The crude product was purified by 
MPLC on C18 reversed-phase silica gel to obtain 45 as white solid (5 % yield) with 91 % 
purity determined by analytical RP-HPLC. 
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Figure 89. Synthetic route of cyclic peptide 45 
4.3.1.2 Synthesis of cyclic peptide 65 
The synthesis strategy for peptide 65 is similar to that of 45. The linear precursor of 65 was 
first synthesized on solid phase using Fmoc strategy with 2-chlorotrityl chloride resin. 
Commercially available amino acid residues Fmoc-d-Ala-OH and Fmoc-l-Lys(Boc)-OH were 
used to build the peptide scaffold (Figure 90). Subsequently Fmoc de-protection (step 3) and 
cleavage yielded the linear precursor 72 as a white solid. 
 
Figure 90. Synthetic route of linear precursor 72 
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The linear precursor 72 was directly used for cyclization without further purification. A 
highly diluted condition (~0.2 mM) was used for the cyclization process under cooling 
condition as described above. The cyclization of 72 yielded protected cyclic peptide 73. Final 
de-protection and purification gave rise to crude product of 65 as a white solid (Figure 91). 
The crude product was purified by MPLC on C18 reversed-phase silica gel to obtain 65 as 
white solid (6.5 % yield) with 90 % purity by analytical RP-HPLC. 
 
Figure 91. Synthetic route of cyclic peptide 65 
4.3.2 Assembling property of cyclic peptides 
  The self-assembling abilities of both peptides were first tested by AFM and TEM. As 
expected, cyclic peptide 65 did not form any ordered nanostructure at pH 7.4 in water (Figure 
92). Most likely charge repulsion between the positively charged ammonium groups in the 
lysine side chains hindered the hydrogen bond induced aggregation of the cyclic peptides. 
This result was also confirmed with dynamic light scattering (DLS) in solution as no 
aggregates could be detected.  
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Figure 92. AFM images of 0.1 mM (A) and 0.5 mM (B) of peptide 65 in pH 7.4 H2O. 
However, to our surprise, modification of peptide 65 with only a single GCP moiety 
completely changed the self-assembly behavior. DLS clearly showed that peptide 45 formed 
large aggregates in buffered water at pH 7.4 (Figure 93); a pH value at which the weakly basic 
GCP might not yet be fully protonated but the remaining three lysine residues are (amine: 
pKa~10, GCP: pKa~7). Therefore, as expected at this pH the aggregates are overall positively 
charged as determined by Zeta potential measurements (+4.08 mV). The size of the 
aggregates assembled from cyclic peptide 45 was around 1 μm with a rather narrow size 
distribution. 
 
Figure 93. Volume distribution of peptide 45 (0.4 mM) in pH 7.4 cacodylate buffer 
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Figure 94. A) TEM and B) AFM images of peptide 45 (0.4 mM, pH 7.4) in water  
Moreover, we studied the morphology of the aggregates formed by 45 with transmission 
electron microscopy (TEM). Due to the organic nature of these peptide assemblies, it must be 
stained with uranyl formate solution for the visualization of the nanostructures. Tubular 
structures as typically seen for other self-aggregated cyclic peptides were observed in TEM 
images (Figure 94A). The lengths of these nanorods-like structures were in the range of 
micrometers. The majority of assemblies was around 200 nm in width. The smallest ones we 
could find in the images had a width of ca. 7 nm. Therefore, it can be deduced that the 
observed the larger assemblies should possess at least 20 smaller units. As consequence, the 
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wall thickness cannot be obtained convincingly from those images. In AFM images rods or 
particles with lengths less than 100 nm were also found (Figure 94B). This might due to the 
different sample preparation protocols for AFM and TEM which could influence the observed 
nanostructures in microscopy. Nevertheless, the results from AFM and TEM clearly showed 
that peptide 45 can form nanorod or nanofiber structures at neutral pH. However, the exact 
internal structure of these aggregates remains so far, unclear. 
To elucidate the assembling mechanism of peptide 45, molecular modelling experiment 
was conducted by Martin Ehlers. The results suggested that the GCP group in 45 could 
stabilize the nanotubes by binding to the backbone of an adjacent cyclic peptide (Figure 95). 
Hence, the GCP groups could function as “extra-clamps” between the stacked cyclic peptides. 
This binding interaction could provide enough extra stabilization to overcome the charge 
repulsion of the remaining lysine allowing nanotube formation even for a positively charged 
cyclic peptide. 
 
Figure 95. Molecular modelling of peptide 45 
There might be other aspects for the explanation of the assembly behavior of peptide 45. 
One further point worth mentioning for example is that peptide 45 is significantly more 
hydrophobic than peptide 65 as e.g. determined by the retention time of HPLC elution profile 
(10 % to 40 % methanol/water, 0.1 % TFA: peptide 45 in 17.6 minute, peptide 65 in 6.6 
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minute). This property may also favor the aggregation of peptide 45 in water relative to 65. 
Nevertheless, it is without doubt that a positively charged cyclic peptide nanofiber or 
nanotube was formed through the assembling of 45. 
4.3.3 Transfection study of cyclic peptides 
4.3.3.1 DNA binding ability 
  We next tested the DNA binding ability of these cationic nanotubes, the premise for any 
gene transfection vector. Addition of ctDNA solution to the aggregates form by peptide 45 did 
not significantly change their overall size (Figure 96). The size of peptide 45/DNA complexes 
was around 900 nm which correlated well with the size of the assembly formed by peptide 45 
(1 μm). This indicated that DNA molecules did not disrupt the assembled tubular structures of 
peptide 45. 
 
Figure 96. Volume distribution of peptide 45 (0.4mM) and its mixture with ctDNA in pH 7.4 
cacodylate buffer 
  The morphology of the assembly formed with 45 was also retained as shown in Figure 97. 
Tubular structures were well observed in TEM images after the addition of ctDNA. Moreover, 
it can be seen that DNA molecules were attached on the surface of nanotubes. This is most 
likely due to the cationic nature of peptide 45 which provides attractive electrostatic 
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interactions with negatively charged DNA backbones.  
 
Figure 97. TEM images of peptide 45 and its mixture with ctDNA in pH 7.4 H2O 
 
Figure 98. Fluorescence images: (A, B, C) mixture of peptide 45 and labeled DNA; (D) droplet of 
labeled DNA 
To further confirm the results, we labeled plasmid DNA with green fluorophore with the 
PromoFluor-500 Nick Translation Labeling Kit (PromoKine) according to the manufacturer’s 
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instructions and mixed it with peptide 45. The resulting mixture was directly examined with 
confocal fluorescence microscopy. Figure 98 clearly showed that labeled DNA was 
successfully attached onto the peptide nanotubes which must be formed from the assembling 
of peptide 45. As comparison, only diffusive fluorescence signals can be observed in a single 
droplet of the labeled DNA without the addition of peptide 45 nanotube. 
4.3.3.2 Gene transfection ability 
  As DNA obviously attaches to the nanotubes, we determined whether the peptide 
nanotubes could be applied as vectors in gene delivery. Therefore, green fluorescent protein 
(GFP) plasmid, a typical used reporter DNA in gene transfection, was mixed with the peptide 
nanotubes. The resulting mixture was directly subjected to HeLa cells. No other helper 
molecules such as lipids were added which are often required for other artificial transfection 
vectors to enable gene transfection. The widely used, commercial available polycationic 
polymer polyethyleneimine (PEI) was used as a positive control. The cell experiment was 
conducted with the cooperation from prof. Shirley Knauer in biology department with the 
help of Stefanie Schlesiger. 
 
Figure 99. A) Transfection results with 2 μg pF143-GFP plasmid using 45, 65, or PEI (all 0.4 mM). 
Brightfield (a–c) and fluorescence images (d–f) of HeLa cells 24 h after transfection with 45 (a, d), 65 
(b, e), or PEI (c, f) B) Transfection efficiency of peptide 45, 65, or PEI (all 0.4 mM) 
Transfection results were imaged 24h after incubation with HeLa cells. As shown in Figure 
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99A, peptide 65, being even more positively charged than 45 but not forming any nanotubes, 
was not able to transfer plasmid into cells. In striking contrast to this, the nanotubes formed 
by peptide 45 successfully transported the GFP plasmid into cells as seen by the expression of 
the green fluorescent protein. Moreover, the transfection efficacy of peptide 45 was even 
comparable to PEI (Figure 99B) which highlighted the utilization of supramolecular 
nanotubes in gene transfection experiments.  
 
  Figure 100. Transfection results with 2 μg pF143-GFP plasmid using 45, 65, or PEI (all 0.4 mm) in 
HEK cell lines 24h after incubation 
  The transfection ability of cyclic peptide analogue 45 was also confirmed in human 
embryonic kidney HEK-293 cell lines. As shown in Figure 100, control peptide 65, unable to 
form any nanotubes, did not show any detectable transfection. In contrast, peptide 45 still 
enabled the transfection of plasmid DNA into HEK cells although with a lower transfection 
efficiency than in HeLa cells. The reason for the decreased efficiency is however unclear. 
Anyway, cyclic peptide nanotubes formed from the assembling of 45 has the potential to serve 
as an universal gene delivery vector in future study. 
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4.3.3.3 Gene transfection mechanism 
 To further elucidate the mechanism of gene transfection result by peptide 45, transfection 
experiments with the addition of either chloroquine or bafilomycin were conducted. 
Chloroquine can enhance endosomal release of cargo molecules trapped within endosomes 
after cell uptake while bafilomycin can block this process by inhibiting the acidification of the 
endosomes. The addition of chloroquine prior to transfection did not improve the transfection 
efficiency of peptide 45 (Figure 101A). This suggested that either the plasmid DNA entered 
into cells already successfully escaped from endosome or, the internalization of plasmid DNA 
was endocytosis independent.  
 
Figure 101 Transfection efficiency of 45 and PEI (all 0.4 mm) with the addition of chloroquine or 
bafilomycin prior to incubation in HeLa cells 
It has been demonstrated that endocytosis is the major uptake pathway for PEI mediated 
gene transfection. Thus, when the cells were treated with bafilomycin prior to transfection, the 
endocytosis pathway was blocked and accordingly transfection with PEI was completely 
inhibited (Figure 101B). However, bafilomycin did not have any effect on the gene 
transfection by our peptide 45 which again underlined an alternate cellular uptake mechanism 
other than endocytosis. One possible mechanism could be direct membrane translocation 
through the interactions between the positively charged peptide nanotube 45 and negatively 
charged cell membrane.  
Taken together, the above results indicated that an endocytic pathway was unlikely 
responsible for the cellular uptake process in 45 mediated gene transfection. Thus, a more 
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reasonable explanation is that nanotubes formed by cyclic peptide 45 function as an 
electronic-bridge between DNA and cell membrane so that DNA molecules could enter into 
cells without the involvement of endocytosis. 
4.3.3.4 Cytotoxicity of cyclic peptide 
To apply any newly developed gene transfection vector in future appications, its toxicity in 
cells must be examined. We therefore conducted alamar blue cytotoxicity assay to determine 
the influence of transfection with peptide 45 in the metabolic activity of cells. The results 
showed that this novel type gene transfection vector was less toxic than the common used 
gene transfection standard PEI (Figure 102). 
 
Figure 102. Alamar blue cell viability assay. The graph illustrates the fluorescence level of the redox 
indicator 24 h after transfection with 45 and PEI. 
  In summary, the functionalization of a cyclic peptide with a GCP group resulted in a novel 
peptide nanotube. The interactions between GCP group and cyclic peptide backbone possibly 
stabilized the tubular structure by offsetting charge repulsions. Hence, a positively charged 
cyclic peptide nanotube was obtained under physiological conditions. The resulting nanotube 
could bind with negatively charged DNA and showed an astonishing ability in gene 
transfection.  
  
RESULTS AND DISCUSSION 
117 
4.4 Development of a supramolecular β-helix mimetic peptide  
Peptide assembly aiming to resemble α-helix structure has been demonstrated by several 
studies.
298-300
 However, self-assembling systems mimicking a β-helix are rarely reported. One 
of the reasons might be that α-helix is among the most commonly observed secondary 
structures in protein and enzymes. Examples on such structures are thus abundant. We then 
determined to apply the superior anion recognition ability of GCP moiety to design 
self-assembling system that could mimic β-helices.   
4.4.1 β-helix structure  
The structural feature of α-helix is well studied. An α-helix is a right-handed coil of amino 
acid residues on a polypeptide chain, typically ranging between 4 and 40 residues. It normally 
adopts a spiral conformation (helix) in which every backbone amide NH group donates a 
hydrogen bond to the backbone carbonyl group of another amino acid residue. Such a 
hydrogen bond is formed exactly every 4 amino acid residues (Oi to Ni+4), and every complete 
turn of the helix requires 3.6 amino acid residues. The structure repeats itself every 5.4 Å 
along the helix axis, i.e. the α-helix has a pitch of 5.4 Å. In proteins, individual α-helices are 
connected by loops to form more complex structures. 
 
Figure 103. The non-channel form (A) and channel form (B) of gramicidin A. Reprinted from 
reference 302, copyright (2016), with permission from Elsevier 
On the other hand, the structure of β-helix is significantly different. The term ‘‘β-helix’’ 
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was first used to describe the structure of gramicidin in 1980’s.301 Gramicidin can form 
transmembrane ion channels which are selective for cations. Natural mixture of gramicidin 
consisted mostly of gramicidin A, a linear pentadecapeptide constructed by alternative D and 
L amino acids. It can easily incorporate into cell membrane since the amino acid composition 
of gramicidin A is highly hydrophobic with no charged or hydrophilic side chains present. In 
addition, both the N- and C-terminus are blocked, the former with a formyl group and the 
latter with an ethanolamine group.
302
 As consequence, it is generally believed that gramicidin 
A can only form a unique head-to-head associated dimer of two single stranded β-helices (the 
channel form) in the presence of membrane mimics, such as vesicles (Figure 103B). In 
organic solvent it exists in totally different structures such as double strand intertwined helix 
(Figure 103A, the non-channel form).
303,304
 Both forms are composed of β-sheet-like 
secondary structures with their side chains protruding on one surface due to the alternating L- 
and D-amino acids. The β-helix is then produced by rolling up of these β-sheets. 
Another β-helix related structure is a parallel β-helix. It refers to the structure which uses 
β-sheet alone to form complex structures connected by repeating individual coils. A typical 
parallel β-helix is a three-stranded parallel β-helices. 305,306 These structures are constructed by 
a single polypeptide chain in which three parallel β-sheets are separated by three turns 
forming a single rung of a larger helical structure. The top view of this structure reveals a pore 
inside the parallel β-helix. The whole helix is mostly stabilized by hydrogen bonds.  
4.4.2 Synthesis of β-helix mimetic peptide   
Peptide 46 was designed to mimic gramicidin A by using alanine as basic building block. 
Alanine has a strong preference to form helix structure and it is also a weak former of β-sheet 
structure.
307
 It has a moderate hydrophobicity which makes it suitable to be applied in 
aqueous conditions. GCP moiety was coupled to the N-terminus of an alanine octamer to 
establish multiple H-bond interactions with carboxylate group in the C-terminus. 
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Figure 104. Synthetic route of peptide 46  
The synthesis was achieved with Fmoc solid phase peptide synthesis. Wang resin was 
selected to leave a free carboxylate group at the C-terminus. Commercially available 
Fmoc-d-Ala-OH and Fmoc-l-Ala-OH were used to build the peptide scaffold (Figure 104). 
The first attachment of amino acid residue with Wang resin was done under argon atmosphere 
with HCTU and DIPEA (step 1). Subsequent coupling and de-protection gave rise to a free 
amino group at the N-terminus of peptide (step 2 and 3). GCP moiety was then coupled and 
cleavage with TFA yielded the crude product. Purification with MPLC resulted in peptide 46 
as a white solid in 10 % yield with 97 % purity.  
A control peptide 66 without GCP group modification was also synthesized as shown in 
Figure 105. Commercially available Fmoc-d-Ala-OH and Fmoc-l-Ala-OH were used to build 
the peptide scaffold. The target peptide 66 was obtained as a white solid in 20 % yield with 
93 % purity.  
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Figure 105. Synthetic route of peptide 66  
4.4.3 Structure determination for β-helix mimetic peptide 
Circular dichroism (CD) experiment was measured with the cooperation from prof. Ivo 
Piantanida by Dr. Marijana Radić Stojković. CD was first applied to study the structures of 
both peptides in pH 5.0 water. At this pH, GCP moiety (pKa~7) on the N terminus is 
positively charged while carboxylate group (pKa~3-4) on the C terminus is negatively 
charged. Thus both peptides existed as zwitterion in water which is ideally for self-assembling. 
The results showed that the CD spectrum of peptide 46 was concentration dependent. At 
lower concentration, only very weak CD signal of β-helix (positive band at 220 nm and 
negative band at 230 nm) was observed (Figure 106A). It is possibly that the assembling of 
peptide 46 did not occur when it was dissolved in a diluted condition. However, when the 
concentration increased to 0.1 mM, the CD spectrum showed characteristic signals for β-helix 
structures which were in excellent agreement with the signals of gramicidin A in 
distearoylphosphatidylcholine (DSPC) vesicles (Figure 106B).
308
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Figure 106. A) CD spectra of different concentrations of peptide 46 in pH 5.0 water B) CD spectrum 
of gramicidin A in (○) DLPC, (●) DMPC (■) DPPC, and (Δ) DSPC at 20℃ (lipid/peptide=30:1). 
Reprinted with permission. Copyright (2015) American Chemical Society 
 
Figure 107. CD spectra of peptide 46 and 66 in pH 5.0 water 
As shown in Figure 107, a strong positive peak at 220 nm and even stronger negative peak 
at 230 nm were well observed. A weaker positive peak around 242 nm was also found. It is 
known that the long lipid chains in vesicle components could help the stabilization of β-helix 
conformation of gramicidin A since such signals cannot be observed in organic solvent. 
However, in sharp contrast to this, peptide 46 was able to adopt same structure even without 
the presence of vesicles. Compared to peptide 66 which did not demonstrate any 
characteristics of β-helices, most likely the favorable interactions between GCP moiety and 
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carboxylate stabilized the β-helix conformation of peptide 46 which eventually allowed 
hydrogen bonding interactions between each adjacent peptide backbones to occur.  
The strong and broad positive peak at around 300 nm, which corresponds to the adsorption 
of pyrrole, indicated that the GCP groups were aligned in a helical fashion in the assembly of 
peptide 46. Indeed, molecular modelling study (done by Martin Ehlers) suggested that the 
GCP groups incorporated only in peptide 46 interacted with adjacent carboxylate groups 
(Figure 108A).  
 
Figure 108. Molecular modelling of peptide 46 (A) and its comparison with (B) insect antifreeze 
protein (PDB code: 1EZG) 
The modelled structure of peptide 46 was compared with the known crystal structure of 
β-helix insect antifreeze protein (Figure 108B).309 The structure of insect antifreeze protein 
demonstrated that the individual β-sheets in its β-helix were connected with loops comprised 
of peptide chains. In comparison, the modelled structure of peptide 46 showed that the 
individual β-sheets, constructed with alanine residues, were linked by the recognition between 
N-terminal GCP and C-terminal carboxylate. This result indicated that supramolecular 
recognition motif (GCP
+
-COO
-
) can be applied to simulate bio-conjunction to construct 
secondary structures. 
Furthermore, we determined the solvent accessible surface area for the modelled structure 
of peptide 46. A top view of the solvent accessible surface area model of peptide 46 clearly 
demonstrated the existence of a pore which is characteristic of β-helix structure (Figure 109). 
It can also be seen that the side chains of alanine residues were pointed out of the modelled 
structure. This is in consistent with the feature of β-helix structure of gramicidin due to the 
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alternative D and L amino acid composition.  
 
Figure 109. A) Side view of the modelled structure of 46 and top view of the solvent accessible 
surface area [1.4 Å radius for water] B) Additional images of the modelled structure of 46 
4.4.4 Growth process of β-helix mimetic peptide  
4.4.4.1 Assembly of β-helix mimetic peptide 
We further studied the structure of peptide 46 and 66 by atomic force microscopy (AFM) 
and transmission electron microscopy (TEM). As expected, peptide 66 did not form any 
ordered structures in water (Figure 110). Also DLS experiments did not detect any aggregates 
of 66 in water solution. This suggested that the modification with GCP moiety is required to 
trigger the self-assembly process. 
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Figure 110. AFM images of 0.1 mM peptide 66 in pH 5 water. 
 Left: Amplitude image; Right: Height image.  
 
Figure 111. AFM (A) and TEM (B) images of a fresh prepared 0.1 mM peptide 46 in pH 5 water 
  Surprisingly, we observed that peptide 46 exhibited aging effect in water. For freshly 
prepared sample of peptide 46, only small particles can be found in both AFM and TEM 
(Figure 111). The sizes of those particles were ranging from 20 nm to 35 nm. They exhibited a 
spherical shape which possibly was formed through the aggregation of individual helices. 
However, the morphology of these particles significantly changed when the sample solution 
was aged at room temperature. We found in AFM images that after 5 days incubation, the 
particles observed in the beginning transformed into short rod-like structures. As can be seen 
in Figure 112, these rods, varying in their lengths, were composed of smaller nanoparticles 
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which suggested that peptide 46 continued the self-assembling process even after the particles 
were formed. Therefore, the morphology of the assembly formed by peptide 46 was time 
dependent. 
 
Figure 112. AFM height images of 5 days old sample of 0.1 mM peptide 46 in pH 5 water 
 
Figure 113. AFM (A) and TEM (B) images of 8 days old sample of 0.1 mM peptide 46 in pH 5 water 
  After 8 days incubation of the same sample solution at room temperature, the morphology 
of the aggregates formed by peptide 46 was completely different from the structures observed 
before. Fibrous structures with length of several micrometers were well distributed in solution 
as shown in both TEM and AFM images (Figure 113). Curiously, these fibers seemed to be 
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intertwined with each other in a helical fashion as can be seen in AFM images (Figure 113A). 
Regular wounded fibers were observed throughout the sample plate. Small rod-like structures 
can also be found in TEM images (Figure 113B). This might indicate a growth process for the 
long fibers assembled from 46.  
Therefore, the morphology of the assemblies formed by peptide 46 significantly changed 
through the aging process. It first formed small particles around 20 nm in diameter. 
Afterwards those particles transformed into short rod-like structures which eventually evolved 
into long fibers.   
 
Figure 114. CD spectra of fresh prepared (black), 8 days (red) and 10 days (green) old sample of 0.1 
mM peptide 46 in pH 5 water 
Correlated to the different morphology of the assembly of peptide 46, the CD signals also 
changed accordingly. Figure 114 clearly showed that after 8 days incubation at room 
temperature, the intensity of both peaks at 220 nm and 230 nm was significantly enhanced. 
Meanwhile, the positive peak at 280 nm - 320 nm, corresponding to the absorbance of pyrrole, 
was unaffected, indicating that the conformation of GCP moiety in peptide 46 remained 
unchanged during the aging process. The shape of CD curve for the aged sample was identical 
to freshly prepared samples which suggested that the overall β-helix structure of peptide 46 
was retained. The enhancement of the intensity of CD signals should then only reflect more 
β-helix conformation contents of peptide 46 in its water solution. Therefore, it is reasonable to 
assume that in the freshly prepared sample solution of peptide 46, individual monomer 
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co-existed with oligomers in equilibrium. During the aging process, these monomers could 
further assemble into higher ordered structures such as fibers which could stabilize the 
β-helices. It is indeed observed in AFM and TEM images that the small particles formed by 
peptide 46 transferred into fibers after several days’ incubation at room temperature. 
4.4.4.2 Growth mode of β-helix mimetic peptide 
For the growth process of supramolecular polymerization, two aggregation modes have 
been proposed: isodesmic and cooperative modes. Isodesmic mode is featured with a single 
equilibrium constant in the elongation process of the assembly. As shown in Figure 115A, the 
addition of each monomeric unit to previous aggregates is governed by the same 
thermodynamics. In the cooperative mode, however, nuclei are firstly formed to activate the 
following growth process (Figure 115B). This step is thus named “nucleation” which is 
featured with a larger nucleation equilibrium constant than the elongation equilibrium 
constant (K2 > Ke). Afterwards, a rapid growth of self-assembly is occurred which eventually 
leads to the formation of final aggregates. 
 
Figure 115. A) the isodesmic and B) the cooperative self-assembly mechanism for monomers M. C) 
Schematic representation of the degree of aggregation, α, versus concentration and temperature  
We then studied the growth process of peptide 46 with dynamic laser scattering experiment 
in solution. It was found that the hydrodynamic size of the aggregates formed by peptide 46 
correlated well with the results from AFM and TEM. For freshly prepared samples of 46, only 
very small aggregates with sizes around 20 nm can be found. This size was in agreement with 
the size of the particles found in AFM and TEM. After 8 days, very large aggregates were 
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observed in water solution with sizes around 1 µm. Following the hydrodynamic diameter of 
aggregates during the aging process revealed a cooperative-like growth mode. As can be seen 
in Figure 116, the size of aggregates remained unchanged until 137h. Afterwards a fast growth 
of the sizes of aggregates formed by peptide 46 was observed which corresponded well with 
the nucleation-elongation mechanism in supramolecular systems. Thus, the particles formed 
in the fresh prepared sample of peptide 46 may rearrange itself during the aging process to 
form the nuclei. The fibers which were observed after 8 days then represented the final 
thermodynamically stable assembly. 
 
Figure 116. Hydrodynamic diameters of peptide 46 in pH 5.0 water during the aging process obtained 
with DLS. 
  To confirm the nucleation-elongation mechanism for the assembling of peptide 46, we 
monitored the UV-vis adsorptions of an aged sample at different temperatures. The adsorption 
of pyrrole in GCP units (295 nm) and peptide backbone (241 nm) were both followed along 
with the increases of temperature. It was shown in Figure 117 that the disassembling process 
of those fibers formed by peptide 46 followed the typical nucleation-elongation mechanism. 
Both adsorptions from 295 nm and 241 nm decreased dramatically when the temperature 
increased to 305 K which implied the sudden break-up of the whole assembly. The degree of 
aggregation was calculated based on the assumption that at 290 K, the aggregation of peptide 
46 was fully completed thus representing degree of aggregation of 1.When the temperature 
increased to 335 K, the assembly formed by 46 was disassembled which means the degree of 
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aggregation is 0. The adsorption data thus can be transferred to the degree of aggregation as 
shown in Figure 117B. This result then further demonstrated the cooperative growth mode of 
peptide 46 
 
Figure 117. A) Temperature-dependent UV-vis adsorption of peptide 46 in pH 5.0 water. B) Degree 
of aggregation calculated from the adsorption on 295 nm. 
4.4.5 pH response of β-helix mimetic peptide 
Additionally, the helical fibers formed by peptide 46 were responsive towards pH stimuli. 
When sodium hydroxide solution was added to an old sample of peptide 46 to adjust the pH to 
10, the helical fibers were immediately transformed into vesicles (Figure 118A). This is not 
surprising because the pKa of GCP moiety is around 7. At pH 10, the GCP groups are not 
protonated anymore therefore the recognition between the GCP and carboxylate are not strong 
enough to induce fiber formation. Peptide 46 at basic pH is just a simple amphiphile which 
accordingly formed vesicles (Figure 118A). The sizes of the vesicles were around 25 nm. 
Similarly, DLS results showed that the sizes of the aggregates formed by peptide 46 in water 
changed from ca. 1000 nm at pH 5 to 25 nm at pH 10 (Figure 118B). 
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Figure 118. AFM phase images (A) and DLS number distribution (B) of 0.1 mM peptide 46 at pH 5 
and pH 10 water 
Also no aging effect was observed when peptide 46 was dissolved in pH 10 water solutions. 
As shown in Figure 121, the differences in the CD spectrum of peptide 46 were negligible 
after incubation for 8 days. Yet at this basic pH, the CD signals of peptide 46 within 200-240 
nm range still resembled the signals of gramicidin A and CD signals of 46 at pH 5 (Figure 
119), but the intensity of GCP-attributed CD band at 295 nm was much weaker (Figure 114; 
only 20% intensity of the signals at 220 and 230 nm at pH 5). Such almost negligible CD 
band suggested that GCP moiety was not uniformly oriented within the peptide chiral helix, 
which again pointed to the importance of protonation of GCP-guanidine at pH 5. Most likely, 
the binding between neutral-GCP and carboxylate is not strong enough to maintain fiber 
configurations but still provides sufficient stabilization for β-helix conformation to an extent. 
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Figure 119. CD spectrum of freshly prepared (black) and 8 days old sample (red) of 0.1 mM peptide 
46 at pH 10 
  In conclusion, peptide 46 is not only the first example for a self-assembled supramolecular 
β-helix in pure water but it also highlights the application of supramolecular recognition 
motifs for obtaining such secondary structures. Without the tailor made GCP binding motif no 
β-helix is formed in this case. The pH dependent switch of peptide 46 between fibers and 
vesicles also showed interesting potentials in constructing responsive materials. 
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4.5 Development of functionalized amphiphilic peptide assembly 
Fmoc-based dipeptide assembling systems are highly interesting in the development of 
supramolecular materials. However, due to the use of hydrophobic amino acid residues, the 
exterior surface of the resulting assembly (fiber, sheet etc.) usually cannot be modified. 
Therefore, we hypothesized that introduction of GCP moiety in the side chains of Fmoc 
containing dipeptide could allow further manipulation of the assembled peptide 
nanostructures. Two dipeptides with GCP group modification were thus designed.   
4.5.1 Synthesis of Fmoc-dipeptide analogues 
Dipeptide analogue 47 was first designed and synthesized. GCP units were introduced into 
the side chains of lysine through conventional coupling reactions. The preparation of 40 was 
performed on solid phase using Fmoc peptide synthesis strategy (Figure 120). Rink amide 
MBHA resin was again selected because it could leave amide functionality at the C-terminus 
after final cleavage. Commercial available amino acid Fmoc-l-Lys(Alloc)-OH was used to 
build the peptide scaffold (step 2). De-protection of Alloc group with Pd(PPh3)4 resulted in 
free amino groups on the side chains of lysine (step 3). Subsequently coupling with GCP 
moiety (step 4) and cleavage from the resin (step 5) yielded the crude product of peptide 47. 
The crude product was purified by MPLC on C18 reversed-phase silica gel to obtain 47 as 
white solid (38 % yield) with 93 % purity determined by analytical RP-HPLC. 
 
Figure 120. Synthetic route of Fmoc-dipeptide analogue (47) 
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 Dipeptide analogue 67 was also designed and synthesized similar to that of 47. However, 
peptide 67 was constructed with D amino acid residues instead of L amino acid (Figure 121). 
Thus, commercially available Fmoc-d-Lys(Alloc)-OH was selected to build the peptide 
scaffold (step 2). The crude product was purified by MPLC on C18 reversed-phase silica gel 
to obtain 67 as white solid (19 % yield) with 94 % purity. 
 
Figure 121. Synthetic route of Fmoc-dipeptide analogue (67) 
 
Figure 122. Synthetic route of Fmoc-dipeptide (68) 
For the comparison of assembling property, we also synthesized peptide 68, composed of 
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two lysine residues, as control group. The preparation of 68 was performed on solid phase 
using Fmoc peptide synthesis strategy (Figure 122). Rink amide MBHA resin was selected. 
Commercially available amino acid Fmoc-l-Lys(Boc)-OH was used to construct the peptide 
scaffold (step 2). The crude product was purified by MPLC on C18 reversed-phase silica gel 
to obtain 68 as yellow solid (19 % yield) with 94 % purity determined by analytical 
RP-HPLC. 
4.5.2 Assembling of Fmoc-dipeptide analogues 
  The assembling properties of these Fmoc based peptide analogues were studied with 
circular dichroism (CD) in solution and also with atomic force microscopy (AFM), 
transmission electron microscopy (TEM).   
4.5.2.1 AFM and TEM study 
  The assembling behavior of peptide 47 was firstly studied with AFM. Fmoc-containing 
short peptide is known to assemble in water. Therefore, peptide 47 was first dissolved in pure 
water to form a white suspension. Heating at 70 ℃ for 3 minutes resulted in a transparent 
solution which was cooled down to room temperature gradually. The pH of the solution of 
peptide 47 was adjusted to 7 and directly examined with high resolution AFM. 
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Figure 123. AFM height images of 0.1 mM 47 in water 
  As shown in Figure 123, peptide 47 readily assembled into fibers in water. The length of 
these fibers exceeded several micrometers with diameters around 20 nm. It can also be clearly 
seen in the AFM images that these fibers were helical in nature. Most likely, the chirality of 
lysine residues endowed the right handedness of the assembled fibers.  
  The fibers formed with 47 were also examined with TEM. Due to the organic nature of 47, 
the sample was stained with uranyl formate prior to the examination. We found in TEM 
images that these fibers were well distributed throughout the sample plate around several 
micrometers in length (Figure 124). Similarly, the fibers formed by 67 were also exceeded 
several micrometers in length and well distributed throughout sample plate (Figure 125). The 
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average diameter of fibers found in TEM was around 7.5 nm, corresponded well with the 
height of the fibers found in AFM (7.4 nm).  
 
Figure 124. TEM images (negative stain) of 0.1 mM 47 in water 
 
Figure 125. TEM images ( negative stain) of 0.1 mM 67 in water 
 In comparison to peptide 47 and 67, control peptide 68 without GCP group modifications did 
not show any detectable self-assembling when it was dissolved in water at the same 
conditions. Moreover, only very few particle-like structures were observed even when a rather 
high concentration of 68 (1.0 mM, ten folds as 47) was used as shown in Figure 126. This is 
most likely because of the pKa value of the amine group on the side chain of lysine (~ 9). As 
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consequence, the side chains in 68 were both positively charged at pH 7. The charge 
repulsions then prevented the formation of any higher ordered supramolecular structures. 
 
Figure 126. AFM phase (A) and height images (B) of 1.0 mM 68 in water 
4.5.2.2 CD spectroscopy study in solution 
  The aggregation property of these GCP modified peptides was also studied with CD 
spectroscopy in solution. Different concentrations of peptide 47 were first tested. The CD 
experiment was measured with the cooperation from prof. Ivo Piantanida by Dr. Marijana 
Radić Stojković. 
 
Figure 127. CD spectra (A) and absorption at 299 nm (B) of different concentrations of peptide 47 in 
water 
  As shown in Figure 127A, peptide 47 displayed two peaks in its CD spectrum. A strong 
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negative peak at 262 nm and a positive peak at 299 nm were observed. The peak at 262 nm 
was assigned to the absorption of the Fmoc fluorenyl group while the positive peak at 299 nm 
was from the combination of Fmoc and GCP. The intensity of both peaks was significantly 
enhanced when the concentration of peptide 47 increased from 1 μM to 20 μM. The biggest 
enhancement was achieved when the last aliquot of the stock solution of 47 was added. 
Accordingly, the last aliquot caused a slight deviation from Lambert-Beer law (Figure 127B). 
The extinction coefficient deviated from 81045 to 67007 when the last addition was included 
in the calculation. This deviation hinted that the aggregation of peptide 47 might be triggered 
within the concentration range from 10 μM to 20 μM.  
  Owing to its D amino acid compositions, peptide 67 exhibited opposite CD curves when it 
was dissolved at the same concentration (Figure 128A). A strong positive peak at 262 nm and 
a negative peak at 299 nm were observed. The intensity of both peaks was also concentration 
dependent. Similar deviation of extinction coefficient from 81471 to 63839 occurred when the 
concentration of 67 reached to 20 μM (Figure 128B).      
 
Figure 128. CD spectra (A) and absorption at 299 nm (B) of different concentrations of peptide 67 in 
water 
  In comparison, peptide 68 displayed very weak signals in CD spectroscopy as shown in 
Figure 129. The absorption at 260 nm was negligible which indicated that the Fmoc group in 
peptide 68 was not aligned helically. This further highlighted that GCP groups indeed boosted 
the assembling of Fmoc based peptide system in water.  
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Figure 129. CD spectra of 10 μM peptide 47, 67 and 68 in water 
4.5.2 Application of Fmoc-dipeptide analogues 
  The results from AFM and CD demonstrated that peptide 47 and 67 with GCP group 
modification indeed assembled into fibers when they were dissolved in water. The GCP 
groups on the surface should be able to recognize anionic species which might provide unique 
property to these fibers. Therefore, we studied the application of these fibers with two anionic 
moieties respectively: bio-macromolecule DNA and small organic molecule terpyridine.   
4.5.2.1 Interaction with DNA 
  We first studied the interaction of these GCP functionalized fibers with DNA using AFM. 
Calf thymus DNA was selected as model DNA. Peptide 47 and 67 were dissolved in water 
and the pH was adjusted to 7, respectively. Afterwards, an equivalence of DNA was added 
and the mixture was incubated for 5 minutes. The resulting mixture was then examined with 
AFM. As can be seen in Figure 130A, the fibers formed by peptide 47 were transformed into 
particles when the DNA was added. It might due to the interactions between Fmoc group and 
the base pairs in DNA that disrupted the assembly of peptide. Similar transition was also 
observed with peptide 67 which demonstrated that the interaction of these fibers with DNA is 
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independent of the chirality of amino acid composition (Figure 130B).  
 
Figure 130. AFM images of peptide 47 (A) and 67 (B) before and after the addition of DNA 
4.5.2.2 Gene transfection of 47 
We hypothesized that the transition of peptide 47 from fibers to nanoparticles might also 
provide gene transfection ability. Therefore, peptide 47 was mixed with GFP plasmid in 
buffered water and incubated for 5 minutes. The resulting mixture was directly applied to 
transfect HeLa cells. Transfection result was imaged 24 hours after the incubation.  
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Figure 131. Transfection results of 0.4 mM peptide 47 and PEI with 2 μg GFP plasmid in HeLa cells 
  As shown in Figure 131, peptide 47 successfully transported the GFP plasmid into cells. 
The transfection efficiency was however, lower than that of PEI. Notably, some fibrous 
structures can also be observed in the brightfield image of the cells treated with 47. This 
might indicate that the fibers formed by peptide 47 did not fully transformed into particles 
when plasmid DNA was added. 
4.5.2.3 Interaction with terpyridine 
  We next tested a post-assembly modification with a small organic molecule. A carboxyl 
group functionalized terpyridine 69 was added to the fibers formed by peptide 47. Due to the 
favorable ion-pair assisted hydrogen bonding interaction between GCP and carboxylate 
(Figure 132A), terpyridine molecule 69 was thus attached on the surface of the fibers formed 
by peptide 47. After incubation at room temperature for 5 minutes, iron (II) chloride was 
added. It is well known that the nitrogen atoms in terpyridine can coordinate with metal ions 
to form rather stable complex (Figure 132B). Therefore, the iron (II) atoms acted as “glue” to 
strengthen the terpyridine decorated surfaces. A metal-organic nanowire was thus obtained 
with peptide fibers as template.  
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Figure 132. Anion recognition of GCP and carboxylate (A) and terpyridine-Fe(II) coordination (B) 
  We therefore examined the resulting metal-organic nanowire with AFM and TEM. AFM 
images showed that the addition of terpyridine and metal ions did not change the morphology 
of the assembly of peptide 47. Long fibers or wires were again observed in the AFM sample 
plate (Figure 133A). However, the helical property of 47 was clearly altered as shown in 
Figure 133B. The helicity found in the fibers formed by 47 alone was around 19 nm. Addition 
of terpyridine and iron (II) thus completely altered the helicity in 47 to around 53 nm. This is 
the first hint that terpyridine molecules were aligned on the surface of peptide 47 and the 
addition of Iron (II) significantly resulted in different nanowires. 
  The presence of metal ions on the surface of those nanowires was confirmed with TEM. 
Organic molecules such as peptide 47 are not visible in TEM experiment. A staining solution 
for example, uranyl formate is required to increase the electron density of the nanostructures 
formed with organic materials. In contrast, the fibers observed in Figure 125A should be 
visible in TEM without staining step owing to the presence of iron (II) atoms. Indeed, we 
found in TEM images that nanowires with length around several micrometers were well 
distributed in the sample (Figure 134). Notably, the diameter of these nanowires (12 nm) was 
slightly bigger than the fibers formed by peptide 47 alone (7.4 nm). This further supported the 
presence of terpyridine molecules and metal ions on the surface of nanowires. 
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Figure 133. (A) AFM images of the mixture of 0.5 mM peptide 47 + 1 eq. terpyridine + 1 eq. 
FeCl2 and (B) Comparison of the helicity of 47+ terpyridine + Fe (upper channel) with 47 
(lower channel)  
 
 Figure 134. TEM images (no stain) of the mixture of 0.5 mM peptide 47 + 1 eq. terpyridine + 1 eq. 
FeCl2  
RESULTS AND DISCUSSION 
144 
In conclusion, we demonstrated in this project that through the introduction of an anion 
recognition moiety GCP into the side chains of a Fmoc containing short peptide, a novel class 
of peptide fibers was obtained through its assembly process. Owing to the GCP presented on 
the surface of the nanofibers assembled from 47, the fibers could interact with anionic 
macromolecules such as DNA and shuttle DNA into cells. More interestingly, we showed that 
metal ions such as iron (II) could be adsorbed on the surface of the peptide fibers using a 
carboxylate functionalized terpyridine ligand. Metal-organic hybrid nanofibers were thus 
obtained which could benefit the future preparation of supramolecular nanomaterials.  
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5. SUMMARY AND OUTLOOKS 
5.1 Development of novel cell penetrating peptide 
  Functionalization of a short peptide with GCP moiety resulted in a novel peptide analogue 
40 (Figure135). Owing to the superior anion binding ability of the GCP groups on the side 
chains of 40, its binding affinity with model glycosaminoglycan, heparin, reached to the 
magnitude of 10
7
.  
 
Figure 135. Chemical structure of peptide 40. 
  The enhanced affinity with glycosaminoglycan eventually led to a significantly improved 
cellular uptake behavior. Peptide 40, with only two amino acid residues, is the smallest cell 
penetrating peptide which has been reported. Moreover, the cellular distribution of this short 
peptide was concentration dependent. At lower concentration, the internalized peptides were 
mostly entrapped in lysosomes. When the concentration reached to 20 μM, peptide 40 was 
well distributed in cytosol.  
  In summary, the designed peptide 40 demonstrated amazing ability of cell penetration. We 
envisioned that the small size of 40 would make it an ideal carrier for the transport of a 
variety of drug molecules into cells. However, the exact cell penetration mechanism is still not 
clear. The role of glycosaminoglycan on cell membrane in the cellular uptake process of 40 
should be further explored. 
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5.2 Development of a novel cell penetrating peptide based gene 
delivery vector 
  In this project, seven tetra peptide analogues with different number of GCP modifications 
were prepared (Figure 136). Their binding properties with DNA were thoroughly studied with 
ITC, EB displacement assay. The DNA condensation ability was also examined with DLS and 
AFM. We demonstrated that with more GCP modification, the binding process with DNA 
became more enthalpy favored. This might provide a unique strategy to shift the 
thermodynamic profiles of peptide/DNA binding.  
The transfection with these tetra peptide analogues gave rise to a surprising result. Peptide 
42 successfully transfect GFP plasmid into cells while peptide 61 and 62, with only one less 
GCP modification than 42, did not show any transfection. The reason for that is not clear at 
present. One possible reason might be that 42 condensed DNA into smaller particles which 
were suitable for cellular uptake.  
 
Figure 136. Chemical structures of designed tetra peptide analogues 
  In summary, this research highlights the potential of specific tailor-made anion binding 
sites, such as our GCP group, to improve CPP mediated gene delivery. Such supramolecular 
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binding motifs not only allow for more specific interactions with the DNA but also with the 
cell membrane. This enormously enhances the cellular uptake of corresponding peptide/DNA 
polyplexes relative to peptides with only natural amino acids. Tetra peptide 42 with only four 
of these artificial GCP groups is a highly efficient transfection vector, even better than the 
commercial reagent PEI but at the same time with significant lower cytotoxicity.  
5.3 Development of a cyclic peptide nanotube based gene delivery 
vector 
  The synthesis of a cyclic peptide 45 with a GCP group modification on the side chain of 
lysine was achieved (Figure 137). This strategy resulted in a novel cationic peptide nanotube. 
As far as we know, peptide 45 is the first example that a positively charged cyclic peptide 
forms nanotubes under physiological conditions. Modelling results suggested that the 
interactions between GCP group and cyclic peptide backbone stabilized the tubular structure 
by offsetting charge repulsions.  
 
Figure 137. Chemical structure of peptide 45. 
  Moreover, we demonstrated that peptide 45 can be applied as gene delivery vector. DNA 
was successfully attached on the surface of nanotubes. The resulted nanotube showed an 
astonishing ability in gene transfection through non-endocytic cellular uptake pathway. 
Nanotubes formed by cyclic peptide 45 functioned as a bridge between DNA and cell 
membrane so that DNA molecules could enter into cells without the involvement of 
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endocytosis. To the best of our knowledge, this is the first report that a cyclic peptide 
nanotube can be applied as gene transfection vector.  
However, it should be noted that the exact internal structure of the nanotube formed by 
peptide 45 is not clear due to the detection limit of the method used. Further studies of the role 
of GCP modifications are in process. 
5.4 Development of supramolecular β-helix mimetic peptide 
The first example of artificial peptide forming β-helix structure was described in this 
project. The alternative D and L alanine construction designed to mimic the structure of 
gramicidin A endowed the helical property of peptide 46 (Figure 138). However, in sharp 
contrast to typical β-helix structures which have been reported so far, the β-helix formation of 
peptide 46 required no involvement of membrane mimics. Characteristic CD signals for 
β-helix of peptide 46 were observed in pure water. It is known that the overall hydrophobic 
nature of gramicidin A played an important role for its conformation in membranes. Therefore, 
endeavors to mimic its structure have focused on hydrophobic residues to construct peptides. 
As consequence, these peptides can only be applied to organic solvents which limited their 
further application. We now firstly demonstrated that peptide constructed from only alanine, a 
moderate hydrophobic residue, can successfully mimic β-helix structures in water without the 
addition of vesicles. Molecular modelling results suggested that the binding between 
N-terminal GCPs and C-terminal carboxylates were the key force to form energetically stable 
β-helix structures. Similar structural property can be found in native insect antifreeze proteins 
(AFP) in which the individual β-sheets were connected with loops to stabilize the β-helix 
conformation. While in the case of peptide 46, the individual β-sheets were connected by 
supramolecular recognition motif (GCP
+
-COO
-
). Thus, the ability of peptide 46 to adopt 
β-helix conformation in water represented a rather simple and promising strategy to construct 
secondary structures in biological system. 
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Figure 138. Chemical structure of peptide 46 
The aging effect of peptide 46 in water is really intriguing. Based on the results of CD 
spectroscopy, the overall curve shape which corresponded to β-helix conformation is retained 
during the aging process. The intensity enhancements of CD signals should then only reflect 
more β-helix conformation contents of peptide 46 water solution. Therefore, it is reasonable to 
assume that in the freshly prepared sample solution of peptide 46, individual monomer 
co-existed with oligomers in equilibrium. During the aging process, these monomers could 
further assemble into higher ordered structures such as fibers which would stabilize the 
β-helix conformation. It is indeed observed in AFM and TEM that the small particles formed 
by peptide 46 transferred into fibers after several days’ incubation at room temperature. 
However, the curious aspect for the fibers formed by peptide 46 is that these fibers seemed to 
be intertwined with each other regularly which can be better observed in AFM. One possible 
reason which cannot be ruled out is that the drying process for the sample preparation of AFM 
may influence the resulting morphology of the fibers formed by peptide 46. Nevertheless, the 
growth process of peptide 46 fiber followed the classical nucleation-elongation mechanism in 
supramolecular self-assembly as determined by variable temperature experiment. 
In overall, the self-assembly of peptide 46 not only demonstrated the first supramolecular 
β-helix mimic in water but also highlighted the application of supramolecular recognition 
motif in constructing secondary structures. The switch of peptide 46 between fibers and 
vesicles also showed interesting potentials in constructing responsive materials. 
5.5 Development of functionalized amphiphilic peptide assembly 
  In this project, GCP group was introduced into Fmoc-containing dipeptide. Due to its low 
pKa value, GCP groups facilitated the assembly of peptide 47 and 67 (Figure 139). These two 
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peptides formed helical fibers in water as demonstrated by AFM and CD studies. In 
comparison, peptide 68 without GCP modifications did not show any assembling property. 
Thus, peptide 47 and 67 represented a novel class of peptide assembly. The surface of the 
fibers formed by 47 and 67 were modified with GCP moiety which provided the possibility of 
post-assembly modification. 
  We then demonstrated that the fibers formed by 47 were bifunctional. It can interact with 
DNA and transform into nanoparticles upon DNA binding. This property led to a successful 
gene transfection which made 47 a new type of gene delivery vector. 
 
Figure 139. Chemical structure of peptide 47 and 67 
 On the other hand, it can also act as a template for the fabrication of other materials. We 
showed that simple addition of an organic ligand terpyridine and metal ions led to the 
preparation of metal-organic nanowires. This could benefit the future development of 
supramolecular nanomaterials. 
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6. EXPERIMENTAL SECTION 
6.1 General remarks and analytical methods 
Solvents and Chemicals 
All solvents were dried before use. DCM was distilled from calcium hydride. Methanol was 
distilled. THF and diethyl ether were distilled from sodium with benzophenon as indicator. 
DMF was distilled from calcium hydride under reduced pressure (the first 100 mL were 
discarded). Water used in all measurements was purified with TKA MicroPure ultrapure water 
system. All other solvents and reagents were utilized as supplied from the manufacturer.  
Cell lines and DNA 
The human embryonic kidney cell line HEK293T (ATCC-No. CRL-1573), the Human cervix 
carcinoma cell lines HeLa (ATCC-No.CCL-2), and the murine fibroblast cell line NIH/3T3 
(ATCC-No. CRL-1658) were obtained from the American Type Culture Collection and 
maintained as recommended in complete Dulbecco`s Modified Eagle Medium (DMEM) 
supplemented with 10 % fetal bovine serum, 1 % Glutamine and 1 % Antibiotic-Antimycotic 
(Invitrogen) at 37° C in a humidified atmosphere of 5 % CO2. Calf thymus DNA (ctDNA) 
was obtained from Aldrich, dissolved in sodium cacodylate buffer (0.05 M, pH 7), cooled to 4° 
C for 20 h, sonicated (8 × 4 sec) and filtered through a 0.45 μm PTFE filter. 
Magnetic Stirrer 
Reactions were stirred and heated with the help of magnetic stirring bars and a MR 3001 K 
magnetic stirrer from Heidolph. 
Inert Gas 
Reactions under inert gas were carried out with Argon (99.998 %) from Air Liquide dried with 
Silica Gel Orange. 
Thin layer Chromatography (TLC) 
Analytical TLC was carried out on aluminium foils ALUGRAM-SIL-G/UV254 from 
Macherey-Nagel. The spots were visualized upon irradiation with UV light of 254 nm. 
Column Chromatography 
Flash chromatography was done on columns packed with Silica gel 60M with a spherical size 
of 40-63 μm from Macherey-Nagel. 
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Vacuum Pumps 
Vacuum was generated with a Vacuubrand CVC3000 pump. High vacuum was achieved with 
a RC6 chemistry hybrid pump. 
Rotary Evaporator 
Removal of solvent from the reaction mixture and eluents from chromatography were 
performed under reduced pressure with a Heidolph Hei-VAP Advantage rotary evaporator at 
40° C. 
Orbital Shaker for Peptide Synthesis 
Room temperature solid phase peptide synthesis was carried out on a Yellowline OS 5 basic 
orbital shaker from Heidolph. 
Microwave used in Peptide Synthesis 
Mircowave-assisted solid phase peptide synthesis was carried out with a CEM Discover single 
mode microwave. 
Analytical HPLC 
The analysis of peptides was carried out with an HPLC apparatus from Dionex containing the 
following components: P680 HPLC-pump, ASI-100 Automated Sample Injector, UVD 340U 
detector. The YMC ODS-A RP18 column with a spherical size of 5 μm and a pore size of 12 
nm was utilized. Commercial available ultrapure water and HPLC-grade solvents were used 
for elution. 
Preparative HPLC 
Separation of milligram scales of peptides were performed on a Merck SepTech preparative 
HPLC apparatus equipped with a Knauer Dynamic Mixing Chamber and a Shimadzu 
SPD-10A UV detector. The YMC ODS-A RP18 column (15 cm × 3.0 cm, 5 μm) was utilized 
and the conditions were optimized via analytical HPLC on the corresponding YMC column. 
Preparative MPLC 
Purification of peptides was conducted with reversed phase preparative MPLC on a Liquid 
Chromatography Flash apparatus from Armen Instrument. Glass columns were packed with 
YMC Gel ODS-A RP18 silica of 12 nm pore size and 5 μm diameter. Distilled solvents and 
ultrapure water were used as eluents. UV detector was applied for the detection of the 
products.  
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Centrifuge 
Precipitates in water solution were centrifuged with a Rotofix 32 from Hettich. 
Lyophilization 
Lyophilization of aqueous solutions of peptides was carried out with an Alpha 1-4 LD plus 
drying apparatus obtained from Christ. 
Mass Spectrometry 
MALDI-TOF and ESI MS spectra were received by using a Bruker BioTOF III. 
pH Measurement 
The pH of sample solution was adjusted with pH-Meter 766 Calimatic from Knick. 
Nuclear Magnetic Resonance (NMR) 
500 and 300 MHz NMR spectra in CDCl3 and d
6
-DMSO were recorded with DRX 500 and 
DMX300 from Bruker at 298K. The spectra were calibrated with residual peaks of the 
deuterated solvents as internal standard: DMSO-d6 (δ [1H] = 2.50 ppm), CDCl3 (δ [1H] = 
7.26 ppm). The chemical shifts are reported as δ values in ppm. Coupling constants are 
reported in Hz. The following abbreviations are utilized for the signal multiplicity: s = singlet, 
d = doublet, t = triplet, q = quartet, m = multiplet, br. = broad.  
UV/Vis Spectroscopy 
UV spectrum was recorded with JASCO V-660 spectrometer in 10 mm quartz cuvette with 
following parameters: range = 295 nm, sensitivity = standard, scanning speed = 200nm/min, 
data pitch = 0.1 nm, bandwidth = 1 nm, response = 1 sec. All spectra are corrected for the 
background (buffer solution). 
Fluorescence Spectroscopy 
Fluorescence spectra were recorded with a Varian Carey Eclipse spectrometer in standard 
quartz fluorescence micro-cuvettes of 1 cm width. 
CD Spectroscopy 
Experiments were carried out in 10mm quartz cuvette (total volume of cuvette=2000µl) with 
JASCO J-815 CD Spectrometer. Instrument parameters: range=500-230 nm, 
sensitivity=standard (100mdeg), scanning speed=200nm/min, data pitch=0.2 nm, 
bandwindth=2nm, response=1 sec, accumulation=3. 
Isothermal Titration Calorimetry 
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ITC measurements were performed with a VP-ITC Microcalorimeter purchased from 
MicroCal. Ultrapure, degassed water was used to fill the reference cell. All samples were 
dissolved in degassed, ultrapure buffered water and filtered before measurement. The data 
were analyzed with Origin 7 from Origin Lab including an ITC plugin from MicroCal. 
Dynamic Light Scattering 
All measurements were carried out at 25° C in UV-transparent microcuvettes (1 cm) equipped 
with a stopper. Peptide solution in water was prepared and filtered prior to measuring. The pH 
was adjusted with sodium hydroxide solution accordingly. The autocorrelation functions of 
the backscattered light fluctuations were analyzed with the DTS 6.20 software from Malvern 
providing the hydrodynamic diameter (Z-average), polydispersity, size distribution (NNLS 
analysis). 
Atomic Force Microscopy 
The according samples were prepared and adjusted the pH with sodium hydroxide solution. 
AFM samples were prepared by spin-coating (66rps) the solutions onto a freshly cleaved mica 
surface (Plano GmbH) for 2 minutes. AFM images were obtained in tapping mode using a 
NanoDrive Controller with an Innova Scanning Probe Microscope (Veeco Germany, 
Mannheim) and N-type silicon cantilever (AC 160TS OLYMPUS). The scan rate was about 
5µm/s. The AFM data were analyzed using Gwiddion-2.20 software. 
Transmission Electron Microscope  
The according samples were prepared and adjusted the pH with sodium hydroxide solution. A 
drop of a freshly prepared and 8 days old sample solution was placed on 400-mesh formvar 
copper grid coated with carbon, respectively. About 2 min after the deposition the grid was 
tapped with filter paper to remove remaining solvent from the surface. Negative staining was 
performed by addition of a drop of an ethanol solution of uranyl acetate (0.5 %) onto the 
copper grid. After 1 min, the liquid on the surface of the grid was removed by tapping it with 
a filter paper. TEM images were obtained using a CM 200 FEG (Phillips Company). 
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6.2 General procedure for solid phase peptide synthesis 
Solid phase peptide synthesis was performed in Schlenck glass vessels equipped with frit 
and stopper under argon atmosphere while shaking. The solvent was removed through 
vacuum filtration after the reaction is finished.  
Kaiser test 
To examine the free amino groups on the resin, ninhydrin (1.00 g) and phenol (40 g) were 
dissolved in 10 mL ethanol, respectively. A small amount of resins were then suspended in a 
mixture of 0.5 mL of each of the two solutions and heated for 1-2 min at 110 ℃. 
Consequently, resins with free amines showed deeply blue color while resin without free 
amino functions remained white. 
Fmoc Deprotection 
The resin was shaken with 20 % piperidine in DMF two times for 20 min in order to 
remove Fmoc protecting groups. Afterwards, it was thoroughly washed six times with DMF. 
The reaction is monitored with Kaiser test. 
Alloc Deprotection 
The removal of Alloc group was achieved by treatment with Pd(PPh3)4 (0.1 eq) in the 
presence of PhSiH3 (24 eq) in DCM. This procedure was repeated two times for 20 min. Then 
the resin was washed three times with DCM and DMF for 5 min. The reaction is monitored 
with Kaiser test. 
Coupling Procedure 
The amino acid (3 eq) was attached to the resin using PyBop (3eq) as the coupling reagent 
and DIPEA (6 eq) as base in distilled DMF under argon atmosphere at room temperature by 
shaking the reaction mixture for 8h. Then the resin was washed with DMF for three times 
each for 5 min. For the attachment of each amino acid, the coupling and washing steps were 
repeated twice. The reaction is monitored with Kaiser test. 
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6.3 General Procedures for Microwave-Assisted SPPS 
Microwave-assisted solid phase peptide synthesis was performed in a 
microwave-transparent polyethylene tubes using CEM Discover microwave apparatus 
equipped with a frit. The reaction mixtures were bubbling with argon.  
Fmoc Deprotection 
Fmoc protecting group was removed with 20% piperidine in DMF. For each deprotection, 
the reaction was carried out under irradiation condition (20W, Tmax= 60 °C, ΔT = ±5 °C) two 
times for 1.5 min and 5 min, respectively. Then the resin was thoroughly washed six times 
with DMF each for 2min with argon bubbling. The reaction is monitored with Kaiser test.  
Alloc Deprotection 
The removal of Alloc protecting group was performed by treatment with Pd(PPh3)4(0.1 eq) 
in the presence of PhSiH3 (24 eq) in DCM for 10 min under irradiation condition (20W, Tmax= 
30 °C). Then the resin was washed three times with DCM and DMF each for 2 min with the 
help of argon bubbling. The reaction is monitored with Kaiser test. 
Coupling Procedure 
The amino acid was attached to the resin using PyBop as the coupling reagent and DIPEA 
as base in distilled DMF. The reaction was facilitated by irradiation condition (20W, Tmax= 
60 °C, ΔT = ±5 °C) and repeated two times each for 20 min with the help of argon bubbling. 
Then the resin was washed with DMF for three times each for 5 min. The reaction is 
monitored with Kaiser test. 
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6.4 Synthesis of peptide analogues 
6.4.1 Synthesis of dipeptide analogues 
Microwave Assisted Solid-Phase Peptide Synthesis of (40): 
 
The reaction was carried out in a microwave-transparent 25 ml polyethylene column with a 
CEM Discover microwave apparatus. Rink-Amide MBHA resin (200 mg, 0.62mmol/g) was 
swollen in DCM (5 ml) for 2 h. Fmoc removal was achieved by irradiating the resin in 20 % 
piperidine/DMF (5 ml) for 1 min and 5 min at 20 W and a maximum temperature of 60° C 
followed by washing with DMF (6 × 5 ml). The first residue Fmoc-Alloc-Lys-OH (169 mg, 
0.37 mmol, 3 eq) was attached to the resin by microwave irradiation for 20 min at 20 W and a 
maximum temperature of 60° C under argon atmosphere with PyBOP (194 mg, 0.37 mmol, 3 
eq), DIPEA (130 µl, 0.74 mmol, 6 eq) in DMF (5 ml) and consequent washing with DMF (3 × 
5 ml). Coupling and washing steps were repeated. After Fmoc deprotection the second residue 
Fmoc-Alloc-Lys-OH was attached to the resin as described above, also repeating coupling and 
washing steps. Alloc removal was achieved by Pd(PPh3)4 (28 mg, 0.02 mmol, 0.2 eq), PhSiH3 
(183 µl, 1.50 mmol, 24 eq) in 7 ml DCM for 30 min at room temperature under argon 
bubbling and consequent washing with DMF (3 × 5 ml). The deprotection and washing 
process was repeated. The GCP groups (197 mg, 0.99 mmol, 4 eq) were attached to the resin 
by microwave irradiation for 20 min at 20 W and a maximum temperature of 60° C under 
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argon atmosphere with PyBOP (258 mg, 0.55 mmol, 4 eq), DIPEA (168 µl, 0.99 mmol, 8 eq) 
in DMF (5 ml) and consequent washing with DMF (3 × 5 ml).  The coupling process was 
repeated until Kaiser Test showed negative result. After Fmoc deprotection the resin was 
washed with DCM (3 × 5 ml), methanol (3 × 5 ml), and DCM (3 × 5 ml) and dried under 
reduced pressure for one hour. To cleave the product, the resin was transferred to a flask 
equipped with a frit onto a Heidolph Rotamax 120 shaker. There it was shaken under argon 
atmosphere in a mixture containing 95 % TFA, 2.5 % water, and 2.5 % TIS for three hours 
and washed twice with the cleavage mixture. The filtrates were combined and concentrated in 
high vacuum at room temperature. Diethyl ether (40 ml) was added and the resulting 
suspension was centrifuged. The supernatant solvent was decanted and the solid was washed 
with diethyl ether and centrifuged again. After decanting, the raw product was dissolved in 
little methanol, water (30 ml) was added, and the mixture was freeze-dried in vacuum. The 
resulting solid was purified by MPLC on C18 reversed-phase silica gel (10 % to 50 % 
methanol/water in 45 min, 0.1 % TFA) to obtain 40 as white solid (20 mg, 25 %) with 96 % 
purity determined by analytical RP-HPLC.  
1
H-NMR (500 MHz, d
6
-DMSO): δ [ppm] = 1.36-1.38 (m, 4H, Lys-CH2), 1.48-1.50 (m, 
4H, Lys-CH2), 1.71-1.73 (m, 4H, Lys-CH2), 3.21-3.23 (t, 4H, J = 5 Hz, Lys-CH2), 3.80-3.81 
(m, 1H, Lys-CH), 4.22-4.25 (m, 1H, Lys-CH), 6.85 (s, 2H, pyrrole-CH), 7.05 (s, 1H, pyrrole 
-NH), 7.37 (s, 2H, pyrrole-CH), 7.50 (s, 1H, pyrrole -NH), 8.12-8.13 (m, 3H, amide-NH), 
8.46-8.52 (m, 10H, guanidine-NH), 11.70 (s, 2H, amine-NH2), 12.31 (s, 2H, amide-NH2).  
13
C-NMR (125 MHz, d
6
-DMSO): δ [ppm] = 21.7 (Lys-CH2), 22.9 (Lys-CH2), 28.6 
(Lys-CH2), 28.8 (Lys-CH2), 31.0 (Lys-CH2), 31.9 (Lys-CH2), 38.6 (Lys-CH2), 38.7 (Lys-CH2), 
52.1 (Lys-CH), 52.7 (Lys-CH), 112.4 (pyrrole-CH), 115.9 (pyrrole-CH), 125.4 (Cq), 132.9 
(Cq), 155.4 (Cq), 159.1 (Cq), 159.2 (Cq), 159.7 (Cq), 158.5 (Cq), 173.2 (Cq). 
MALDI-TOF-MS (pos.) m/z calculated for C26H39N13O6 [M + H] 
+
 630.31, found 630.33 
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Microwave Assisted Solid-Phase Peptide Synthesis of (41): 
 
Rink-Amide MBHA resin (200 mg, 0.62mmol/g) was swollen in DCM (5 ml) for 2 h. 
Fmoc removal was achieved by irradiating the resin in 20 % piperidine/DMF (5 ml) for 1 min 
and 5 min at 20 W and a maximum temperature of 60° C followed by washing with DMF (6 × 
5 ml). The first residue Fmoc-Arg(Pbf)-OH (242 mg, 0.37 mmol, 3 eq) was attached to the 
resin by microwave irradiation for 20 min at 20 W and a maximum temperature of 60° C 
under argon atmosphere with PyBOP (193 mg, 0.37 mmol, 3 eq), DIPEA (127 µl, 0.74 mmol, 
6 eq) in DMF (5 ml) and consequent washing with DMF (3 × 5 ml). Coupling and washing 
steps were repeated. After Fmoc deprotection the second residue Fmoc-Arg(Pbf)-OH was 
attached to the resin as described above, also repeating coupling and washing steps. After 
Fmoc deprotection the resin was washed with DCM (3 × 5 ml), methanol (3 × 5 ml), and 
DCM (3 × 5 ml) and dried under reduced pressure for one hour. To cleave the product, the 
resin was shaken under argon atmosphere in a mixture containing 95 % TFA, 2.5 % water, 
and 2.5 % TIS for three hours and washed twice with the cleavage mixture. The filtrates were 
combined and concentrated in high vacuum at room temperature. Diethyl ether (40 ml) was 
added and the resulting suspension was centrifuged. The supernatant solvent was decanted 
and the solid was washed with diethyl ether and centrifuged again. After decanting, the raw 
product was dissolved in little methanol, water (30 ml) was added, and the mixture was 
freeze-dried in vacuum. The resulting solid was purified by MPLC on C18 reversed-phase 
silica gel (5 % to 50 % methanol/water in 45 min, 0.1 % TFA) to obtain 41 as white solid (10 
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mg, 25 %).  
1
H-NMR (500 MHz, D2O): δ [ppm] = 1.67-1.72 (m, 4H, Arg-CH2), 1.84-1.85 (m, 2H, 
Arg-CH2), 1.97-1.98 (m, 2H, Arg-CH2), 3.22-3.25 (m, 4H, Arg-CH2), 4.13 (s, 1H, Arg-CH), 
4.32-4.35 (m, 1H, Arg-CH). 
13
C-NMR (125 MHz, D2O): δ [ppm] = 23.4 (Arg-CH2), 24.4 (Arg-CH2), 28.0 (Arg-CH2), 
28.1 (Arg-CH2), 40.4 (Arg-CH2), 40.6 (Arg-CH2), 52.6 (Arg-CH), 53.6 (Arg-CH), 156.8 
(guanidine-C), 169.8(Cq), 175.9 (Cq).  
  ESI-MS (pos.) m/z calculated for C12H28N9O2 [M + H] 
+
 330.2, found 330.2 
Synthesis of Rhodamine labeled peptide (58): 
 
To a reaction mixture of 57 (9.6mg, 0.02 mmol) in 10 mL DMF, PyBop (12mg, 0.024mmol) 
and DIPEA (4.1µl, 0.024mmol) were added under argon atmosphere at room temperature 
avoid of light. The solution was stirred for 30 minutes and peptide 40 (12mg, 0.02mmol) was 
added subsequently. The reaction solution was stirred for overnight at room temperature. 
Afterwards, DMF was removed under reduced pressure. 20 mL water was then added to the 
residue oil and lyophilized. The crude product was purified with MPLC on C18 
reversed-phase silica gel (10 % to 100 % methanol/water in 45 min, 0.1 % TFA) to obtain 58 
as red solid (8 mg, 38%). 
1
H-NMR (500 MHz, d
6
-DMSO): δ [ppm] = 1.20-1.23 (m, 8H, Lys-CH2), 1.42-1.44 (m, 
12H, Lys-CH2, Rhodamine-CH3), 1.45-1.49 (m, 4H, Lys-CH2), 2.83 (m, 2H, Lys-CH2), 
3.14-3.28 (m, 10H, Lys-CH2, Rhodamine-CH2), 3.92-4.08 (m, 1H, Lys-CH), 4.09-4.10 (m, 1H, 
Lys-CH), 6.32 (s, 2H, pyrrole-CH), 6.83 (s, 2H, pyrrole-CH), 6.90-7.10 (m, 7H, amide-NH, 
pyrrole-NH), 7.43-7.53 (m, 4H, amide-NH), 7.75-7.80 (m, 3H, amide-NH), 8.35-8.40 (m, 
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10H, guanidine-NH), 11.14 (s, 2H, amide-NH), 12.29-12.33 (m, 2H, amide-NH2).  
13
C-NMR (125 MHz, d
6
-DMSO): δ [ppm] = 12.3 (Rhodamine-CH3), 12.4 
(Rhodamine-CH3), 13.9 (Rhodamine-CH3), 22.1 (Lys-CH2), 28.1 (Lys-CH2), 28.4 (Lys-CH2), 
28.7 (Lys-CH2), 29.0 (Lys-CH2), 31.2 (Lys-CH2), 32.3 (Lys-CH2), 38.6 (Lys-CH2), 43.7 
(Rhodamine-CH2), 45.2 (Rhodamine-CH2), 46.2 (Rhodamine-CH2), 52.1 (Lys-CH), 52.7 
(Lys-CH), 112.3 (pyrrole-CH), 114.4 (pyrrole-CH), 115.4 (pyrrole-CH), 125.3 
(Rhodamine-CH), 132.8 (Rhodamine-CH), 152.6 (Rhodamine-CH), 155.0 (Rhodamine-CH), 
158.0 (Cq), 158.7 (Cq), 158.9 (Cq), 159.5 (Cq), 167.3 (Cq),172.9 (Cq). 
MALDI-TOF-MS (pos.) m/z calculated for C54H69N15O8 [M + H] 
+
 1055.54, found 
1056.47 
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Synthesis of FITC labeled peptide (60): 
 
To a reaction mixture of 59 (7.8 mg, 0.02 mmol) in 10 mL DMF, DIPEA (4.1µl, 0.024 
mmol) was added under argon atmosphere at room temperature avoid of light. The solution 
was stirred for 30 minutes and peptide 40 (12mg, 0.02 mmol) was added subsequently. The 
reaction solution was stirred for 2 hours at room temperature. Afterwards, DMF was removed 
under reduced pressure. 20 mL water was then added to the residue oil and lyophilized. The 
crude product was purified with MPLC on C18 reversed-phase silica gel (10 % to 100 % 
methanol/water in 45 min, 0.1 % TFA) to obtain 60 as yellow solid (18 mg, 90%). 
1
H-NMR (500 MHz, d
6
-DMSO): δ [ppm] = 1.53-1.54 (m, 8H, Lys-CH2), 1.55-1.59 (m, 
4H, Lys-CH), 1.70-1.83 (m, 2H, isothiocyanate-NH), 3.23-3.24 (m, 4H, Lys-CH2), 3.75 (m, 
1H, Lys-CH), 4.23 (m, 1H, Lys-CH), 4.91 (s, 1H, FITC-OH), 6.54-6.56 (m, 3H, FITC-CH), 
6.58-6.60 (m, 2H, FITC-CH), 6.67-7.32 (m, 7H, amide-NH, pyrrole-NH, pyrrole-CH), 7.75 (s, 
1H, amide-NH), 8.20-8.23 (m, 8H, guanidine-NH), 8.42-8.43 (m, 2H, guanidine-NH), 
10.12-10.19 (m, 2H, amine-NH), 11.05 (s, 2H, amine-NH), 12.34 (m, 2H, amide-NH2).  
13
C-NMR (125 MHz, d
6
-DMSO): δ [ppm] = 13.9 (Lys-CH2), 22.0 (Lys-CH2), 22.4 
(Lys-CH2), 23.0 (Lys-CH2), 24.4 (Lys-CH2), 28.7 (Lys-CH2), 28.8 (Lys-CH2), 29.0 (Lys-CH2), 
31.2 (Lys-CH2), 31.6 (Lys-CH2), 32.1 (Lys-CH2), 52.5 (Lys-CH), 56.7 (Lys-CH), 82.9 
(FITC-CH), 102.2 (FITC-CH), 109.6 (FITC-CH), 112.2 (pyrrole-CH), 112.5 (pyrrole-CH), 
115.4 (pyrrole-CH), 125.2 (FITC-CH), 129.0 (FITC-CH), 132.9 (FITC-CH), 151.8 (Cq), 
154.8 (Cq), 157.8 (Cq), 158.0 (Cq), 158.9 (Cq), 159.4 (Cq), 173.4 (Cq),179.9 (Cq). 
ESI-MS (pos.) m/z calculated for C47H52N14O11S [M + H] 
2+
 510.2, found 510.7 
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6.4.2 Synthesis of tetra-peptide analogues 
Microwave Assisted Solid-Phase Peptide Synthesis of (42): 
 
The reaction was carried out in a fritted, microwave-transparent 25 ml polyethylene column 
with a CEM Discover microwave apparatus. Rink-Amide MBHA resin (200 mg, 0.62mmol/g) 
was swollen in DCM (5 ml) for 2 h. Fmoc removal was achieved by irradiating the resin in 
20 % piperidine/DMF (5 ml) for 1 min and 5 min at 20 W and a maximum temperature of 60° 
C followed by washing with DMF (6 × 5 ml). The first residue Fmoc-Alloc-Lys-OH (169 mg, 
0.37 mmol, 3 eq) was attached to the resin by microwave irradiation for 20 min at 20 W and a 
maximum temperature of 60° C under argon atmosphere with PyBOP (194 mg, 0.37 mmol, 3 
eq), DIPEA (130 μl, 0.74 mmol, 6 eq) in DMF (5 ml) and consequent washing with DMF (3 × 
5 ml). Coupling and washing steps were repeated. After Fmoc deprotection the second to the 
fourth residues Fmoc-Alloc-Lys-OH was attached to the resin as described above, also 
repeating coupling and washing steps. Alloc removal was achieved by Pd(PPh3)4 (57 mg, 0.05 
mmol, 0.4 eq), PhSiH3 (366 μl, 2.98 mmol, 24 eq) in 7 ml DCM for 30 min at room 
temperature under argon bubbling and consequent washing with DMF (3 × 5 ml). The 
deprotection and washing process was repeated. The GCP groups (591 mg, 1.48 mmol, 12 eq) 
were attached to the resin by microwave irradiation for 20 min at 20 W and a maximum 
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temperature of 60° C under argon atmosphere with PyBOP (774mg, 1.48 mmol, 12 eq), 
DIPEA (505 μl, 2.97 mmol, 24 eq) in DMF (5 ml) and consequent washing with DMF (3 × 5 
ml). The coupling process was repeated until Kaiser Test showed negative result. After Fmoc 
deprotection the resin was washed with DCM (3 × 5 ml), methanol (3 × 5 ml), and DCM (3 × 
5 ml) and dried under reduced pressure for one hour. To cleave the product, the resin was 
transferred to a flask equipped with a frit onto a Heidolph Rotamax 120 shaker. There it was 
shaken under argon atmosphere in a mixture containing 95 % TFA, 2.5 % water, and 2.5 % 
TIS for three hours and washed twice with the cleavage mixture. The filtrates were combined 
and concentrated in high vacuum at room temperature. Diethyl ether (40 ml) was added and 
the resulting suspension was centrifuged. The supernatant solvent was decanted and the solid 
was washed with diethyl ether and centrifuged again. After decanting, the raw product was 
dissolved in little methanol, water (30 ml) was added, and the mixture was freeze-dried in 
vacuum. The resulting solid was purified by MPLC on C18 reversed-phase silica gel (5 % to 
45 % methanol/water in 45 min, 0.1 % TFA) to obtain 42 as white solid (8 mg, 5%) with 93% 
purity by analytical RP-HPLC.  
1
H-NMR (500 MHz, d
6
-DMSO): δ [ppm] = 1.29-1.40 (m, 8H, Lys-CH2), 1.48-1.70 (m, 16H, 
Lys-CH2), 3.20 (s, 8H, Lys-CH2), 3.69-3.79 (m, 1H, Lys-CH), 4.16-4.22 (m, 2H, Lys-CH), 
4.46 (s, 1H, Lys-CH), 5.32-5.52 (m, 1H, amino-NH), 6.83 (s, 4H, pyrrole-CH), 7.02-7.17 (m, 
2H, amide-NH), 7.26-7.31 (m, 2H, amide-NH2), 7.42(s, 4H, pyrrole-CH), 7.78(s, 1H, 
guanidine-NH), 7.93(br. s, 1H, guanidine-NH), 8.18-8.68 (m, 19H, amide-NH, guanidine-NH), 
11.88 (br.s, 3H, guanidine-NH), 12.26 (br.s, 3H, guanidine-NH).  
13
C-NMR (125 MHz, d
6
-DMSO): δ [ppm] = 22.7 (Lys-CH2), 22.9 (Lys-CH2), 23.1 
(Lys-CH2), 28.9 (Lys-CH2), 31.4 (Lys-CH2), 31.7 (Lys-CH2), 38.7 (Lys-CH2), 52.2 (Lys-CH), 
52.6 (Lys-CH), 52.9 (Lys-CH), 112.3 (pyrrole-CH), 113.4 (pyrrole-CH), 115.8 (pyrrole-CH), 
125.4 (pyrrole-CH), 155.5 (Cq), 158.9 (Cq), 159.7 (Cq), 171.2 (Cq), 171.6 (Cq), 171.8 (Cq), 
173.4 (Cq).  
MALDI-TOF-MS (pos.) m/z calculated for C52H76N25O12 [M + H] 
+
 1242.61, found 1242.01 
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Microwave Assisted Solid-Phase Peptide Synthesis of (62): 
 
The reaction was carried out in a fritted, microwave-transparent 25 ml polyethylene column 
with a CEM Discover microwave apparatus. Rink-Amide MBHA resin (200 mg, 0.62mmol/g) 
was swollen in DCM (5 ml) for 2 h. Fmoc removal was achieved by irradiating the resin in 
20 % piperidine/DMF (5 ml) for 1 min and 5 min at 20 W and a maximum temperature of 60° 
C followed by washing with DMF (6 × 5 ml). The first residue Fmoc-Alloc-Lys-OH (169 mg, 
0.37 mmol, 3 eq) was attached to the resin by microwave irradiation for 20 min at 20 W and a 
maximum temperature of 60° C under argon atmosphere with PyBOP (194 mg, 0.37 mmol, 3 
eq), DIPEA (130 μl, 0.74 mmol, 6 eq) in DMF (5 ml) and consequent washing with DMF (3 × 
5 ml). Coupling and washing steps were repeated. After Fmoc deprotection the second to the 
third residues Fmoc-Alloc-Lys-OH was attached to the resin as described above, also 
repeating coupling and washing steps. Afterwards, the fourth residue Fmoc-Boc-Lys-OH 
(173mg, 0.37 mmol, 3 eq) was attached to the resin. Alloc removal was achieved by 
Pd(PPh3)4 (42 mg, 0.04 mmol, 0.3 eq), PhSiH3 (366 μl, 2.98 mmol, 24 eq) in 7 ml DCM for 
30 min at room temperature under argon bubbling and consequent washing with DMF (3 × 5 
ml). The deprotection and washing process was repeated. The GCP groups (443 mg, 1.11 
mmol, 9 eq) were attached to the resin by microwave irradiation for 20 min at 20 W and a 
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maximum temperature of 60° C under argon atmosphere with PyBOP (580 mg, 1.11 mmol, 9 
eq), DIPEA (379 μl, 2.22 mmol, 18 eq) in DMF (5 ml) and consequent washing with DMF (3 
× 5 ml). The coupling process was repeated until Kaiser Test showed negative result. After 
Fmoc deprotection the resin was washed with DCM (3 × 5 ml), methanol (3 × 5 ml), and 
DCM (3 × 5 ml) and dried under reduced pressure for one hour. To cleave the product, the 
resin was transferred to a flask equipped with a frit onto a Heidolph Rotamax 120 shaker. 
There it was shaken under argon atmosphere in a mixture containing 95 % TFA, 2.5 % water, 
and 2.5 % TIS for three hours and washed twice with the cleavage mixture. The filtrates were 
combined and concentrated in high vacuum at room temperature. Diethyl ether (40 ml) was 
added and the resulting suspension was centrifuged. The supernatant solvent was decanted 
and the solid was washed with diethyl ether and centrifuged again. After decanting, the raw 
product was dissolved in little methanol, water (30 ml) was added, and the mixture was 
freeze-dried in vacuum. The resulting solid was purified by MPLC on C18 reversed-phase 
silica gel (5 % to 45 % methanol/water in 45 min, 0.1 % TFA) to obtain 62 as white solid (6 
mg, 4%) with 95% purity by analytical RP-HPLC.  
1
H-NMR (500 MHz, d
6
-DMSO): δ [ppm] = 1.37-1.39 (m, 8H, Lys-CH2), 1.51-1.72 (m, 16H, 
Lys-CH2), 2.61-2.74 (s, 2H, Lys-CH2), 3.20 (s, 6H, Lys-CH2), 3.83 (s, 1H, Lys-CH), 4.16-4.22 
(m, 2H, Lys-CH), 4.32 (s, 1H, Lys-CH), 6.85-6.87 (m, 2H, pyrrole-CH), 7.04-7.50 (m, 5H, 
amide-NH), 7.85(s, 4H, pyrrole-CH), 8.17-8.63 (m, 18H, amide-NH, guanidine-NH), 12.0 (s, 
2H, amine-NH2), 12.29(s, 2H, amide-NH2).  
13
C-NMR (125 MHz, d
6
-DMSO): δ [ppm] = 21.6 (Lys-CH2), 22.8 (Lys-CH2), 22.9 
(Lys-CH2), 26.5 (Lys-CH2), 28.4 (Lys-CH2), 28.7 (Lys-CH2), 30.8 (Lys-CH2), 31.4 (Lys-CH2), 
31.5 (Lys-CH2), 38.5 (Lys-CH2), 51.9 (Lys-CH), 52.7 (Lys-CH), 112.3 (pyrrole-CH), 112.4 
(pyrrole-CH), 115.8 (pyrrole-CH), 155.4 (Cq), 159.0 (Cq), 159.6 (Cq), 168.5 (Cq), 171.2 (Cq), 
173.3 (Cq).  
MALDI-TOF-MS (pos.) m/z calculated for C45H70N21O10 [M + H] 
+
 1064.55, found 1065.36 
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Microwave Assisted Solid-Phase Peptide Synthesis of (63): 
 
The reaction was carried out in a fritted, microwave-transparent 25 ml polyethylene column 
with a CEM Discover microwave apparatus. Rink-Amide MBHA resin (200 mg, 0.62mmol/g) 
was swollen in DCM (5 ml) for 2 h. Fmoc removal was achieved by irradiating the resin in 
20 % piperidine/DMF (5 ml) for 1 min and 5 min at 20 W and a maximum temperature of 60° 
C followed by washing with DMF (6 × 5 ml). The first residue Fmoc-Alloc-Lys-OH (169 mg, 
0.37 mmol, 3 eq) was attached to the resin by microwave irradiation for 20 min at 20 W and a 
maximum temperature of 60° C under argon atmosphere with PyBOP (194 mg, 0.37 mmol, 3 
eq), DIPEA (130 μl, 0.74 mmol, 6 eq) in DMF (5 ml) and consequent washing with DMF (3 × 
5 ml). Coupling and washing steps were repeated. After Fmoc deprotection the second to the 
third residues Fmoc-Boc-Lys-OH was attached to the resin as described above, also repeating 
coupling and washing steps. Afterwards, the fourth residue Fmoc-Alloc-Lys-OH (169mg, 0.37 
mmol, 3 eq) was attached to the resin. Alloc removal was achieved by Pd(PPh3)4 (28 mg, 0.02 
mmol, 0.2 eq), PhSiH3 (366 μl, 2.98 mmol, 24 eq) in 7 ml DCM for 30 min at room 
temperature under argon bubbling and consequent washing with DMF (3 × 5 ml). The 
deprotection and washing process was repeated. The GCP groups (211 mg, 0.49 mmol, 4 eq) 
were attached to the resin by microwave irradiation for 20 min at 20 W and a maximum 
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temperature of 60° C under argon atmosphere with PyBOP (210 mg, 0.49 mmol, 4 eq), 
DIPEA (168 μl, 0.98 mmol, 8 eq) in DMF (5 ml) and consequent washing with DMF (3 × 5 
ml). The coupling process was repeated until Kaiser Test showed negative result. After Fmoc 
deprotection the resin was washed with DCM (3 × 5 ml), methanol (3 × 5 ml), and DCM (3 × 
5 ml) and dried under reduced pressure for one hour. To cleave the product, the resin was 
transferred to a flask equipped with a frit onto a Heidolph Rotamax 120 shaker. There it was 
shaken under argon atmosphere in a mixture containing 95 % TFA, 2.5 % water, and 2.5 % 
TIS for three hours and washed twice with the cleavage mixture. The filtrates were combined 
and concentrated in high vacuum at room temperature. Diethyl ether (40 ml) was added and 
the resulting suspension was centrifuged. The supernatant solvent was decanted and the solid 
was washed with diethyl ether and centrifuged again. After decanting, the raw product was 
dissolved in little methanol, water (30 ml) was added, and the mixture was freeze-dried in 
vacuum. The resulting solid was purified by MPLC on C18 reversed-phase silica gel (5 % to 
45 % methanol/water in 45 min, 0.1 % TFA) to obtain 63 as white solid (8 mg, 7%) with 88% 
purity by analytical RP-HPLC.  
1
H-NMR (500 MHz, d
6
-DMSO): δ [ppm] = 1.33-1.35 (m, 8H, Lys-CH2), 1.51-1.72 (m, 16H, 
Lys-CH2), 2.75 (s, 4H, Lys-CH2), 3.22 (s, 4H, Lys-CH2), 3.72-3.83 (s, 1H, Lys-CH), 4.16-4.45 
(m, 3H, Lys-CH), 6.87-6.89 (m, 1H, amide-NH), 7.03-7.12 (m, 2H, pyrrole-CH), 7.20-7.47 
(m, 2H, pyrrole-CH), 7.82-7.88 (m, 8H, amide-NH, amine-NH2, pyrrole-NH), 8.22-8.58 (m, 
12H, amide-NH, guanidine-NH), 12.0 (s, 1H, amine-NH), 12.3 (s, 1H, amide-NH).  
MALDI-TOF-MS (pos.) m/z calculated for C38H64N17O8 [M + H] 
+
 886.50, found 886.84 
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Microwave Assisted Solid-Phase Peptide Synthesis of (64): 
 
The reaction was carried out in a fritted, microwave-transparent 25 ml polyethylene column 
with a CEM Discover microwave apparatus. Rink-Amide MBHA resin (200 mg, 0.62mmol/g) 
was swollen in DCM (5 ml) for 2 h. Fmoc removal was achieved by irradiating the resin in 
20 % piperidine/DMF (5 ml) for 1 min and 5 min at 20 W and a maximum temperature of 60° 
C followed by washing with DMF (6 × 5 ml). The first residue Fmoc-Alloc-Lys-OH (169 mg, 
0.37 mmol, 3 eq) was attached to the resin by microwave irradiation for 20 min at 20 W and a 
maximum temperature of 60° C under argon atmosphere with PyBOP (194 mg, 0.37 mmol, 3 
eq), DIPEA (130 μl, 0.74 mmol, 6 eq) in DMF (5 ml) and consequent washing with DMF (3 × 
5 ml). Coupling and washing steps were repeated. After Fmoc deprotection the second to the 
fourth residues Fmoc-Boc-Lys-OH was attached to the resin as described above, also 
repeating coupling and washing steps. Alloc removal was achieved by Pd(PPh3)4 (28 mg, 0.02 
mmol, 0.2 eq), PhSiH3 (366 μl, 2.98 mmol, 24 eq) in 7 ml DCM for 30 min at room 
temperature under argon bubbling and consequent washing with DMF (3 × 5 ml). The 
deprotection and washing process was repeated. The GCP groups (106 mg, 0.25 mmol, 2 eq) 
were attached to the resin by microwave irradiation for 20 min at 20 W and a maximum 
temperature of 60° C under argon atmosphere with PyBOP (105 mg, 0.25 mmol, 2 eq), 
DIPEA (84 μl, 0.49 mmol, 4 eq) in DMF (5 ml) and consequent washing with DMF (3 × 5 
ml). The coupling process was repeated until Kaiser Test showed negative result. After Fmoc 
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deprotection the resin was washed with DCM (3 × 5 ml), methanol (3 × 5 ml), and DCM (3 × 
5 ml) and dried under reduced pressure for one hour. To cleave the product, the resin was 
transferred to a flask equipped with a frit onto a Heidolph Rotamax 120 shaker. There it was 
shaken under argon atmosphere in a mixture containing 95 % TFA, 2.5 % water, and 2.5 % 
TIS for three hours and washed twice with the cleavage mixture. The filtrates were combined 
and concentrated in high vacuum at room temperature. Diethyl ether (40 ml) was added and 
the resulting suspension was centrifuged. The supernatant solvent was decanted and the solid 
was washed with diethyl ether and centrifuged again. After decanting, the raw product was 
dissolved in little methanol, water (30 ml) was added, and the mixture was freeze-dried in 
vacuum. The resulting solid was purified by MPLC on C18 reversed-phase silica gel (5 % to 
45 % methanol/water in 45 min, 0.1 % TFA) to obtain 64 as white solid (6 mg, 7%) with 90% 
purity by analytical RP-HPLC.  
1
H-NMR (500 MHz, d
6
-DMSO): δ [ppm] = 1.51-1.58 (m, 8H, Lys-CH2), 1.66-1.76 (m, 16H, 
Lys-CH2), 2.74 (s, 6H, Lys-CH2), 3.21 (s, 2H, Lys-CH2), 3.86-3.90 (m, 1H, Lys-CH), 
4.16-4.33 (m, 3H, Lys-CH), 6.91 (s, 1H, pyrrole-CH), 7.43(s, 1H, pyrrole-CH), 7.93-8.39 (m, 
10H, amide-NH, guanidine-NH), 8.61 (s, 4H, amine-NH2), 8.73-8.79 (m, 3H, amide-NH), 
12.2 (s, 1H, amide-NH), 12.3 (s, 1H, amide-NH).  
13
C-NMR (125 MHz, d
6
-DMSO): δ [ppm] = 22.0 (Lys-CH2), 22.1(Lys-CH2), 22.2 (Lys-CH2), 
26.3 (Lys-CH2), 26.4 (Lys-CH2), 28.4 (Lys-CH2), 30.7 (Lys-CH2), 31.1 (Lys-CH2), 31.3 
(Lys-CH2), 38.5 (Lys-CH2), 51.9 (Lys-CH), 52.5 (Lys-CH), 112.5 (pyrrole-CH), 116.0 
(pyrrole-CH), 125.2 (Cq), 132.9 (Cq), 155.6 (Cq), 159.0 (Cq),159.6 (Cq), 168.5 (Cq), 171.2 
(Cq), 173.4 (Cq).  
MALDI-TOF-MS (pos.) m/z calculated for C31H58N13O6 [M + H] 
+
 708.46, found 708.59 
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Microwave Assisted Solid-Phase Peptide Synthesis of (43): 
 
The reaction was carried out in a fritted, microwave-transparent 25 ml polyethylene column 
with a CEM Discover microwave apparatus. Rink-Amide MBHA resin (200 mg, 0.62mmol/g) 
was swollen in DCM (5 ml) for 2 h. Fmoc removal was achieved by irradiating the resin in 
20 % piperidine/DMF (5 ml) for 1 min and 5 min at 20 W and a maximum temperature of 60° 
C followed by washing with DMF (6 × 5 ml). The first residue Fmoc-Arg(Pbf)-OH (242 mg, 
0.37 mmol, 3 eq) was attached to the resin by microwave irradiation for 20 min at 20 W and a 
maximum temperature of 60° C under argon atmosphere with PyBOP (193 mg, 0.37 mmol, 3 
eq), DIPEA (127 µl, 0.74 mmol, 6 eq) in DMF (5 ml) and consequent washing with DMF (3 × 
5 ml). Coupling and washing steps were repeated. After Fmoc deprotection the second to the 
fourth residues Fmoc-Arg(Pbf)-OH was attached to the resin as described above, also 
repeating coupling and washing steps. After Fmoc deprotection the resin was washed with 
DCM (3 × 5 ml), methanol (3 × 5 ml), and DCM (3 × 5 ml) and dried under reduced pressure 
for one hour. To cleave the product, the resin was transferred to a flask equipped with a frit 
onto a Heidolph Rotamax 120 shaker. There it was shaken under argon atmosphere in a 
mixture containing 95 % TFA, 2.5 % water, and 2.5 % TIS for three hours and washed twice 
with the cleavage mixture. The filtrates were combined and concentrated in high vacuum at 
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room temperature. Diethyl ether (40 ml) was added and the resulting suspension was 
centrifuged. The supernatant solvent was decanted and the solid was washed with diethyl 
ether and centrifuged again. After decanting, the raw product was dissolved in little methanol, 
water (30 ml) was added, and the mixture was freeze-dried in vacuum. The resulting solid was 
purified by MPLC on C18 reversed-phase silica gel (5 % to 50 % methanol/water in 45 min, 
0.1 % TFA) to obtain 43 as white solid (15 mg, 19%) with >90% purity by analytical 
RP-HPLC.   
1
H-NMR (500 MHz, d
6
-DMSO): δ [ppm] = 1.53-1.75 (m, 16H, Arg-CH2), 3.10-3.12 (t, 8H, J 
= 5Hz, Arg-CH2), 3.85-3.86 (m, 1H, Arg-CH), 4.11-4.17 (m, 1H, Arg-CH), 4.19-4.26 (m, 1H, 
Arg-CH), 4.29-4.33 (m, 1H, Arg-CH), 6.85 (br. s, 4H, guanidine-NH), 7.02 (s, 2H, 
amino-NH2), 7.10 (s, 2H, guanidine-NH), 7.18 (s, 2H, guanidine-NH), 7.29 (br. s, 4H, 
guanidine-NH), 7.51-7.52 (m, 4H, amide-NH), 8.10-8.19 (m, 4H, guanidine-NH), 8.52-8.55 
(m, 1H, amide-NH).  
13
C-NMR (125 MHz, d
6
-DMSO): δ [ppm] = 23.9 (Arg-CH2), 24.9 (Arg-CH2), 25.0 
(Arg-CH2), 25.1 (Arg-CH2), 27.9 (Arg-CH2), 28.3 (Arg-CH2), 28.8 (Arg-CH2), 28.9 
(Arg-CH2), 29.0 (Arg-CH2), 29.1 (Arg-CH2), 40.0 (Arg-CH2), 40.1 (Arg-CH2), 40.3 
(Arg-CH2), 40.4 (Arg-CH2), 45.6 (Arg-CH2), 51.7 (Arg-CH), 52.1 (Arg-CH), 52.4 (Arg-CH), 
52.5 (Arg-CH), 156.6 (guanidine-C), 168.4(Cq), 158.9 (Cq), 170.9 (Cq), 171.0 (Cq), 171.2 
(Cq), 173.2 (Cq), 173.4 (Cq). 
MALDI-TOF-MS (pos.) m/z calculated for C24H52N17O4 [M + H] 
+
 642.43, found 643.05 
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Microwave Assisted Solid-Phase Peptide Synthesis of (44): 
 
The reaction was carried out in a fritted, microwave-transparent 25 ml polyethylene column 
with a CEM Discover microwave apparatus. Rink-Amide MBHA resin (200 mg, 0.62mmol/g) 
was swollen in DCM (5 ml) for 2 h. Fmoc removal was achieved by irradiating the resin in 
20 % piperidine/DMF (5 ml) for 1 min and 5 min at 20 W and a maximum temperature of 60° 
C followed by washing with DMF (6 × 5 ml). The first residue Fmoc-Lys(Boc)-OH (175 mg, 
0.37 mmol, 3 eq) was attached to the resin by microwave irradiation for 20 min at 20 W and a 
maximum temperature of 60° C under argon atmosphere with PyBOP (194 mg, 0.37 mmol, 3 
eq), DIPEA (127 µl, 0.74 mmol, 6 eq) in DMF (5 ml) and consequent washing with DMF (3 × 
5 ml). Coupling and washing steps were repeated. After Fmoc deprotection the second to the 
fourth residues Fmoc-Lys(Boc)-OH were attached to the resin as described above, also 
repeating coupling and washing steps. After Fmoc deprotection the resin was washed with 
DCM (3 × 5 ml), methanol (3 × 5 ml), and DCM (3 × 5 ml) and dried under reduced pressure 
for one hour. To cleave the product, the resin was transferred to a flask equipped with a frit 
onto a Heidolph Rotamax 120 shaker. There it was shaken under argon atmosphere in a 
mixture containing 95 % TFA, 2.5 % water, and 2.5 % TIS for three hours and washed twice 
with the cleavage mixture. The filtrates were combined and concentrated in high vacuum at 
room temperature. Diethyl ether (40 ml) was added and the resulting suspension was 
centrifuged. The supernatant solvent was decanted and the solid was washed with diethyl 
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ether and centrifuged again. After decanting, the raw product was dissolved in little methanol, 
water (30 ml) was added, and the mixture was freeze-dried in vacuum. The resulting solid was 
purified by MPLC on C18 reversed-phase silica gel (0 % to 50 % methanol/water in 50 min, 
0.1 % TFA) to obtain 44 as white solid (6.6 mg, 10%) with >90% purity by analytical 
RP-HPLC.  
1
H-NMR (500 MHz, d
6
-DMSO):δ [ppm] = 1.29-1.44 (m, 8H, Lys-CH2), 1.57-1.73 (m, 16H, 
Lys-CH2), 2.75 (s, 8H, Lys-CH2), 3.87 (s, 1H, Lys-CH), 4.16-4.32 (m, 3H, Lys-CH), 
7.12-7.48 (m, 2H, amino-NH2), 7.97-8.04 (m, 10H, amino-NH2, amide-NH), 8.26-8.27 (m, 
2H, amino-NH2), 8.85 (s, 1H, amide-NH).  
13
C-NMR (125 MHz, d
6
-DMSO): δ [ppm] = 20.9 (Lys-CH2), 22.1 (Lys-CH2), 26.3 
(Lys-CH2), 30.3 (Lys-CH2), 30.9 (Lys-CH2), 31.3 (Lys-CH2), 38.3 (Lys-CH2), 51.6 (Lys-CH), 
52.1 (Lys-CH), 52.5 (Lys-CH), 52.6 (Lys-CH), 168.4 (Cq), 171.1 (Cq), 173.4 (Cq).  
MALDI-TOF-MS (pos.) m/z calculated for C24H52N9O4 [M + H] 
+
 530.41, found 530.21 
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6.4.3 Synthesis of cyclic peptide analogues 
Synthesis of linear precursor (70): 
 
2-Chlorotrityl chloride resin (200 mg) was swollen in DMF (5 ml) for 2 h. The first residue 
Fmoc-D-Ala-OH (3 eq.) was attached to the resin at room temperature under argon 
atmosphere with DIPEA (6 eq.) in DMF (5 ml) for 2 h and consequent washing with DMF (3 
× 5 ml). Coupling and washing steps were repeated. Methanol was then added to block 
remaining chloride residues. The resin was filtered and washed with DMF, DCM and 
methanol, and left to dry under vacuum. The Fmoc protecting group was then removed by 
stirring the resin in 20% piperidine in DMF solution for 20 mins. After Fmoc deprotection the 
remaining solid was washed intensively with DMF. A solution of PyBop (3eq.) and 
Fmoc-L-Lys-(Boc)-OH (3eq.) in DMF was added to the loaded resin, followed by the addition 
of DIPEA (6eq.). The mixture was left to stir in 2h and consequent washed with DMF. The 
reaction was repeated with fresh reagents. The resin was filtered and washed with DMF, DCM 
and methanol, and left to dry under vacuum. The Fmoc protecting group was then removed as 
described above, and the same procedure was done for the next five amino acids. After Fmoc 
removal, Fmoc-L-Lys-(Alloc)-OH (3eq.) was attached to the resin as described above, also 
EXPERIMENTAL SECTION 
176 
repeating coupling and washing steps. Alloc removal was achieved by Pd(PPh3)4 (0.1 eq.), 
PhSiH3 (6 eq.) in 7 ml DCM for 30 min at room temperature under argon bubbling and 
consequent washing with DMF (3 × 5 ml). The deprotection and washing process was 
repeated. The GCP groupS (3 eq.) were attached to the resin under argon atmosphere with 
PyBop (6 eq.), DIPEA (337 µl, 1.98 mmol, 6 eq) in DMF (5 ml) and consequent washing with 
DMF (3 × 5 ml).  The coupling process was repeated until Kaiser Test showed negative 
result. After Fmoc deprotection the resin was washed with DCM (3 × 5 ml), methanol (3 × 5 
ml), and DCM (3 × 5 ml) and dried under reduced pressure for one hour.  
To cleave the linear precursor, the resin was shaken under argon atmosphere in a mixture 
containing 1% TFA, 2.5 % water, and 2.5 % TIS in DCM for 20 minutes and washed twice 
with DCM. The filtrates were combined and concentrated in high vacuum at room 
temperature. Diethyl ether (20 ml) was added and the resulting suspension was centrifuged. 
The supernatant solvent was decanted and the solid was washed with diethyl ether and 
centrifuged again. After decanting, the raw product was dissolved in methanol, water (30 ml) 
was added, and the mixture was freeze-dried in vacuum. The resulting white solid (200 mg, 
60%) was used to next step without further purification. 
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Synthesis of cyclic peptide (45): 
 
The linear precursor (200mg, 143 μmol) was dissolved in DMF (90 mL). The solution was 
cooled to 0 °C in an ice bath. PyBop (223 mg, 429 μmol) was dissolved in DMF (30 mL), 
cooled to 0 °C, was slowly added to the solution mixture while stirring at 0 °C. DIPEA (148 
μL, 858 μmol) was added slowly to the mixture. The reaction mixture was left to stir for 6 
hours at 0 °C and then at room temperature for two days. DMF was removed by vacuum 
distillation at 55 °C, resulting in a gel-like residue. The crude product was used without 
further purification. 
The cyclized product was dissolved in 10mL of 95% v/v TFA, 2.5% v/v TIS and 2.5% v/v 
H2O. The mixture was left to stir for two hours at room temperature. The deprotected product 
was then precipitated using cold ether (100 mL). The mixture was centrifuged, and ether was 
then decanted. This step was repeated twice, resulting in an off-white precipitate. The product 
was then dissolved in H2O (5 mL), and lyophilized giving an off-white fluffy solid. The crude 
product was purified by MPLC on C18 reversed-phase silica gel (15% to 55% methanol/water 
in 45 min, 0.1 % TFA) to obtain 45 as white solid (5 mg, 5%) with 91% purity by analytical 
RP-HPLC.  
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1
H-NMR (500 MHz, d
6
-DMSO): δ [ppm] = 1.14-1.23 (m, 21H, Lys-CH2, Ala-CH3), 
1.26-1.59 (m, 15H, Lys-CH2), 2.73-2.74 (s, 6H, Lys-CH2),  3.18 (s, 2H, Lys-CH2), 
4.21-4.40(m, 8H, Ala-CH, Lys-CH), 6.84 (s, 1H, pyrrole-CH), 7.10 (s, 1H, pyrrole-CH), 
7.68-7.71 (s, 9H, amine-NH3+), 8.09-8.19 (m, 8H, amide-NH),  8.41 (br.s, 4H, 
guanidine-NH). 
13
C-NMR (125 MHz, d
6
-DMSO): δ [ppm] = 19.0 (Ala-CH3), 22.0-22.6 (Lys-CH2), 26.5 
(Lys-CH2), 26.6 (Lys-CH2), 28.4 (Lys-CH2), 38.5 (Lys-CH2), 47.8-47.9 (Ala-CH), 51.8-51.9 
(Lys-CH), 112.3 (pyrrole-CH), 155.0 (GCP-carbonyl), 157.7 (GCP-carbonyl), 170.7-170.9 
(Ala-carbonyl), 171.7-171.8 (Lys-carbonyl). 
MALDI-TOF-MS (pos.) m/z calculated for C43H75N16O10 [M + H] 
+
 975.58, found 975.85 
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Synthesis of linear precursor (72): 
 
2-chlorotrityl chloride resin was swollen in DMF (5 ml) for 2 h. The first residue 
Fmoc-D-Ala-OH (3 eq.) was attached to the resin at room temperature under argon 
atmosphere with DIPEA (6 eq.) in DMF (5 ml) for 2h and consequent washing with DMF (3 
× 5 ml). Coupling and washing steps were repeated. Methanol was then added to block 
remaining chloride residues. The resin was filtered and washed with DMF, DCM and 
methanol, and left to dry under vacuum. The Fmoc protecting group was then removed by 
stirring the resin in 20% piperidine in DMF solution for 20 mins. After Fmoc deprotection the 
remaining solid was washed intensively with DMF. A solution of PyBop (3eq.) and 
Fmoc-L-Lys-(Boc)-OH (3eq.) in DMF was added to the loaded resin, followed by the addition 
of DIPEA (6eq.). The mixture was left to stir in 2h and consequent washed with DMF. The 
reaction was repeated with fresh reagents. The resin was filtered and washed with DMF, DCM 
and methanol, and left to dry under vacuum. The Fmoc protecting group was then removed as 
described above, and the same procedure was done for the next six amino acids. After final 
Fmoc removal the resin was washed with DCM (3 × 5 ml), methanol (3 × 5 ml), and DCM (3 
× 5 ml) and dried under reduced pressure for one hour. 
To cleave the linear precursor, the resin was shaken under argon atmosphere in a mixture 
containing 1% TFA, 2.5 % water, and 2.5 % TIS in DCM for 20 minutes and washed twice 
with DCM. The filtrates were combined and concentrated in high vacuum at room 
temperature. Diethyl ether (20 ml) was added and the resulting suspension was centrifuged. 
The supernatant solvent was decanted and the solid was washed with diethyl ether and 
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centrifuged again. After decanting, the raw product was dissolved in little methanol, water (30 
ml) was added, and the mixture was freeze-dried in vacuum. The resulting white solid (210 
mg, 70%) was used to next step without further purification. 
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Synthesis of cyclic peptide (65): 
 
The linear precursor (210mg, 173 μmol)) of cyclic peptide 2 was dissolved in DMF (90 mL). 
The solution was cooled to 0 °C in an ice bath. PyBop (270 mg, 519 μmol) was dissolved in 
DMF (30 mL), cooled to 0 °C, was slowly added to the solution mixture while stirring at 0 °C. 
DIPEA (179 μL, 1.04 mmol) was added slowly to the mixture. The reaction mixture was left 
to stir for 6 hours at 0 °C and then at room temperature for two days. DMF was removed by 
vacuum distillation at 55 °C, resulting in a gel-like residue. The crude product was used 
without further purification. 
The cyclized product was dissolved in 10mL of 95% TFA, 2.5% TIS and 2.5% H2O. The 
mixture was left to stir for two hours at room temperature. The deprotected product was then 
precipitated using cold ether (100 mL). The mixture was centrifuged, and ether was then 
decanted. This step was repeated twice, resulting in an off-white precipitate. The product was 
then dissolved in H2O (5 mL), and lyophilized giving an off-white fluffy solid. The crude 
product was purified by MPLC on C18 reversed-phase silica gel (5 % to 45 % methanol/water 
in 45 min, 0.1 %TFA) to obtain 65 as white solid (9 mg, 6.5%) with >90% purity by 
analytical RP-HPLC.  
1
H-NMR (500 MHz, d
6
-DMSO):δ [ppm] = 1.27-1.29 (m, 20H, Lys-CH2, Ala-CH3), 
1.43-1.60 (m, 16H, Lys-CH2), 2.73-2.75 (s, 8H, Lys-CH2), 4.17-4.45(m, 8H, Lys-CH, 
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Ala-CH), 7.72(s, 12H, amine-NH3+), 8.07-8.09 (d, J= 5Hz, 4H, amide-NH),  8.18-8.20 (d, , 
J= 5Hz, 4H, amide-NH).  
13
C-NMR (125 MHz, d
6
-DMSO):  δ [ppm] = 18.9 (Ala-CH3), 22.0 (Lys-CH2), 26.6 
(Lys-CH2), 31.8 (Lys-CH2), 38.6 (Lys-CH2), 47.9 (Ala-CH), 51.8 (Lys-CH), 170.8 
(Ala-carbonyl), 171.8 (Lys-carbonyl). 
MALDI-TOF-MS (pos.) m/z calculated for C36H68N12O8Na [M + Na] 
+
 819.53, found 819.88 
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6.4.4 Synthesis of β-helix mimetic peptide 
Synthesis of peptide 46: 
 
Wang resin was swollen in DMF (5 ml) for 2 h. The first residue Fmoc-L-Ala-OH (3 eq.) 
was attached to the resin at room temperature under argon atmosphere with HCTU (3 eq.), 
DIPEA (6 eq.) in DMF (5 ml) for 2 h and consequent washing with DMF (3 × 5 ml). 
Coupling and washing steps were repeated. The resin was filtered and washed with DMF, 
DCM and methanol, and left to dry under vacuum. The Fmoc protecting group was then 
removed by stirring the resin in 20% piperidine in DMF solution for 20 mins. After Fmoc 
deprotection the remaining solid was washed intensively with DMF. A solution of HCTU 
(3eq.) and Fmoc-D-Ala-OH (3eq.) in DMF was added to the loaded resin, followed by the 
addition of DIPEA (6eq.). The mixture was shaken for 2h and subse-quently washed with 
DMF. The reaction was repeated with fresh reagents. The resin was filtered and washed with 
DMF, and left to dry under vacuum. The Fmoc protecting group was then removed as 
described above and the same procedure was done for the rest amino acids. After Fmoc 
removal, the GCP group (2 eq.) were attached to the resin under argon atmosphere with 
HCTU (3 eq.), DIPEA (6 eq) in DMF (5 ml) for 8h and subsequently washing with DMF (3 × 
5 ml). The coupling process was repeated until Kaiser Test showed negative result. Afterwards 
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the resin was washed with DCM (3 × 5 ml), methanol (3 × 5 ml), and DCM (3 × 5 ml) and 
dried under reduced pressure for one hour. To cleave the peptide, the resin was shaken under 
argon atmosphere in a mixture containing 10mL of 95% v/v TFA, 2.5% v/v TIS and 2.5% v/v 
H2O for 3h and washed with TFA. The filtrates were combined and concentrated in high 
vacuum at room temperature. The product was then precipitated using cold ether (50 mL). 
The mixture was centrifuged, and ether was then decanted. This step was repeated twice, 
resulting in an off-white precipitate. The product was then dissolved in H2O (5 mL), and 
lyophilized giving a white fluffy solid. The crude product was purified by MPLC on C18 
reversed-phase silica gel (20 % to 50 % methanol/water in 45 min, 0.1 % TFA) to obtain 46 as 
white solid (10 mg, 10 %) with 97 % purity by analytical RP-HPLC.  
1
H-NMR (500 MHz, D2O): δ [ppm] = 1.22-1.23 (d, 3H, J = 5 Hz, Ala-CH3), 1.34-1.40 (m, 
18H, Ala-CH3), 1.48-1.49 (d, 3H, J = 5 Hz, Ala-CH3),  4.20-4.33 (m, 7H, Ala-CH), 4.49-4.52 
(q, 1H, J = 5 Hz, Ala-CH), 6.93-6.94 (d, 1H, J = 5 Hz, pyrrole-CH), 7.12-7.13 (d, 1H, J = 5 
Hz, pyrrole-CH).  
13
C-NMR (500 MHz, D2O): δ [ppm] = 16.1-16.6 (m, Ala-CH3), 49.0-50.2 (m, Ala-CH), 
113.1 (pyrrole-CH), 115.6 (pyrrole-CH), 155.2 (guanidine-CH), 160.7 (guanidine-carbonyl), 
161.6 (Ala-carbonyl), 174.4-175.2 (m, Ala-carbonyl), 176.8 (Ala-carboxylate).  
ESI-MS (pos.) m/z calculated for C31H49N12O11 [M + H] 
+
 765.36, found 765.41. 
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Synthesis of peptide 66: 
 
Wang resin was swollen in DMF (5 ml) for 2 h. The first residue Fmoc-L-Ala-OH (3 eq.) 
was attached to the resin at room temperature under argon atmosphere with HCTU (3 eq.), 
DIPEA (6 eq.) in DMF (5 ml) for 2 h and consequent washing with DMF (3 × 5 ml). 
Coupling and washing steps were repeated. The resin was filtered and washed with DMF, 
DCM and methanol, and left to dry under vacuum. The Fmoc protecting group was then 
removed by stirring the resin in 20% piperidine in DMF solution for 20 mins. After Fmoc 
deprotection the remaining solid was washed intensively with DMF. A solution of HCTU 
(3eq.) and Fmoc-D-Ala-OH (3eq.) in DMF was added to the loaded resin, followed by the 
addition of DIPEA (6eq.). The mixture was shaken for 2h and subsequently washed with DMF. 
The reaction was repeated with fresh reagents. The resin was filtered and washed with DMF, 
and left to dry under vacuum. The Fmoc protecting group was then removed as described 
above and the same procedure was done for the rest amino acids. Afterwards the resin was 
washed with DCM (3 × 5 ml), methanol (3 × 5 ml), and DCM (3 × 5 ml) and dried under 
reduced pressure for one hour. To cleave the peptide, the resin was shaken under argon 
atmosphere in a mixture containing 10mL of 95 % v/v TFA, 2.5 % v/v TIS and 2.5 % v/v H2O 
for 3 h and washed with TFA. The filtrates were combined and concentrated in high vacuum 
at room temperature. The product was then precipitated using cold ether (50 mL). The mixture 
was centrifuged, and ether was then decanted. This step was repeated twice, resulting in an 
off-white precipitate. The product was then dissolved in H2O (5 mL), and lyophilized giving a 
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white fluffy solid. The crude product was purified by MPLC on C18 reversed-phase silica gel 
(10 % to 50 % methanol/water in 45 min, 0.1 % TFA) to obtain 1 as white solid (20 mg, 20 %) 
with 93 % purity determined by analytical RP-HPLC.  
1
H-NMR (300 MHz, D2O): δ [ppm] = 1.35-1.39 (m, 21H, Ala-CH3), 1.50-1.52 (d, 3H, J = 6 
Hz, Ala-CH3), 4.03-4.10 (q, 1H, J = 5 Hz, Ala-CH), 4.21-4.36 (m, 7H, Ala-CH).  
13
C-NMR (300 MHz, D2O): δ [ppm] = 16.1-16.6 (m, Ala-CH3), 49.0-50.2 (m, Ala-CH), 
161.6 (Ala-carbonyl), 174.4-175.2 (m, Ala-carbonyl), 176.8 (Ala-carboxylate).  
ESI-MS (pos.) m/z calculated for C24H43N8O9 [M + H] 
+
 587.31, found 587.46. 
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6.4.5 Synthesis of Fmoc-dipeptide analogues 
Synthesis of peptide (47): 
 
Rink-Amide MBHA resin (200 mg, 0.62mmol/g) was swollen in DCM (5 ml) for 2 h. 
Fmoc removal was achieved by shaking the resin in 20 % piperidine/DMF (5 ml) for 20 min 
twice followed by washing with DMF (6 × 5 ml). The first residue Fmoc-Alloc- l-Lys-OH 
(169 mg, 0.37 mmol, 3 eq) was attached to the resin with PyBOP (194 mg, 0.37 mmol, 3 eq), 
DIPEA (130 µl, 0.74 mmol, 6 eq) in DMF (5 ml) for 8 hours and consequent washing with 
DMF (3 × 5 ml). Coupling and washing steps were repeated. After Fmoc deprotection, the 
second residue Fmoc-Alloc-l-Lys-OH was attached to the resin as described above, also 
repeating coupling and washing steps. Alloc removal was achieved by Pd(PPh3)4 (28 mg, 0.02 
mmol, 0.2 eq), PhSiH3 (183 µl, 1.50 mmol, 24 eq) in 7 ml DCM for 30 min at room 
temperature under argon bubbling and consequent washing with DMF (3 × 5 ml). The 
deprotection and washing process was repeated. The GCP groups (197 mg, 0.99 mmol, 4 eq) 
were attached to the resin by microwave irradiation for 20 min at 20 W and a maximum 
temperature of 60° C under argon atmosphere with PyBOP (258 mg, 0.55 mmol, 4 eq), 
DIPEA (168 µl, 0.99 mmol, 8 eq) in DMF (5 ml) and consequent washing with DMF (3 × 5 
ml). The coupling process was repeated until Kaiser Test showed negative result. Afterwards, 
the resin was washed with DCM (3 × 5 ml), methanol (3 × 5 ml), and DCM (3 × 5 ml) and 
dried under reduced pressure for one hour. To cleave the product, the resin was transferred to 
a flask equipped with a frit onto a Heidolph Rotamax 120 shaker. There it was shaken under 
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argon atmosphere in a mixture containing 95 % TFA, 2.5 % water, and 2.5 % TIS for three 
hours and washed twice with the cleavage mixture. The filtrates were combined and 
concentrated in high vacuum at room temperature. Diethyl ether (40 ml) was added and the 
resulting suspension was centrifuged. The supernatant solvent was decanted and the solid was 
washed with diethyl ether and centrifuged again. After decanting, the raw product was 
dissolved in little methanol, water (30 ml) was added, and the mixture was freeze-dried in 
vacuum. The resulting solid was purified by MPLC on C18 reversed-phase silica gel (10 % to 
100 % methanol/water in 45 min, 0.1 % TFA) to obtain 47 as white solid (40 mg, 38%) with 
93 % purity determined by analytical RP-HPLC.  
1
H-NMR (500 MHz, d
6
-DMSO): δ [ppm] = 1.31-1.64 (m, 12H, Lys-CH2), 3.20 (s, 4H, 
Lys-CH2), 3.99-4.36 (m, 5H, Lys-CH, Fmoc-CH2, Fmoc-CH), 6.85 (s, 2H, pyrrole-CH), 
7.01-7.07 (m, 3H, phenyl-CH, pyrrole-CH), 7.27-7.41 (m, 4H, phenyl-CH), 7.51 (s, 1H, 
amide-NH), 7.67 (m, 2H, pyrrole-NH), 7.81-7.88 (m, 2H, amide-NH), 8.21-8.50 (m, 10H, 
guanidine-NH), 11.22 (s, 2H, amine-NH2), 12.30 (s, 2H, amide-NH2).  
13
C-NMR (125 MHz, d
6
-DMSO): δ [ppm] = 22.8 (Lys-CH2), 22.9 (Lys-CH2), 28.8 
(Lys-CH2), 31.6 (Lys-CH2), 31.9 (Lys-CH2), 38.8 (Lys-CH2), 45.8 (Lys-CH2), 46.7 
(Fmoc-CH), 52.2 (Lys-CH), 54.8 (Lys-CH), 65.7 (Fmoc-CH2), 112.7 (pyrrole-CH), 120.1 
(pyrrole-CH), 125.4 (phenyl-CH), 127.1 (phenyl-CH), 127.7 (phenyl-CH), 140.8 (Cq), 143.7 
(Cq), 143.9 (Cq), 156.0 (Cq), 159.1 (Cq), 171.9 (Cq), 173.6 (Cq). 
MALDI-TOF-MS (pos.) m/z calculated for C41H50N13O8 [M + H] 
+
 852.38, found 852.78 
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Synthesis of peptide (67): 
 
Rink-Amide MBHA resin (200 mg, 0.62mmol/g) was swollen in DCM (5 ml) for 2 h. 
Fmoc removal was achieved by shaking the resin in 20 % piperidine/DMF (5 ml) for 20 min 
twice followed by washing with DMF (6 × 5 ml). The first residue Fmoc-Alloc-d-Lys-OH 
(169 mg, 0.37 mmol, 3 eq) was attached to the resin with PyBOP (194 mg, 0.37 mmol, 3 eq), 
DIPEA (130 µl, 0.74 mmol, 6 eq) in DMF (5 ml) for 8 hours and consequent washing with 
DMF (3 × 5 ml). Coupling and washing steps were repeated. After Fmoc deprotection the 
second residue Fmoc-Alloc- d-Lys-OH was attached to the resin as described above, also 
repeating coupling and washing steps. Alloc removal was achieved by Pd(PPh3)4 (28 mg, 0.02 
mmol, 0.2 eq), PhSiH3 (183 µl, 1.50 mmol, 24 eq) in 7 ml DCM for 30 min at room 
temperature under argon bubbling and consequent washing with DMF (3 × 5 ml). The 
deprotection and washing process was repeated. The GCP groups (197 mg, 0.99 mmol, 4 eq) 
were attached to the resin by microwave irradiation for 20 min at 20 W and a maximum 
temperature of 60° C under argon atmosphere with PyBOP (258 mg, 0.55 mmol, 4 eq), 
DIPEA (168 µl, 0.99 mmol, 8 eq) in DMF (5 ml) and consequent washing with DMF (3 × 5 
ml). The coupling process was repeated until Kaiser Test showed negative result. Afterwards, 
the resin was washed with DCM (3 × 5 ml), methanol (3 × 5 ml), and DCM (3 × 5 ml) and 
dried under reduced pressure for one hour. To cleave the product, the resin was transferred to 
a flask equipped with a frit onto a Heidolph Rotamax 120 shaker. There it was shaken under 
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argon atmosphere in a mixture containing 95 % TFA, 2.5 % water, and 2.5 % TIS for three 
hours and washed twice with the cleavage mixture. The filtrates were combined and 
concentrated in high vacuum at room temperature. Diethyl ether (40 ml) was added and the 
resulting suspension was centrifuged. The supernatant solvent was decanted and the solid was 
washed with diethyl ether and centrifuged again. After decanting, the raw product was 
dissolved in little methanol, water (30 ml) was added, and the mixture was freeze-dried in 
vacuum. The resulting solid was purified by MPLC on C18 reversed-phase silica gel (10 % to 
100 % methanol/water in 45 min, 0.1 % TFA) to obtain 67 as white solid (20 mg, 19%) with 
94 % purity determined by analytical RP-HPLC.  
1
H-NMR (500 MHz, d
6
-DMSO): δ [ppm] = 1.31-1.66 (m, 12H, Lys-CH2), 3.21 (s, 4H, 
Lys-CH2), 3.99-4.27 (m, 5H, Lys-CH, Fmoc-CH2, Fmoc-CH), 6.82 (s, 2H, pyrrole-CH), 
7.02-7.29 (m, 3H, phenyl-CH, pyrrole-CH), 7.31-7.41 (m, 5H, phenyl-CH, amide-NH), 7.52 
(s, 1H, amide-NH), 7.68 (m, 2H, pyrrole-NH), 7.70-8.40 (m, 11H, guanidine-NH), 12.10 (br.s, 
1H, amide-NH2).  
13
C-NMR (125 MHz, d
6
-DMSO): δ [ppm] = 18.4 (Lys-CH2), 22.7 (Lys-CH2), 23.0 
(Lys-CH2), 28.8 (Lys-CH2), 29.0 (Lys-CH2), 31.6 (Lys-CH2), 31.9 (Lys-CH2), 38.7 (Lys-CH2), 
46.6 (Fmoc-CH), 52.1 (Lys-CH), 54.7 (Lys-CH), 65.6 (Fmoc-CH2), 112.1 (pyrrole-CH), 116.3 
(pyrrole-CH), 118.3 (pyrrole-CH), 120.1 (pyrrole-CH), 125.3 (phenyl-CH), 127.1 
(phenyl-CH), 127.6 (phenyl-CH), 140.7 (Cq), 143.7 (Cq), 143.9 (Cq), 156.0 (Cq), 157.9 (Cq), 
158.1 (Cq), 159.1 (Cq), 171.8 (Cq), 173.5 (Cq). 
MALDI-TOF-MS (pos.) m/z calculated for C41H50N13O8 [M + H] 
+
 852.38, found 853.80 
  
EXPERIMENTAL SECTION 
191 
Synthesis of peptide (68): 
 
Rink-Amide MBHA resin (200 mg, 0.62mmol/g) was swollen in DCM (5 ml) for 2 h. 
Fmoc removal was achieved by shaking the resin in 20 % piperidine/DMF (5 ml) for 20 min 
twice followed by washing with DMF (6 × 5 ml). The first residue Fmoc-Boc-l-Lys-OH (169 
mg, 0.37 mmol, 3 eq) was attached to the resin with PyBOP (194 mg, 0.37 mmol, 3 eq), 
DIPEA (130 µl, 0.74 mmol, 6 eq) in DMF (5 ml) for 8 hours and consequent washing with 
DMF (3 × 5 ml). Coupling and washing steps were repeated. After Fmoc deprotection the 
second residue Fmoc-Boc-l-Lys-OH was attached to the resin as described above, also 
repeating coupling and washing steps. Afterwards, the resin was washed with DCM (3 × 5 ml), 
methanol (3 × 5 ml), and DCM (3 × 5 ml) and dried under reduced pressure for one hour. To 
cleave the product, the resin was shaken under argon atmosphere in a mixture containing 95 % 
TFA, 2.5 % water, and 2.5 % TIS for three hours and washed twice with the cleavage mixture. 
The filtrates were combined and concentrated in high vacuum at room temperature. Diethyl 
ether (40 ml) was added and the resulting suspension was centrifuged. The supernatant 
solvent was decanted and the solid was washed with diethyl ether and centrifuged again. After 
decanting, the raw product was dissolved in little methanol, water (30 ml) was added, and the 
mixture was freeze-dried in vacuum. The resulting solid was purified by MPLC on C18 
reversed-phase silica gel (10 % to 100 % methanol/water in 45 min, 0.1 % TFA) to obtain 68 
as white solid (20 mg, 19%) with 94 % purity determined by analytical RP-HPLC.  
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1
H-NMR (500 MHz, d
6
-DMSO): δ [ppm] = 1.35-1.36 (m, 4H, Lys-CH2), 1.56-1.66 (m, 8H, 
Lys-CH2), 2.73 (s, 4H, Lys-CH2), 4.15-4.25 (m, 5H, Lys-CH, Fmoc-CH2, Fmoc-CH), 7.05 (s, 
1H, amide-NH), 7.31-7.74 (m, 9H, phenyl-CH, amide-NH), 7.88-8.02 (m, 8H, amide-NH2, 
amine-NH3
+
),  
   
MALDI-TOF-MS (pos.) m/z calculated for C27H38N5O4 [M + H] 
+
 496.28, found 497.13 
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6.5 Analytical methods 
6.5.1. Development of novel cell penetrating peptide 
6.5.1.1 Isothermal Titration Calorimetry 
 All measurements were carried out in sodium cacodylate buffer (0.05 M, pH 7.40 ± 0.01) 
at 25° C. All solutions were ultrasonicated and degassed in vacuum prior to the experiments. 
Aliquots of heparin sulfate (1.0 mM, 5μL) were injected from a 297μl rotating syringe (307 
rpm) into the calorimeter reaction cell containing 1.45 ml of corresponding peptide 40, and 41 
solutions (0.05mM). Blank experiments were conducted to determine the heats of dilution of 
heparin sodium. These were subtracted from the heats measured in the titration experiments. 
Data was analyzed using Origin 7.0 software according to a single set of sites binding mode. 
6.5.1.2 Cellular Uptake Study 
Human cervix carcinoma cell lines (HeLa) were seeded in 8-well plates and grown for 24 h. 
Afterwards, cells were incubated with 5 μM, 10 μM, 15 μM, 20 μM 58 and 10 μM, 20 μM 60, 
respectively. After the incubation for 1 h, cells were thoroughly washed with PBS buffer for 
three times. Fresh DMEM cell culture medium was supplemented and examined under a 
confocal fluorescence microscope (SP5 LCSM, Leica). Images were processed using LAS AF 
software (Leica) and Adobe Photoshop CS2. 
6.5.1.3 Cell Co-localization Study 
Golgi-apparatus 
HeLa cells were seeded in 8-well plates, grown for 24 h and transfected with 2 μg of Golgi 
marker plasmid-DNA mixed with 1 mM PEI. After an additional incubation of 24 h, cells 
were incubated with 10 μM 58 for 1 h. Afterwards, DAPI was added to stain nucleus and 
incubated for 5 minutes. Cells were then thoroughly washed with PBS buffer for three times 
and examined under a confocal fluorescence microscope (SP5 LCSM, Leica). Images were 
processed using LAS AF software (Leica) and Adobe Photoshop CS2. 
Endosome and lysosome (immunostaining) 
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HeLa cells were seeded in 8-well plates, grown for 24 h and incubated with 10 μM 58 for 1 
h. Fluorochrome-conjugated antibody targeting endosome and lysosome respectively were 
added. Afterwards, DAPI was added to stain nucleus and incubated for 5 minutes. Cells were 
then thoroughly washed with PBS buffer for three times and fixed with fixation examined 
under a confocal fluorescence microscope (SP5 LCSM, Leica). Images were processed using 
LAS AF software (Leica) and Adobe Photoshop CS2. 
6.5.1.4 Alamar Blue Cell Viability Assay 
HeLa cells were grown and incubated with 58 and PEI as described above. Before 
incubation, 24 h after incubation, cells were incubated with Alamar Blue dye (Invitrogen, 10 % 
v/v) for 3 h at 37° C at 5 % CO2. Fluorescence was measured at 590 nm using a multimode 
reader (GloMax-Multi+DetectionSystem, Promega). 
6.5.2. Development of cell penetrating peptide based gene delivery 
vector 
6.5.2.1 EB Displacement Assay 
Spectra were recorded at 25° C in aqueous sodium cacodylate buffer (0.01 M, pH 7.00 ± 
0.01) in quartz fluorescence micro-cuvettes (1 cm) equipped with a stopper. To a solution of 
ethidium bromide (900 μL, 0.75 μM, 1 eq), ctDNA was added and incubated for 15 min. The 
fluorescence emission was then measured from 560 to 650 nm utilizing an excitation 
wavelength of 520 nm. To this mixture a stock solution (50 μM) of 42, 43, 44, 62, 63 or 64 
was added in aliquots (1–32 μl). After each addition the cuvette was gently shaken and the 
mixture was incubated for 1 min to ensure that the equilibria were established (no change was 
observed with longer incubation time). An excerpt of the fluorescence emission at 600 nm 
was corrected for ethidium bromide s´ own emission and plotted against [EB]/[42], [EB]/[43], 
[EB]/[44], [EB]/[62], [EB]/[63] and [EB]/[64], respectively. An exponential decay first order 
function was fitted using Origin 7.0. The reciprocal x-value at half of the maximum 
fluorescence emission is the IC50 value representing the equivalents of 42, 43, 44, 62, 63 or 64 
that are necessary to displace half of the ethidium bromide from the EB/DNA complex. 
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6.5.2.2 Isothermal Titration Calorimetry 
 All measurements were carried out in sodium cacodylate buffer (0.05 M, pH 7.00 ± 0.01) 
at 25° C. All solutions were ultrasonicated and degassed in vacuum prior to the experiments. 
Aliquots of ctDNA (0.7 mM, 5μL) were injected from a 297μl rotating syringe (307 rpm) into 
the calorimeter reaction cell containing 1.45 ml of corresponding peptide 42, 43, 44, 62, 63 
and 64 solutions (0.05mM). Blank experiments were conducted to determine the heats of 
dilution of heparin sodium. These were subtracted from the heats measured in the titration 
experiments. Data was analyzed using Origin 7.0 software according to a single set of sites 
binding mode. 
6.5.2.3 DLS Experiments 
All measurements were carried out in sodium cacodylate buffer (0.01 M, pH 7.00 ± 0.01) at 
25° C in UV-transparent micro-cuvettes (1 cm) equipped with a stopper. Mixtures of ctDNA 
(50 μM) and solution (150 μM) of 42, 43, 44, 62, 63 or 64 were prepared respectively and 
filtered prior to measuring via 0.20 μm nylon filters. The autocorrelation functions of the 
backscattered light fluctuations were analyzed with the DTS 6.20 software from Malvern 
providing the hydrodynamic diameter (Z-average), polydispersity, size distribution (NNLS 
analysis) and Zeta potential. 
6.5.2.4 AFM Measurements 
AFM images were obtained in tapping mode using a NanoDrive Controller with an Innova 
Scanning Probe Microscope (Veeco Germany, Mannheim) and N-type silicon cantilever (AC 
160TS OLYMPUS). The scan rate was about 5 μm/s. Mixtures of ctDNA (50 μM) and 
solution (150 μM) of 42, 44, or 64 were prepared respectively. Samples were spin-coated (66 
rps) onto a freshly cleaved mica surface (Plano GmbH) for 2 minutes. The AFM data were 
analyzed using Gwiddion-2.20 software. 
6.5.2.5 Spectrophotometric Titrations 
UV/Vis Titrations 
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All measurements were carried out in aqueous sodium cacodylate buffer (0.01 M, pH 7.00 
± 0.01) in quartz UV micro-cuvettes (1 cm) equipped with a stopper at 25℃. The pH was 
adjusted with aqueous HCl or NaOH solution. To a solution of 42, 43, or 64 (800 μL, 2 × 
10
-5
 M) a stock solution of ctDNA, pdAdT2, pdGdC2, pApU were added in aliquots (5–100 
μL). 
Fluorimetric Titrations 
All measurements were carried out in aqueous sodium cacodylate buffer (0.01 M, pH 7.00 
± 0.01) in quartz fluorescence micro-cuvettes (1 cm) equipped with a stopper at 25℃. The 
pH was adjusted with aqueous HCl or NaOH solution. To a solution of 42, 43, or 64 (800 μL, 
2 × 10-5 M) a stock solution of ctDNA, pdAdT2, pdGdC2, pApU were added in aliquots 
(5–100 μL). 
CD Titrations 
All measurements were carried out in aqueous sodium cacodylate buffer (0.01 M, pH 7.00 
± 0.01) in quartz UV micro-cuvettes (1 cm) equipped with a stopper at 25℃. The pH was 
adjusted with aqueous HCl or NaOH solution. To a solution of 42, 43, or 64 (800 μL, 2 × 
10
-5
 M) a stock solution of ctDNA, pdAdT2, pdGdC2, pApU were added in aliquots (5–100 
μL). 
6.5.2.6 Transfection and Microscopy  
Per well, 1 × 10
4
 cells were seeded in 96 well cell culture plates (Greiner bio-one) in a total 
medium volume of 200 μl 24 h before transfection. The cationic transfection reagent 
polyethylenimine (PEI, pH 6.8, Sigma-Aldrich) was used at a concentration of 0.15 mM in 
PBS (Invitrogen) with 2 μg of plasmid DNA per well. Transfection with 42, 43, 44, 61, 62, 63 
or 64  were carried out in a concentration range of 0.05, 0.10, 0.15 and 0.25 mM with 2 μg 
plasmid DNA in a total volume of 30 μl in PBS buffer. Transfection efficiency was analyzed 
24 and 48 h after transfection with an inverted fluorescence microscope (Axiovert 200M, Carl 
Zeiss) with a 10X air objective. Images were processed and analyzed using MetaMorph 6.3r6 
(Molecular Devices) and Adobe Photoshop CS2 (Adobe Systems). 
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6.5.2.7 Endosomal Escape Assay  
Cells were incubated with complete medium containing 25 μM chloroquine and 150 nM 
bafilomycin 30 min before transfection. Transfection was carried out with 0.15 mM 42, 43, 44, 
61, 62, 63, 64 or PEI and 2 μg plasmid-DNA.  
6.5.2.8 Alamar Blue Cell Viability Assay 
HeLa cells were grown and transfected as described above. Before transfection, 24 h and 
48 h after transfection cells were incubated with Alamar Blue dye (Invitrogen, 10 % v/v) for 3 
h at 37°C at 5% CO2. Fluorescence was measured at 590 nm using a multimode reader 
(GloMax-Multi+DetectionSystem, Promega). 
6.5.3 Development of cyclic peptide nanotube based gene delivery 
vector 
6.5.3.1 DLS Experiments 
All measurements were carried out in sodium cacodylate buffer (0.01 M, pH 7.40 ± 0.01) at 
25° C in UV-transparent micro-cuvettes (1 cm) equipped with a stopper. Mixtures of ctDNA 
(0.02 mM) and solution (0.4 mM) of 45 and 65 were prepared respectively and filtered prior 
to measuring. The autocorrelation functions of the backscattered light fluctuations were 
analyzed with the DTS 6.20 software from Malvern providing the hydrodynamic diameter 
(Z-average), polydispersity, size distribution (NNLS analysis) and Zeta potential. 
6.5.3.2 AFM Experiments 
AFM images were obtained in tapping mode using a NanoDrive Controller with an Innova 
Scanning Probe Microscope (Veeco Germany, Mannheim) and N-type silicon cantilever (AC 
160TS OLYMPUS). The scan rate was about 5 μm/s. 0.4 mM of 45 and 65 sample solutions 
in water were prepared and spin-coated (66rps) onto a freshly cleaved mica surface (Plano 
GmbH) for 2 minutes. The AFM data were analyzed using Gwiddion-2.20 software. 
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6.5.3.3 TEM Experiments 
TEM images were obtained using a CM 200 FEG (Phillips Company). A drop of a freshly 
prepared sample solution of 45 and 45/ctDNA was placed on 400-mesh formvar copper grid 
coated with carbon. About 2 min after the deposition the grid was tapped with filter paper to 
remove remaining solvent from the surface. Negative staining was performed by addition of a 
drop of an ethanolic solution of uranyl formate (0.5 %) onto the copper grid. After 1 min, the 
liquid on the surface of the grid was removed by tapping it with a filter paper. 
6.5.3.4 Transfection Experiments  
Per well, 1 × 10
4
 cells were seeded in 96 well cell culture plates (Greiner bio-one) in a total 
medium volume of 200 μl 24 h before transfection. The cationic transfection reagent 
polyethylenimine (PEI, pH 6.8, Sigma-Aldrich) was used at a concentration of 0.15 mM in 
PBS (Invitrogen) with 2 μg of plasmid DNA per well. Transfections with 45 or 65 were 
carried out in a concentration of 0.4 mM with 2 μg plasmid DNA in a total volume of 30 μl in 
PBS buffer. Transfection efficiency was analyzed 24 and 48 h after transfection with an 
inverted fluorescence microscope (Axiovert 200M, Carl Zeiss) with a 10X air objective. 
Images were processed and analyzed using MetaMorph 6.3r6 (Molecular Devices) and Adobe 
Photoshop CS2 (Adobe Systems). 
6.5.3.5 Plasmid DNA Labeling and Co-localization  
Plasmid DNA was labeled with the PromoFluor-500 Nick Translation Labeling Kit 
(PromoKine) according to the manufacturer’s instructions. Briefly, following nick translation 
of the pF143-GFP vector with PromorFluor-500-dUTPs for 2 h at 15℃, cleanup of the 
mixture was performed using a DNA purification Kit (Macharey-Nagel) as advised. 
Afterwards, 1 μL labeled DNA (1 μg/μL) was added to 10μL of 0.4 mM peptide 45. The 
resulting mixture was directly dropped on a glass bottom culture dish and then examined with 
confocal fluorescence microscopy (SP5 LCSM, Leica). 
6.5.3.6 Endosomal Escape Assay  
Cells were incubated with complete medium containing 25 μM chloroquine and 150 nM 
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bafilomycin 30 min before transfection. Transfection was carried out with 0.4 mM 45 or PEI 
and 2 μg plasmid-DNA as described above. 
6.5.3.7 Alamar Blue Cell Viability Assay 
HeLa cells were grown and transfected as described above. Before transfection and 24 h 
after transfection, cells were incubated with Alamar Blue dye (Invitrogen, 10 % v/v) for 3 h at 
37°C at 5% CO2. Fluorescence was measured at 590 nm using a multimode reader 
(GloMax-Multi+DetectionSystem, Promega). 
6.5.3.8 Molecular Modelling 
Virtual molecular studies were carried out by a conformational search using Macro Model 
with the OPLS2005 force-field, GB/SA solvent model for water, 500000 iterations and a 
convergence threshold of 0.05. The conformational search has been processed with mixed 
torsional / low-mode sampling with 1000 maximum steps and 100 steps per rotable bond. The 
collected conformations have been in an energy window of 5kJ/mol and have been of similar 
shape, so that the shown structure represents all found conformations in that specific energy 
window. For the illustration of peptide 45, PyMOL was used with arrow cartoon mode for a 
better representation. 
6.5.4 Development of supramolecular β-helix mimetic peptide  
6.5.4.1 Circular dichroism (CD)  
Stock solutions of 5 mM peptide 46 and 66 were prepared respectively (dissolved in water). 
CD spectrum was recorded with JASCO J-815 CD Spectrometer at 25℃ in 10 mm quartz 
cuvette with following   parameters: range = 600-210 nm, sensitivity = standard (100 mdeg), 
scanning speed = 200 nm/min, data pitch = 0.1 nm, bandwidth = 1 nm, response = 1 sec, 
accumulation = 3. The corresponding samples were freshly prepared and adjusted the pH with 
HCl or sodium hydroxide. The CD spectrum was recorded first and the samples were left at 
room temperature for 8 days; after 8 days the same solution was recorded again with the same 
parameters as last time. 
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6.5.4.2 UV-Vis spectroscopy  
UV spectrum was recorded with JASCO V-660 spectrometer at 25℃ in 10 mm quartz 
cuvette with following parameters: sensitivity = standard, scanning speed = 200nm/min, data 
pitch = 0.1 nm, bandwidth = 1 nm, response = 1 sec. The according sample was prepared and 
adjusted the pH with sodium hydroxide solution and left at room temperature for several 
weeks. The temperature of the sample solution was gradually increased and UV-vis adsorption 
at 295 nm was recorded under different temperatures. The data was analyzed with Origin 8.0 
software. 
6.5.4.3 DLS Experiments 
All measurements were carried out at 25° C in UV-transparent micro-cuvettes (1 cm) 
equipped with a stopper. 0.1 mM peptide 46 solution in water was prepared and filtered prior 
to measuring. The pH was adjusted with sodium hydroxide solution accordingly. The aging 
effect of peptide 46 was followed every hour. The autocorrelation functions of the 
backscattered light fluctuations were analyzed with the DTS 6.20 software from Malvern 
providing the hydrodynamic diameter (Z-average), polydispersity, size distribution (NNLS 
analysis). 
6.5.4.4 AFM Experiments 
AFM images were obtained in tapping mode using a NanoDrive Controller with an Innova 
Scanning Probe Microscope (Veeco Germany, Mannheim) and N-type silicon cantilever (AC 
160TS OLYMPUS). The scan rate was about 5 μm/s. Fresh prepared, 5 days and 8 days old 
0.1 mM of 45 and 65 sample solutions in water were spin-coated (66rps) onto a freshly 
cleaved mica surface (Plano GmbH) for 2 minutes. The AFM data were analyzed using 
Gwiddion-2.20 software. 
6.5.4.5 TEM Experiments 
TEM images were obtained using a CM 200 FEG (Phillips Company). A drop of a freshly 
prepared and 8 days old sample solution of 45 was placed on 400-mesh formvar copper grid 
coated with carbon. About 2 min after the deposition the grid was tapped with filter paper to 
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remove remaining solvent from the surface. Negative staining was performed by addition of a 
drop of an ethanolic solution of uranyl formate (0.5 %) onto the copper grid. After 1 min, the 
liquid on the surface of the grid was removed by tapping it with a filter paper. 
6.5.5 Development of functionalized amphiphilic peptide assembly 
6.5.5.1 AFM Experiments 
AFM images were obtained in tapping mode using a NanoDrive Controller with an Innova 
Scanning Probe Microscope (Veeco Germany, Mannheim) and N-type silicon cantilever (AC 
160TS OLYMPUS). The scan rate was about 5 μm/s. Fresh prepared sample solutions in 
water were spin-coated (66rps) onto a freshly cleaved mica surface (Plano GmbH) for 2 
minutes. The AFM data were analyzed using Gwiddion-2.20 software. 
6.5.5.2 TEM Experiments 
TEM images were obtained using a CM 200 FEG (Phillips Company). A drop of a freshly 
prepared sample solution was placed on 400-mesh formvar copper grid coated with carbon. 
About 2 min after the deposition the grid was tapped with filter paper to remove remaining 
solvent from the surface. For negative staining, a drop of an ethanolic solution of uranyl 
formate (0.5 %) was added onto the copper grid. After 1 min, the liquid on the surface of the 
grid was removed by tapping it with a filter paper. 
6.5.5.3 Circular dichroism (CD)  
Stock solutions of 5 mM peptide 47, 67 and 68 were prepared respectively (dissolved in 
DMSO). CD spectrum was recorded with JASCO J-815 CD Spectrometer at 25℃ in 10 mm 
quartz cuvette with following   parameters: range = 600-210 nm, sensitivity = standard (100 
mdeg), scanning speed = 200 nm/min, data pitch = 0.1 nm, bandwidth = 1 nm, response = 1 
sec, accumulation = 3. The corresponding samples were freshly prepared and adjusted the pH 
with HCl or sodium hydroxide.  
6.5.5.4 Transfection Experiments  
Per well, 1 × 10
4
 cells were seeded in 96 well cell culture plates (Greiner bio-one) in a total 
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medium volume of 200 μl 24 h before transfection. The cationic transfection reagent 
polyethylenimine (PEI, pH 6.8, Sigma-Aldrich) was used at a concentration of 0.15 mM in 
PBS (Invitrogen) with 2 μg of plasmid DNA per well. Transfection with 47 was carried out in 
a concentration of 0.4 mM with 2 μg plasmid DNA in a total volume of 30 μl in PBS buffer. 
Transfection efficiency was analyzed 24 and 48 h after transfection with an inverted 
fluorescence microscope (Axiovert 200M, Carl Zeiss) with a 10X air objective. Images were 
processed and analyzed using MetaMorph 6.3r6 (Molecular Devices) and Adobe Photoshop 
CS2 (Adobe Systems)
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7. APPENDIX 
7.1 Abbreviations 
δ chemical shift 
℃ Celsius 
λ wavelength 
μ micro 
ε extinction coefficient 
π pi 
ζ zeta potential 
Å Ångstrom 
A alanine/adenine 
AA amino acid 
Aβ amyloid beta 
abs absolute 
Ac acetyl 
AD adamantane 
ADP adenosine diphosphate 
AFM atomic force microscopy 
Ala alanine 
Alloc allyloxycarbonyl 
AMP adenosine monophosphate 
Ar argon 
Arg arginine 
Asp aspartic acid 
ATP adenosine triphosphate 
Au gold 
NPs nanoparticles 
Bn benzyl 
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Boc tert-butyloxycarbonyl 
tBu tert-butyl 
br broad 
c concentration 
C cytosine 
ca. circa 
CD circular dichroism 
CDCl3 deuterated chloroform 
Chol cholesterol 
cm centimeter 
CPP cell penetrating peptide (s) 
d doublet / diameter/ day  
dAdT deoxyadenylic-deoxythymidylic acid 
dGdC deoxyguanylic-deoxycytidylic acid 
D diffusion constant 
Da dalton 
DCM dichloromethane 
DIPEA N,N -´diisopropylethyl amine        
DLS dynamic light scattering 
DMF N,N -´dimethyl formamide 
DMSO dimethyl sulfoxide 
d6-DMSO deuterated dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DOPE dioleoylphosphatidylethanolamine 
ds double strand 
dsDNA double strand deoxyribonucleic acid 
dsRNA double strand ribonucleic acid 
E glutamic acid  
EB ethidium bromide 
e.g. for example 
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eq equivalent 
ESI electrospray ionization 
ESI-MS electrospray ionization mass spectrometry 
Et3N triethylamine 
F phenylalanine 
Fmoc 9-fluorenylmethyloxycarbonyl 
FT-IR fourier transform infrared spectroscopy 
g gram 
G glycine/guanine 
GFP green fluorescence protein 
Gln glutamine 
Glu glutamic acid 
Gly glycine 
GCP guanidiniocarbonyl pyrrole 
GSH glutathione 
h hour (s) 
HCTU 1-H-Benzotriazolium 1-[bis(dimethylamino)methylene] 
-5chloro-,hexafluorophosphate (1-),3-oxide 
H-donor hydrogen bond donor 
His histidine 
HIV human immunodeficiency virus 
HOBt 1-hydroxybenzotriazole 
H2O water 
HPLC high performance liquid chromatography 
HRMS high resolution mass spectrometry 
Hz Hertz 
IC50 half maximal displacement concentration 
ICD induced circular dichroism 
Ile isoleucine 
ITC isothermal titration calorimetry 
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K lysine/kelvin 
kJ kilo Joule 
Kd dissociation constant 
L liter/ leucine 
Leu leucine 
Lys lysine 
m milli / multiplett / meter 
M mol/L 
m/z mass per charge 
max maximum 
MBHA p-methylbenzhydrylamine 
Me methyl 
MeOH methanol 
MHz megahertz 
min minute (s) 
μM micromolar 
mM millimolar 
MPLC medium performance liquid chromatography 
MS mass spectrometry 
n nano 
nm nanometer 
nM nanomolar 
NMM N-methylmorpholin 
NMR nuclear magnetic resonance 
NPs nanoparticles 
p para 
PAMAM polyamidoamine dendrimer 
Pbf 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl 
PEG polyethylenglycol 
PEI polyethylenimine 
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PLL polylysine 
Pd palladium 
Pd/C palladium on charcoal 
Pd(PPh3)4 Tetrakis(triphenylphosphine)palladium(0) 
PDI polydispersity index 
pH pondus hydrogenii 
Phe phenylalanine 
PhSiH3 phenylsilane 
pKa logarithmic acid dissociation constant 
PNA peptide nucleic acid 
ppm parts per million 
Pro proline 
PyBOP benzotriazol-1-yl-N-oxy-tris(pyrrolidino)phosphonium 
hexafluorophosphate 
q quadruplet 
QSAR quantitative structure–activity relationship 
r radius 
R arginine 
RNA ribonucleic acid 
RP reversed phase 
rt room temperature 
s singulett / second(s) 
Ser serine 
siRNA small interfering ribonucleic acid 
SPPS solid phase peptide synthesis 
t time 
T temperature/thymine 
Tat Trans-Activator of Transcription 
TEM transmission electron microscopy 
TFA trifluoroacetic acid 
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THF tetrahydrofuran 
TIS triisopropylsilane 
Trt trityl 
Trp tryptophan 
Tyr tyrosine 
U uracil 
UV ultraviolet 
UV/Vis ultraviolet/ visible 
V volume / valine 
Val valine 
W tryptophan 
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7.2 Supplementary Experiment Data 
7.2.1 HPLC data 
 
Figure 7.1 Analytical HPLC run of peptide 40 with 96% purity, solvent: 10% to 50% MeOH/H2O (0.05 % TFA) 
in 30 min, flow rate: 0.43 ml/min, retention time tR= 14.4 min; the peak integration is based on detection at 254 
nm. 
 
Figure 7.2 Analytical HPLC run of peptide 42 with 93% purity, solvent: 30% to 50% MeOH/H2O (0.05 % TFA) 
in 30 min, flow rate: 0.43 ml/min, retention time tR= 13.4 min; the peak integration is based on detection at 280 
nm. 
 
Figure 7.3 Analytical HPLC run of peptide 62 with 95% purity, solvent: 10% to 100% MeOH/H2O (0.05 % TFA) 
in 30 min, flow rate: 0.43 ml/min, retention time tR= 11.7 min; the peak integration is based on detection at 290 
nm. 
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Figure 7.4 Analytical HPLC run of peptide 61 with 95% purity, solvent: 20% to 40% MeOH/H2O (0.05 % TFA) 
in 30 min, flow rate: 0.43 ml/min, retention time tR= 14.7 min; the peak integration is based on detection at 280 
nm. 
 
Figure 7.5 Analytical HPLC run of peptide 63 with 91% purity, solvent: 10% to 60% MeOH/H2O (0.05 % TFA) 
in 30 min, flow rate: 0.43 ml/min, retention time tR= 13.0 min; the peak integration is based on detection at 290 
nm. 
 
Figure 7.6 Analytical HPLC run of peptide 64 with 89% purity, solvent: 10% to 100% MeOH/H2O (0.05 % TFA) 
in 30 min, flow rate: 0.43 ml/min, retention time tR= 6.1 min; the peak integration is based on detection at 254 
nm. 
APPENDIX 
211 
 
Figure 7.7 Analytical HPLC run of peptide 43 with 92% purity, solvent: 0% to 20% MeOH/H2O (0.05 % TFA) in 
30 min, flow rate: 0.43 ml/min, retention time tR= 11.1 min; the peak integration is based on detection at 220 nm. 
 
Figure 7.8 Analytical HPLC run of peptide 44 with 97% purity, solvent: 0% to 20% MeOH/H2O (0.05 % TFA) in 
30 min, flow rate: 0.43 ml/min, retention time tR= 2.3 min; the peak integration is based on detection at 220 nm. 
 
Figure 7.9 Analytical HPLC run of peptide 45 with 90% purity, solvent: 10% to 40% MeOH/H2O (0.05 % TFA) 
in 30 min, flow rate: 0.43 ml/min, retention time tR= 17.6 min; the peak integration is based on detection at 290 
nm. 
APPENDIX 
212 
 
Figure 7.10 Analytical HPLC run of peptide 65 with 98% purity, solvent: 10% to 40% MeOH/H2O (0.05 % TFA) 
in 30 min, flow rate: 0.43 ml/min, retention time tR= 6.6 min; the peak integration is based on detection at 280 
nm. 
 
Figure 7.11 Analytical HPLC run of peptide 46 with 97% purity, solvent: 20% to 50% MeOH/H2O (0.05 % TFA) 
in 30 min, flow rate: 0.43 ml/min, retention time tR= 14.6 min; the peak integration is based on detection at 290 
nm. 
 
Figure 7.12 Analytical HPLC run of peptide 66 with 93% purity, solvent: 10% to 50% MeOH/H2O (0.05 % TFA) 
in 30 min, flow rate: 0.43 ml/min, retention time tR= 10.9 min; the peak integration is based on detection at 220 
nm. 
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Figure 7.13 Analytical HPLC run of peptide 47 with 91% purity, solvent: 10% to 100% MeOH/H2O (0.05 % 
TFA) in 30 min, flow rate: 0.43 ml/min, retention time tR= 20.8 min; the peak integration is based on detection at 
254 nm. 
 
Figure 7.14 Analytical HPLC run of peptide 67 with 85% purity, solvent: 10% to 100% MeOH/H2O (0.05 % 
TFA) in 30 min, flow rate: 0.43 ml/min, retention time tR= 20.8 min; the peak integration is based on detection at 
254 nm. 
 
Figure 7.15 Analytical HPLC run of peptide 68 with 91% purity, solvent: 10% to 100% MeOH/H2O (0.05 % 
TFA) in 30 min, flow rate: 0.43 ml/min, retention time tR= 17.0 min; the peak integration is based on detection at 
254 nm. 
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7.2.2 ITC data 
 
Figure 7.16 Top: ITC experiments were carried out in sodium cacodylate buffer (0.01 M) at neutral pH by 
titrating aliquots of 5 μL of ctDNA (0.7 mM) to 42, 62 or 63 (c = 0.05 mM). Bottom: the titrations were 
corrected for dilution and fitted with a one-site model. The titrations with 42, 62 or 63 are corrected for the first 
data point. 
 
Figure 7.17 Top: ITC experiments were carried out in sodium cacodylate buffer (0.01 M) at neutral pH by 
titrating aliquots of 5 μL of ctDNA (0.7 mM) to 64, 43 or 44 (c = 0.05 mM). Bottom: the titrations were 
corrected for dilution and fitted with a one-site model. The titrations with 64, 43 or 44 are corrected for the first 
data point. 
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7.2.3 Molecular modeling data 
 
Figure 7.18 Additional images (side view and top view) of molecular modeling results of peptide 46 
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7.3 Curriculum viate 
The biography is not included in the online version for reasons of data protection. 
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7.4 List of Publications 
Journal (Peer-Reviewed) 
1. M. Li, M. R. Stojković, M. Ehlers, E. Zellermann, I. Piantanida, C. Schmuck; Supramolecular 
beta-helix mimic self-assembled into pH responsive helical peptide fiber; Submitted 
2. M. Li, S. Schlesiger, S. K. Knauer, C. Schmuck; Enhanced affinity with cell surface glycosaminoglycan 
resulted in the smallest cell penetrating dipeptide analogue; Submitted 
3. M. Li, E. Zellermann, M. R. Stojković, Christian Schlütting, I. Piantanida, C. Schmuck; A 
multifunctional self-assembled peptide template for the fabrication of metal-organic nanowire; In 
Preparation.. 
4. M. Li, C. Schmuck; A straightforward approach to shift the thermodynamic profile of peptide/DNA 
binding; In Preparation. 
5. M. Li, M. Ehlers, S. Schlesiger, E. Zellermann, S. K. Knauer, C. Schmuck; Incorporation of a 
non-natural arginine analogue into a cyclic peptide leads to formation of positively charged nanotubes 
capable of gene transfection; Angew. Chem. Int. Edit. 2016, 55, 598-601. 
6. M. Li, S. Schlesiger, S. K. Knauer, C. Schmuck; A Tailor-Made Specific Anion-Binding Motif in the 
Side Chain Transforms a Tetra peptide into an Efficient Vector for Gene Delivery; Angew. Chem. Int. 
Edit. 2015, 54, 2941-2944. 
Activities 
1. 3rd German Symposium in Supramolecular Chemistry, SupraChem 2015 (Germany), Poster presentation 
2. 1st CRC1093 International Symposium Supramolecular Chemistry on Proteins (Germany), 2015, 
Participant 
3. Mini-symposium on Supramolecular Polymers (Germany), 2014, Participant 
4. 7th National Conference on Chemical Biology (China), 2011, Poster presentation 
5. 3rd Technology and Application Conference of small Nucleic Acid (China), 2011, Participant 
6. 2nd Roundtable on Chemical Biology of Nucleic Acid and Carbohydrates in China, 2009, Participant 
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